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ABSTRACT 
Amyloidosis is a degenerative protein misfolding disorder that leads to the 
extracellular accumulation of amyloid deposits containing protein fibrils, heparan sulfate 
proteoglycans, glycoproteins and apolipoproteins.  To date, at least 27 proteins have 
been identified as components of pathologic amyloid fibrils.  In systemic forms of the 
disease, amyloid deposits can evade the immune system and expand throughout various 
tissues.  As the deposits grow, tissue architecture is disrupted, leading to organ 
dysfunction and death. 
 In the US, there are ~3500 newly diagnosed patients with amyloidosis annually.  
The deposition of light chains as amyloid (AL amyloidosis) is the most common form of 
visceral disease.  The prognoses for patients varies (median survival for AL 12-40 
months), but those with cardiac involvement have a considerably less favorable prognosis 
(~9 months median survival).  Many researchers and physicians believe that early 
detection of amyloidosis could improve patient survival.  The current gold standard for 
diagnosis involves histological examination of biopsy-derived tissue specimens.  This 
method is invasive, subject to sampling error, and can be quite challenging.  In an attempt 
to facilitate diagnosis, molecular imaging techniques using amyloid-reactive tracers have 
been developed such that a whole body, non-invasive “picture” of amyloid burden in 
patients may be established.  There are several imaging agents used clinically world-
wide, but each of these has limitations regarding its adoption in the US (i.e. 123[123]I-SAP 
is not FDA-approved and cannot image cardiac amyloid deposits, 124[124]I-11-1F4 only 
images ~60% of patients, and 99m[99m]Tc-labeled bone-seeking agents cannot image the 
most common forms of amyloid disease in patients).  Given these limitations, there is an 
 vii 
 
unmet clinical need for a facile method of quantitatively detecting whole body amyloid 
burden in patients. 
 To this end, we have developed synthetic, pan-amyloid-reactive peptides for use 
as radiotracers by using SPECT/CT or PET/CT molecular imaging to non-invasively 
detect whole body amyloid load in patients.  Through numerous preclinical experiments 
using ex vivo and transgenic murine models of amyloidosis, the structurally related 
peptides were found to have unique in vivo characteristics.  Our findings suggest that, if 
further optimized, certain peptides could have clinical merit for the early detection of 
multiple types of amyloidosis. 
 
 
 
 
 
 
 
 
 
 
 viii 
 
TABLE OF CONTENTS 
 
Chapter 1 Literature Review ......................................................................................... 1 
1. Amyloidosis .......................................................................................................... 1 
1.1. Overview ........................................................................................................ 1 
1.2. Amyloid structure ........................................................................................... 4 
1.2.1 Fibrils and fibrillogenesis ..................................................................... 5 
1.2.2 Heparan sulfate proteoglycan ............................................................ 12 
1.2.3 Serum amyloid P component ............................................................ 16 
2. Clinical manifestations ........................................................................................ 19 
2.1. Overview ...................................................................................................... 19 
2.2. Light chain amyloidosis—AL ........................................................................ 19  
2.3. Transthyretin amyloidosis—ATTR ................................................................ 24  
2.4. Reactive amyloidosis—AA ........................................................................... 28  
2.5. Other types of amyloidosis ........................................................................... 32 
2.6. Non-human amyloid-associated diseases .................................................... 41 
3. Diagnosis ............................................................................................................ 43 
3.1. Pathobiology ................................................................................................ 43 
3.2. Imaging ........................................................................................................ 46 
3.2.1 Modalities .................................................................................... 47 
CT and MRI ........................................................................ 47 
PET Imaging ....................................................................... 51 
 ix 
 
SPECT Imaging .................................................................. 54 
Dual Modality Imaging ........................................................ 56 
3.2.2 Tracers ........................................................................................ 58 
3.2.2.1 Small molecules ......................................................... 60 
3.2.2.2 Antibodies and proteins ............................................. 64 
3.2.2.3 Visceral amyloid-related agents ................................. 71 
4. Preclinical amyloid targeting ............................................................................... 75 
4.1. Model Systems............................................................................................. 75 
4.1.1 Synthetic fibrils .................................................................................  75 
4.1.2 Tissue extracts .................................................................................. 76 
4.1.3 Mice ................................................................................................... 77 
4.1.4 Naturally occurring disease models ................................................... 83 
4.2. Preclinical amyloid-targeting agent: Peptide p5 ........................................... 84 
Chapter 2 Project Rationale ....................................................................................... 93 
Chapter 3 Materials and Methods .............................................................................. 97 
           3.1. Peptides and proteins .................................................................................. 97 
           3.2. Reagents ..................................................................................................... 97 
           3.3. Mice ............................................................................................................. 99 
           3.4. AL amyloid extract preparation .................................................................. 101 
           3.5. Radiolabeling peptides with Iodine-125 or Iodine-123 ............................... 102 
           3.6. Radiolabeling peptides with Iodine-124 ..................................................... 103 
           3.7. Radiolabeling peptides with Technetium-99m ........................................... 105 
           3.8. Radiochemical purity testing ...................................................................... 106 
 x 
 
           3.9. Tissue homogenate preparation ................................................................ 107 
           3.10. Ex vivo peptide binding assays ............................................................... 108 
                      3.10.1. Tissue homogenates ................................................................. 109 
                      3.10.2. AL extracts and rVλ6Wil fibrils ................................................... 110 
           3.11. Assessment of relative peptide affinity to amyloid using NaCl titration .... 110 
           3.12. Imaging acquisitions ................................................................................ 111 
                      3.12.1. SPECT imaging ......................................................................... 111 
                      3.12.2. Dynamic PET imaging ............................................................... 113 
                      3.12.3. CT imaging ................................................................................ 114 
           3.13. Image analysis ........................................................................................ 114 
                      3.13.1. SPECT/CT analysis ................................................................... 114 
                      3.13.2. Dynamic PET/CT analysis ......................................................... 115 
           3.14. Necropsy ................................................................................................. 115 
           3.15. Biodistribution measurements ................................................................. 116 
           3.16. Autoradiography and Histology ............................................................... 117 
           3.17. Statistical analyses .................................................................................. 118 
Chapter 4 Peptide characterization studies ............................................................ 119 
           4.1. Overview ................................................................................................... 119 
           4.2. AL extract binding studies with p5 ............................................................. 120 
           4.3. Peptide binding to amyloid-laden tissue homogenates ............................. 124 
           4.4. Binding studies in the presence of increasing concentrations of sodium      
chloride to assess the relative strength of electrostatic binding of peptides with 
amyloid ........................................................................................................................ 128 
 xi 
 
            4.5. Conclusions .............................................................................................. 134 
Chapter 5 Dual isotope SPECT/CT imaging of peptides in ApoA2c mice ............ 137 
            5.1. Overview .................................................................................................. 137  
            5.2. Dual-isotope SPECT/CT imaging of peptides in ApoA2c mice ................. 138 
            5.3. Conclusions .............................................................................................. 150  
Chapter 6 Comparison of in vivo and ex vivo ApoA2c amyloid binding with p5R+14
 .................................................................................................................................... 153 
            6.1. Overview .................................................................................................. 153 
            6.2. Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice ... 155 
            6.3. 125I-p5R+14 binding assay on ApoA2c tissue homogenates .................... 157 
            6.4. Comparison of in vivo and ex vivo peptide binding data ........................... 160 
            6.5. Conclusions .............................................................................................. 163 
Chapter 7 Assessment of modified peptides designed to enhance quantitative 
ApoA2c amyloid detection ....................................................................................... 165 
            7.1. Overview .................................................................................................. 165 
            7.2. Studies using 125I-p5+14: A peptide addressing amyloid affinity and binding   
site barrier effects ........................................................................................................ 166 
            7.3. Studies using PEGylated 125I-p5R+14: A peptide to study the effects of longer 
serum half-life .............................................................................................................. 173 
            7.4. Conclusions .............................................................................................. 180 
Chapter 8   A non-dehalogenable, novel peptide for amyloid targeting ............... 184 
            8.1. Overview .................................................................................................. 184 
            8.2. Ex vivo tissue binding assays with 125I-p43 and 125I-p50 .......................... 187 
 xii 
 
            8.3. Time course biodistribution and SPECT/CT studies with 125I-p43 and 125I-p50
 .................................................................................................................................... 192 
            8.4. Dynamic PET/CT analysis of 124I-p43 in WT mice .................................... 205 
            8.5. Conclusion ................................................................................................ 211 
Chapter 9 Summary and future directions .............................................................. 213 
List of References ..................................................................................................... 221 
Vita .............................................................................................................................. 243 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
 
LIST OF FIGURES 
Figure 1.1: Schematic of amyloid composition on the cell membrane ............................. 6 
Figure 1.2: Structural characteristics of amyloid .............................................................. 7 
Figure 1.3: Congo red binding to amyloid ........................................................................ 9 
Figure 1.4: Nucleation-dependent mechanism of fibrillogenesis ................................... 10 
Figure 1.5: Structures of common glycosaminoglycans ................................................ 13 
Figure 1.6: Crystal structure of serum amyloid P component ........................................ 17 
Figure 1.7: Basic mechanism of AL amyloidosis ........................................................... 22 
Figure 1.8: Clinical manifestations of AL amyloid in various tissues ............................. 23 
Figure 1.9: Crystal structure of homotetrameric transthyretin ........................................ 26 
Figure 1.10: Mechanism of AA amyloidogenesis .......................................................... 30 
Figure 1.11: Possible outcomes of SAA proteolysis leading to fibril formation .............. 31 
Figure 1.12: Mechanism of β2m pathogenicity leading to dialysis-related amyloidosis.. 34 
Figure 1.13: Proposed methods of AIAPP toxicity leading to β-cell death and amyloid 
formation associated with type 2 diabetes .......................................................... 37 
Figure 1.14: Crystal structure of Aβ(1-42) peptide fragment and demonstration of the 
fragment within amyloid plaques of a sample of AD brain tissue ........................ 38 
Figure 1.15: CT image demonstrating visualization of air and bone in a patient ........... 49 
 xiv 
 
Figure 1.16: Types of coincidence events associated with PET photons ...................... 53 
Figure 1.17: Dual energy SPECT imaging with 125I-SAP and 99mTc-p5 in an amyloid-
laden mouse ....................................................................................................... 57 
Figure 1.18: Dual modality SPECT/CT images ............................................................. 59 
Figure 1.19: Co-localization of mAb 124I-11-1F4 with a sc AL amyloid xenograft as 
evidenced by PET/CT ......................................................................................... 66 
Figure 1.20: The mAb 124I-11-1F4 can image amyloid-laden liver in an AL patient ....... 67 
Figure 1.21: SPECT/CT imaging and ARG of both AA and AL amyloid with mAb 125I-
2A4 ..................................................................................................................... 69 
Figure 1.22: 123I-SAP planar scintigraphy acquired 24 h pi in an AL patient and a healthy 
control ................................................................................................................. 73 
Figure 1.23: Predicted structure of peptide p5 .............................................................. 87 
Figure 1.24: Microautoradiography (ARG) of 125I-p5 distribution in various AA mouse 
tissues and Congo red (CR) histological confirmation of peptide co-localization 
with amyloid ........................................................................................................ 87 
Figure 1.25: Dual energy SPECT/CT images illustrating 99mTc-p5 and 125I-SAP 
distribution in an individual AA mouse ................................................................ 89 
Figure 1.26: 124I-p5 PET dynamic time activity curves ................................................... 91 
Figure 1.27: SPECT/CT images revealing the stability of 125I-p5 binding to amyloid ..... 91 
 xv 
 
Figure 4.1: 125I-p5 binding to AL extracts ..................................................................... 121 
Figure 4.2: Positive correlation of 125I-p5 binding and ThT fluorescence in heparinase-
treated samples ................................................................................................ 123 
Figure 4.3: 125I-p5 binds to synthetic recombinant Vλ6Wil fibrils ................................. 123 
Figure 4.4: Peptide binding to tissue homogenates .................................................... 126 
Figure 4.5: Peptide binding to AA tissues in the presence of NaCl ............................. 130 
Figure 4.6: Peptide binding to ApoA2c tissues in the presence of NaCl ...................... 132 
Figure 4.7: Peptide affinity for recombinant synthetic Vλ6Wil fibrils measured by NaCl 
titration .............................................................................................................. 133 
Figure 4.8: 125I-p5R+14 binding to rVλ6Wil fibrils in the presence of both NaCl and urea 
treatments......................................................................................................... 135 
Figure 4.9: Urea treatment of rVλ6Wil fibrils ................................................................ 135 
Figure 5.1: Quality assurance of radiolabeled p5 and p5R+14 ................................... 139 
Figure 5.2: Dual energy SPECT/CT image representing the distribution of 125I-p5R+14 
and 99mTc-p5 at 2 h pi ....................................................................................... 142 
Figure 5.3: Dual energy SPECT/CT image demonstrating the distribution of both 99mTc-
p5 and 125I-p5R+14 in a representative ApoA2c mouse ................................... 143 
Figure 5.4: Biodistribution measurements of 99mTc-p5 in ApoA2c and WT mice at 2 h 
pi ....................................................................................................................... 144 
 xvi 
 
Figure 5.5: Biodistribution measurements of 125I-p5R+14 in ApoA2c and WT mice at 2 h 
pi ....................................................................................................................... 146 
Figure 5.6: Scaled comparisons of 99mTc-p5 and 125I-p5R+14 in ApoA2c mice ........... 148 
Figure 5.7: Image analyses revealed greater 125I-p5R+14 uptake in amyloid-laden 
organs .............................................................................................................. 149 
Figure 5.8: Autoradiographs of 125I-p5R+14 in ApoA2c tissues at 2 h pi ..................... 151 
Figure 6.1: Autoradiograph of 125I-SAP in ApoA2c amyloid-laden spleen ................... 154 
Figure 6.2: Assessment of radiopurity and amyloid-reactivity of 123I-p5R+14 .............. 156 
Figure 6.3: Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice at 4 h 
pi ....................................................................................................................... 158 
Figure 6.4: Ex vivo assessment of 125I-p5R+14 binding to ApoA2c and WT homogenized 
tissues .............................................................................................................. 159 
Figure 6.5: Method for analyzing ex vivo and in vivo data with comparable peptide 
binding values ................................................................................................... 161 
Figure 6.6: Comparative analysis of ex vivo peptide-binding data and in vivo 
biodistribution data in 3 ApoA2c mice ............................................................... 162 
Figure 6.7: ApoA2c amyloid deposits which were unidentified by the 125I-p5R+14 
radiotracer in various tissues ............................................................................ 164 
 xvii 
 
Figure 7.1: Autoradiographs (ARG) indicating disparate AA amyloid targeting with two 
radiotracers....................................................................................................... 167 
Figure 7.2: Assessment of radiopurity and amyloid-laden tissue and synthetic rVλ6Wil 
fibril reactivity .................................................................................................... 169 
Figure 7.3: Biodistribution measurements 2 h pi of either 125I-p5+14 or 125I-p5R+14 in 
ApoA2c mice .................................................................................................... 170 
Figure 7.4: Autoradiographs demonstrating radiotracer accumulation in amyloid-laden 
tissues .............................................................................................................. 172 
Figure 7.5: Radiopurity and fibril reactivity assays ...................................................... 176 
Figure 7.6: Biodistribution of 125I-PEG-p5R+14 and 125I-p5R+14 in WT mice at 15 min 
and 1 h pi .......................................................................................................... 178 
Figure 7.7: SPECT/CT images displaying the distribution of 125I-PEG-p5R+14 and 125I-
p5R+14 in WT mice at 1 h pi ............................................................................ 179 
Figure 7.8: Biodistribution of peptides 125I-PEG-p5R+14 and 125I-p5R+14 in ApoA2c 
mice .................................................................................................................. 181 
Figure 7.9: Autoradiographs of 125I-PEG-p5R+14 in ApoA2c amyloid-laden tissues ... 182 
Figure 8.1: Illustration of both the L-type and D-type conformations of valine ............. 185 
Figure 8.2: Ex vivo peptide-binding assays with 125I-p43 and 125I-p5 .......................... 188 
 xviii 
 
Figure 8.3: Ex vivo peptide-binding assay demonstrating 125I-p50 reactivity with AA 
tissues and WT liver ......................................................................................... 190 
Figure 8.4: NaCl titrations assessing 125I-p43 and 125I-p50 affinity for AA liver and spleen 
homogenates .................................................................................................... 191 
Figure 8.5: Radiopurity and amyloid-reactivity of the radiolabeled peptides................ 193 
Figure 8.6: Biodistribution measurements of 125I-p43 in a time course study with AA 
mice .................................................................................................................. 195 
Figure 8.7: Representative SPECT/CT images of 125I-p43 in AA mice at 1 h, 4 h, and 24 
h pi .................................................................................................................... 196 
Figure 8.8: 3D SPECT/CT representation of 125I-p5 in a WT mouse ........................... 197 
Figure 8.9: Biodistribution of 125I-p43 in WT mice ........................................................ 197 
Figure 8.10: Representative SPECT/CT images of 125I-p43 in WT mice at 1 h, 4 h and 
24 h pi ............................................................................................................... 198 
Figure 8.11: Co-localization of 125I-p43 to AA amyloid at various time points pi .......... 200 
Figure 8.12: Autoradiograph visualization of 125I-p43 binding to healthy kidney and 
cartilage tissue at various time points pi ........................................................... 202 
Figure 8.13: SPECT/CT images of 125I-p50 in WT and AA mice at 1 h, 4 h and 24 h 
pi ....................................................................................................................... 204 
 xix 
 
Figure 8.14: Microautoradiographs displaying 125I-p50 in amyloid-laden tissues 
representative of various time points pi ............................................................ 206 
Figure 8.15: Microautoradiographs demonstrating a lack of 125I-p50 accumulation in 
various WT tissues ........................................................................................... 206 
Figure 8.16: Time activity curves depicting renal accumulation and clearance of 124I-p43 
and 124I-p5 ........................................................................................................ 208 
Figure 8.17: Time activity curves for 124I-p43 in WT mice ............................................ 210 
 
1 
 
Chapter 1 
Literature Review 
 
1.  Amyloidosis 
1.1 Overview 
 Amyloidosis is a protein misfolding disorder which leads to the extracellular 
deposition of a complex clinical pathology known as amyloid.  To date, 27 different 
native proteins have been identified that, after undergoing a conformational, structural 
change, have been found associated with the disease in man [1].  Certain types of 
amyloidosis are localized and affect only the organ in which the precursor protein is 
produced. These include type II diabetes in which the amyloidotic islet amyloid 
polypeptide (AIAPP) aggregates and deposits within the pancreas and Alzheimer’s 
disease where amyloid beta (Aβ) peptides deposit in the brain.  In contrast, the systemic 
amyloidoses show no limitation to the organs that can be involved.  Partial lists of the 
systemic and localized amyloid diseases, including the associated precursor proteins 
and the most typically affected organs, are shown in Table 1.1 [1, 2].  Additionally, there 
are amyloid diseases which have been shown to affect animals.  Many of these 
disorders are systemic in pathology and affect multiple organs much like the systemic 
diseases seen in humans; others induce localized amyloid aggregates in the brain 
which can lead to Alzheimer’s disease [3].  Animals and humans can also be affected 
by prion diseases which result in proteinacious aggregates localized to the brain leading 
to neurological deficits [4]. 
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Table 1.1: Partial list of human amyloidoses 
Light chain amyloidosis (AL)
Heavy chain amyloidosis (AH)
Senile systemic amyloidosis 
(SSA)  # now known as wild 
type transthyretin (wt-TTR)
Familial amyloidotic 
polyneuropathy (FAP; also 
known as ATTR)
Secondary (reactive) 
amyloidosis (AA)
Finnish hereditary amyloidosis 
(AGel)
Cystatin amyloidosis (ACys) Cystatin C Cerebral blood vessels
Apo AI amyloidosis (AApoAI)
Fragments of 
apolipoprotein AI
Kidney, heart, liver
Apo AII amyloidosis (AApoAII)
Fragments of 
apolipoprotein AII
Kidney
Fibrinogen amyloidosis (Afib)
Fibrinogen α chain 
mutants
Kidney
Fragments of gesolin 
mutants
Cornea, facial and 
peripheral nerves, skin
Lysozyme amyloidosis (Alys) Lysozyme Kidney, liver, spleen 
Immunoglobulin heavy 
chain
Kidney, liver
Transthyretin
Heart, vessels, soft 
tissues
Transthyretin
Heart, kidney, central 
nervous system
Serum amyloid A protein Kidney, liver, spleen
Dialysis-related amyloidosis 
(Aβ2M)
β2-microglobulin
Joints, heart, 
gastrointestinal tract, lung
Amyloid disease 
(abbreviation)
Precursor protein Affected tissue(s)
Systemic 
Immunoglobulin light chain Heart, kidney, liver
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Table 1.1. Continued 
Diabetes mellitus type II 
(AIAPP)
Spongiform 
encephalopathies (APrP)
Pituitary prolactinoma (APro)
Senile aortic, medin 
amyloidosis (AMed)
Familial corneal amyloidosis 
(ALac)
#
 The amyloidosis nomenclature committee made this announcement at the 
International Symposium on Amyloidosis 2014.
Lactadherin Heart
Lactoferrin Eyes
Amyloid disease 
(abbreviation)
Precursor protein Affected tissue(s)
Localized
Alzheimer's disease (Aβ)
β-amyloid precursor 
protein
Brain
Islet amyloid polypeptide
Islets of Langerhans 
(pancreas)
Prion protein Brain
Prolactin Pituitary
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The underlying biochemical and biophysical causes of amyloidosis are likely myriad and 
vary widely, but they include hereditary conditions which lead to the production of 
proteins with mutations (e.g. ATTR), acquired diseases due to altered physiological 
conditions resulting in an increase in the production of improperly folded proteins (e.g. 
AL, AA, AIAPP) and acquired diseases associated with aging (e.g. AMed, wild type 
TTR). 
While there are numerous structurally and functionally different precursor 
proteins associated with amyloidosis, the amyloid deposits themselves share certain 
remarkably similar characteristics. The following sections will discuss many of these 
characteristics, a possible mechanism of pathogenesis and a description of the most 
prevalent components of the pathological amyloid deposit. 
 
1.2. Amyloid Structure 
 The term “amyloid” was derived from the Greek word amylon which means 
starch; however, the term was initially a descriptor for plant composition.  Amyloid was 
introduced into the field of medicine in the mid-1800’s when Virchow and others used it 
to describe lardaceous tissue deposits that stained positively, specified by a bluish 
color, with iodine solution, indicating the presence of a starch-like substance [5, 6].  
Amyloid has since been used as a designation for the extracellular, proteinaceous 
deposits which primarily consist of protein fibrils.  However, these deposits also 
ubiquitously include other associated secondary components, whose role in the 
pathogenesis of the disease remains enigmatic, such as proteoglycans, namely 
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heparan sulfate proteoglycan (HSGP), serum amyloid P component (SAP), and 
apolipoproteins. (See Figure 1.1) [5, 7-9].  
1.2.1. Fibrils and fibrillogenesis  
 The initial stage of amyloid fibril formation involves the transition of normally 
soluble, amyloidogenic precursor proteins, which are natively folded, into insoluble, 
linear fibrils.  Researchers have slightly different perspectives on this process; one 
possible mechanism of fibrillogenesis that is commonly seen and has been referred to 
as “widely accepted” [10] will be presented later.  The structure of amyloid fibrils has 
also been a topic of intense discussion amongst amyloid researchers for years, but 
three traits common to all types of amyloid fibril have been identified (see Figure 1.2). 
Firstly, analysis of data generated from electron microscopy studies suggests that fibrils 
are “self-assembling”, unbranching filaments that are approximately ~10 µm in length, 
~10 nanometers wide and display crossovers at regular distances (seen as white 
arrowheads in Figure 1.2A) [11, 12].  In addition to these features, a second defining 
characteristic of amyloid fibrils is the presence of a cross-β-sheet secondary structural 
motif as evidenced in X-ray diffraction studies [13-15].  Characteristic deflections in the 
X-ray diffraction pattern are ever-present in amyloid fibrils, regardless of the precursor 
protein from which the fibrils are formed [16].  These deflections are indicative of 
interstrand and intersheet distances at 4.7 and 10-13 Å, respectively (Figure 1.2B) [17, 
18].  In addition, these data suggest that the β-sheet motifs are arranged perpendicular 
to the long axis of the fibril (see Figure 1.2C). The third common feature associated with 
all amyloid fibrils is the ability to give rise to green-birefringence upon staining with 
Congo red (CR) dye and viewing the sample microscopically with cross-polarized  
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Figure 1.1: Schematic of amyloid composition on the cell membrane.  This model 
demonstrates the complexity of amyloid where HSPG is heparan sulfate proteoglycan 
and SAP is serum amyloid P component.  The various components that are depicted 
have all been found associated ubiquitously with amyloid deposits [5, 7-9, 19].  
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Figure 1.2: Structural characteristics of amyloid. (A) Electron micrograph of amyloid 
fibrils.  The image demonstrates the unbranched structure of amyloid fibrils; arrowheads 
pinpoint to the regularly-spaced crossover positions throughout the length of the fibril. 
(Image taken from [11]).  (B) X-ray diffraction pattern of cross-beta sheet associated 
with fibrils (Image adapted from [17]).  (C) Demonstration of cross-beta sheet 
positioning along fibril axis.  The beta sheets are indicated as yellow or green broad 
arrows.  As shown, they point in opposing directions which creates the cross-beta 
pattern.  This image additionally reveals that the beta sheets align in a perpendicular 
fashion along the length of the fibril axis (Image taken from [20]).  
 
8 
 
illumination [11, 21].  An example of CR-stained heart tissue and the localized green 
birefringence indicating amyloid deposition is shown in Figure 1.3A.  The molecular 
rationale underlying the birefringent properties of fibrils is suggested to be due to the 
intercalation of several CR molecules amidst the cross-β sheet secondary structure of 
the amyloid fibril (Figure 1.3B). 
 While these three characteristics are associated with all types of amyloid fibril, 
they do not give insight into the mechanism by which fibrils form.  Researchers agree 
that there must be a protein conformational change prior to fibrillogenesis – a shift in the 
structure of the native state of the precursor protein that renders it in a pro-amyloid state 
[10, 22-24].  Once misfolded, (and perhaps following the dissociation of multimeric 
complexes, as in the case of TTR) monomeric precursor proteins self-assemble forming 
dimeric and oligomeric “nuclei” which then leads to fibril formation.  This process has 
been called ‘nucleation-dependent’ fibrillogenesis because it requires the association of 
monomers to “seed” the transition, analogous to the formation of salt crystals by the 
addition of a pre-formed “seed” or nucleating crystal.  As Kumar and Walter’s proposed 
mechanism illustrates (see Figure 1.4), the misfolding of the native protein and the 
formation of intermediary species are reversible processes and not thermodynamically 
favorable; thus, the progression to fibrils is not favored, and this phase of fibrillogenesis 
is termed the lag phase  or  nucleation phase [10, 22-24].  Once a sufficient population 
of oligomeric species have been established, likely within affected tissues, they 
progress toward protofibrils, assemblies of protofilaments intertwined to form a pre-
fibrillar state, and mature fibrils proceeds much more rapidly—this step is considered to 
be auto-catalytic (associated with exponential kinetics) and is known as the ‘elongation  
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Figure 1.3: Congo red binding to amyloid.  (A) Congo red (CR) birefringence in 
amyloid laden tissue.  When viewed with cross-polarized light, the golden regions, 
indicated by white arrows, reveal amyloid deposits in cardiac tissue from a murine 
model of amyloidosis. (B) Proposed incorporation of CR onto amyloid fibrils.  The cross-
linking of CR on amyloid fibrils yields birefringent properties which are used for amyloid 
detection (Image adapted from [17]). 
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Figure 1.4: Nucleation-dependent mechanism of fibrillogenesis.  Misfolded 
monomeric proteins self-assemble as dimeric and oligomeric species which “nucleate” 
fibrillogenesis (nucleation phase).  This phase is thermodynamically unfavorable, but 
once a nucleus is formed, the progression to protofibrils and mature fibrils proceeds 
rapidly (elongation phase).  (Image taken from [10]). 
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phase (Figure 1.4).  The sigmoidal curve (green) indicates the different kinetic 
properties of each of these phases.  Furthermore, the schematic shows what happens 
following the addition of pre-formed nuclei to the lag phase of the reaction.  As noted 
above, this is analogous to seeding a crystallization reaction, and in the case of amyloid 
fibrils has been shown to induce the formation of prefibrillar assemblies and increase 
the rate of fibril formation, thus shortening (or even completely eliminating) the lag 
phase (Figure 1.4 red curve).  Many researchers take advantage of this phenomenon in 
preclinical animal studies of amyloidogensis by administering, intravenously, a tissue 
homogenate containing preformed oligomeric species and amyloid fibrils, known as 
amyloid enhancing factor (AEF), to expedite amyloid deposition in vivo [25-27].  This 
process shortens the time necessary for amyloid formation in animal models of the 
disease, and may be the underlying phenomenon governing the transmissibility of 
amyloid-associated diseases such as the spongiform encephalopathies and prion 
diseases [17, 28-30]. 
 Fibrillogenesis and the pathogenesis at each phase of the transformation is not 
fully understood, however.  Some researchers hypothesize that it is the oligomeric 
species that form during the lag phase that may be cytotoxic and result in the death of 
neurons in patients with Alzheimer’s disease (Aβ) or pancreatic β-cells in patients with 
type 2 diabetes (AIAPP) — not the fibril, itself [31-35].  In Alzheimer’s disease, the 
monomeric and fibrillar Aβ peptides are biologically inert, but the oligomeric Aβ species 
have been shown to be cytotoxic and show the best correlation with synapse loss and 
dementia in neuro-psychiatric analyses [36-40].  However, the systemic amyloidoses 
that involve multiple, if not all, visceral organs will be the focus of this thesis, and it is 
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widely accepted that in these patients, the deposition of fibrils and amyloid in the organs 
is responsible for the pathologic affects. 
1.2.2. Heparan Sulfate Proteoglycan 
In addition to the protein fibrils within amyloid, glycosaminoglycans (GAGs), 
namely heparan sulfate, are major secondary (non-fibrillar) components of the deposit.  
GAGs are unbranched heteropolysaccharides that are composed of repeating 
disaccharide units [5, 41, 42].  There are five types of GAGs which include 
heparin/heparan sulfate, chondroitin sulfate, dermatan sulfate, hyaluronan and keratan 
sulfate (See Figure 1.5; Keratan sulfate is not pictured because, unlike the others, it is 
not made with uronate).  Of these, heparan sulfate GAG, which is structurally similar to 
heparin, is ubiquitously associated with amyloid deposits in the form of the perlecan 
proteoglycan.  The role of heparan sulfate (HS) in amyloidogenesis has been widely 
investigated.  In the case of AA amyloidosis, serum amyloid A protein, the precursor 
protein to the disease, has a HS binding-domain within its sequence which allows for 
direct interaction with GAGs on cell surfaces.  In addition, as the deposition of AA 
amyloid increases the quantity of HS increases in parallel in a mouse model of the 
disease [5]. 
Circular dichroism analysis of amyloid precursor proteins, Aβ and SAA, in the 
presence of HS revealed an increase in the β-sheet content within these proteins, 
indicating that the interaction with HS rendered them more likely to become fibrillogenic 
[5, 43-46].  This enhanced β-sheet content was only induced by HS; no other GAG that 
was examined possessed this property [5].  Studies conducted in transgenic mice that 
overexpress human heparanase further suggested the importance of HS in the  
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Figure 1.5: Structures of common glycosaminoglycans (Image adapted from [5]). 
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development of AA amyloid [47].  In this chimeric mouse, organs known to produce high 
quantities of HS, such as the liver and the kidneys, generated drastically shortened HS 
chains.  Due to the improper HS production, these organs failed to develop AA amyloid 
following induction of the disease.  Organs that were capable of producing full chain HS, 
e.g. the spleen, remained susceptible to AA amyloid as evidenced by extensive CR 
birefringence.  These studies unequivocally demonstrated the critical importance of HS 
in amyloid formation [47]. 
It is noteworthy that Lindahl and Lindahl demonstrated, by using 
chromatographic techniques, that the HS found associated with perlecan proteoglycan 
[48] in amyloid-laden liver, spleen and kidney was structurally similar, but this type of 
HS differed from that found in amyloid-free tissues [7]. This observation suggested that 
amyloid-associated HS is structurally different from the HS found in healthy tissues.  
This finding was confirmed by Smits et al. in which a phage display-derived small chain 
variable fragment (scFv), designated NS4F5, was used to show the HS heterogeneity 
between healthy and diseased tissues [49].  The anti-HS scFv specifically bound to a 
region of highly sulfated disaccharides that is commonly found in heparin but is rarely 
seen in HS [49, 50].  When NS4F5 was introduced into a murine model of AA 
amyloidosis [27], the antibody bound to the HS affiliated with amyloid-deposits and did 
not bind to the normally distributed HS throughout healthy tissue as indicated by 
microautoradiography and histological examination of the co-localization of radiolabeled 
NS4F5 in regions observed to be rich in Congo red birefringence [49].  Thus, the major 
difference between amyloid-associated HS and normal HS may be the enhanced 
sulfation pattern found in the amyloid-associated HS; the greater abundance of negative 
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charges generated by the excessive sulfation may enable amyloid-associated HS to 
recruit additional molecules and proteins [49], thereby contributing to amyloidogenesis. 
GAGs are usually found linked to a protein backbone, and this GAG:protein 
complex yields a proteoglycan (PG).  As major components of all mammalian tissues, 
PG play a vital role in mammalian physiology by acting as local regulators of tissue 
function and homeostasis as well as structural elements [51, 52].  They are expressed 
ubiquitously on all cell surfaces and are present within extracellular matrices.  It has 
been widely accepted that GAG and PG are involved in the recruitment of a range of 
proteins which typically aid in tissue remodeling during inflammatory and disease-
induced immune responses [51, 53]; additionally, GAGs bind to matrix 
metalloproteinases and their inhibitors which, together, can be sequestered by PG to 
promote enzymatic regulation following tissue injury [51, 53].  Given these properties of 
tissue PGs, the GAG associated with amyloid deposits may recruit proteins and other 
components to the amyloid which contributes to its complexity.  Immunohistochemical 
techniques have established that HS, likely linked to perlecan core protein, is the PG 
most commonly associated with amyloid deposits in man and animals [5, 26, 54].  
Heparan sulfate proteoglycans are found in all amyloid deposits and, as mentioned 
above, are structurally and electrochemically different from the HSPG contributing to 
healthy tissue physiology.  It has been suggested that these non-protein components 
undoubtedly contribute to the pathological process of fibril formation; additionally,GAGs 
should be considered a part of amyloid—not just “associated” materials [5, 55]. 
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1.2.3. Serum amyloid P component 
Another biological constituent of amyloid is the pentameric glycoprotein, serum 
amyloid P component (SAP) which is a normally, soluble, circulating plasma protein that 
is known to bind to all types of amyloid fibrils in a calcium-dependent manner (Figure 
1.6) [16, 56, 57].  The biological function of SAP is not fully understood, but it has been 
shown to avidly bind to the DNA in chromatin that has been released into extracellular 
spaces in apoptotic or necrotic conditions [58, 59].  Once bound, the SAP is able to 
stabilize and protect the DNA from degradation [59].  Additionally, reproducible 
experimental observations suggest that SAP may contribute to a host’s innate immunity 
against certain bacterial and parasitic infections [57, 59].  When mice with targeted 
deletion of the SAP gene, SAP knockout (KO) mice, were injected with lethal doses of 
smooth E. coli strain O111:B4, they were significantly more susceptible to infection than 
mice with inherent SAP.  The role of SAP in amyloidogenesis is not entirely understood, 
but studies suggest that it may be able to prevent proteolytic digestion of amyloid fibrils, 
thus, contributing to their stability in vivo [8, 16, 59, 60]. Tennet et al. studies showed 
that SAP can prevent fibril digestion in an ex vivo assay but only if SAP is bound to 
them; the addition of SAP in the presence of its specific ligands, a cyclic pyruvate 
acetal, inhibited its binding to fibrils and rendered it incapable of protecting fibrils from 
proteolysis [60].  Additionally, in vivo studies have been conducted which reveal that 
SAP KO mice have delayed and reduced AA amyloid deposition when compared to 
SAP “sufficient” mice that underwent amyloid induction [8, 61, 62].  These studies 
suggested that SAP may indeed play a role in amyloidogenesis; however, Botto et al. 
also concluded that SAP is not a requirement for amyloid formation because, when  
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Figure 1.6:  Crystal structure of serum amyloid P component. (Image taken from 
[16]). 
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given a sufficient stimulus, AA amyloid readily formed in SAP-deficient mice in the 
system as well [8, 62].  Therefore, SAP is associated with, and may provide stability to, 
all amyloid deposits. 
Certain countries, mainly in Europe, utilize the amyloid fibril-binding property of SAP 
as a method of non-invasively detecting and monitoring visceral amyloid deposits in 
patients [56, 57, 63-66].  The use of SAP as a non-invasive amyloid imaging agent will 
be discussed further in a later section.   
Recently, anti-SAP antibodies have been developed for use as a novel 
immunotherapy for systemic amyloidosis [67].  Bodin et al. reported the therapeutic 
efficacy of anti-SAP antibodies in a transgenic mouse model of AA amyloidosis which 
produces human SAP instead of mouse SAP (Notably, mouse SAP does not bind 
amyloid as well as human SAP) [67-69].  Prior to antibody administration, the mice were 
injected with (R)-1-[6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-
carboxylic acid (CPHPC), which has a high affinity for human SAP and can, thus, clear 
the majority (~ 90%) of SAP from the circulation [67, 69, 70].  Some residual SAP 
remains within the amyloid deposits, and this was the material targeted by the 
opsonizing antibody [68, 70].  Since amyloid is typically an acellular deposit with no 
surrounding indication of inflammation, the observance of cell infiltration at 24 hours 
post injection (pi) of anti-SAP antibody was noteworthy [67].  These cells stained 
strongly with antibodies to F4/80 indicating they were likely macrophages; this was not 
observed in amyloid deposits from mice that did not receive the antibody [67].  The anti-
SAP antibody treatment initiated a cellular response which resulted in nearly complete 
amyloid clearance by day 16 pi; at this point, there was evidence of restored tissue 
19 
 
architecture [67].  Given these findings, this therapeutic approach was deemed to be 
clinically relevant and has been implemented into an ongoing clinical trial 
(NCT01777243). 
 Based on the foregoing discussion, biological reagents that bind specifically the 
components of amyloid, such as the small chain variable fragment NS4F5 [71-73] and 
SAP [67] can be expected to yield novel diagnostic and potentially therapeutic agents 
for patients with amyloidosis  The research presented in this thesis will further explore 
and exploit this potential by studying a novel class of amyloid-reactive peptides. 
 
2. Clinical Manifestations 
 
2.1. Overview 
 The clinical impact of the amyloid diseases depends on the type of amyloid and 
the location of the pathological deposits.  
 
2.2. Light chain amyloidosis – AL 
 Of the human amyloidoses, light chain amyloidosis (AL), presenting as either a 
systemic or localized disease, is the most common form with an incidence of 
approximately 1 case in 100,000 per year in Western countries [17, 74, 75].  AL 
amyloidosis is a form of plasma cell dyscrasia that results in an overproduction of 
monoclonal immunoglobulin light chains (IgLCs), the precursor proteins that initiate the 
amyloid cascade for this disease.  Not all secreted monoclonal IgLCs form amyloid.  In 
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patients with multiple myeloma, a related plasma-cell dyscrasia, only 12-15% of patients 
develop amyloidosis regardless of elevated levels of free IgLCs [17].  Additionally, it has 
been stated that the presence of monoclonal free IgLC in the serum or urine of 
individuals over the age of 50 is not uncommon; however, only a minor fraction of these 
individuals will progress to develop AL amyloidosis [1, 75, 76].  Of the 2 IgLC isotypes (λ 
and κ), the λ isotype, in particular, has been shown to have greater amyloidogenic 
propensity [1, 19].  For example, two germline genes that encode for the variable region 
of lambda light chains (Vλ), the 6a and 3r germlines, contribute to 42% of cases of 
lambda IgLC-related amyloidosis, approximately ⅓ of all patients with AL [17, 75, 77, 
78].  In fact, (with singular exception, protein Jto), products of the λ6a germline gene 
have been found exclusively in AL patients and are rarely seen in the normal light chain 
repertoire [1, 19, 77, 79].  One Vλ6a amyloid-related IgLC protein, isolated from patient 
Wil, has 11 somatic mutations and was shown, by using heat and chemical denaturation 
experiments, to be less thermodynamically stable and have a faster kinetic rate of 
fibrillogenesis in vitro relative to the non-AL associated Jto protein and other λ6 proteins 
[1, 80, 81].  These studies were among the first to demonstrate an inverse correlation 
between the thermodynamic stability of a native state folding domain and the propensity 
for, and rate of, fibril formation in vitro [81].  A similar correlation using a series of Vκ4 
IgLC proteins has also been shown [82].  The fibrillogenic characteristics of Vλ6 Wil 
have been exploited in numerous in vitro studies to further elucidate the biochemical 
and biophysical factors that render IgLCs prone to fibrillogenesis [1, 77, 80].  In cases of 
AL amyloidosis, secreted free IgLCs circulate in the blood, and under certain conditions, 
i.e. when their local concentration increases, following proteolytic digestion, or after 
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other modifications of unfolding of the variable domain, they self-associate into amyloid 
fibrils.   A summary of the mechanism of AL amyloidosis, as illustrated by Blancas-Mejía 
and Ramirez-Alvarado, is shown in Figure 1.7. 
The clinical implications of AL amyloidosis depend on the organ involvement. 
Merlini estimated that approximately 25% of AL patients present with only single organ 
involvement; this particular organ would determine the prognoses for these individuals 
[17].  However, the vast majority of AL patients (~ 75%) have multiple organ 
involvement or, albeit less common, deposition of amyloid localized at a single anatomic 
site, including the brain, as a tumor-like amyloidoma [1, 83, 84].   
The site of AL deposition likely depends on numerous different environmental 
factors, e.g., localized high IgLC concentration and low pH, both of which favor the 
formation of fibrils [1, 17, 85-87].  The tissues most typically affected by AL amyloidosis 
are the kidneys, heart, spleen, gastrointestinal tract, peripheral nerves and liver [1, 17, 
88].  Gross clinical manifestations in several organs are shown in Figure 1.8.  The 
lardaceous, white material present within the kidneys is amyloid deposition (Figure 
1.8A).  The gastrointestinal tract may be affected, and if so, it can lead to internal 
bleeding (Figure 1.8B). The liver and heart, both of which are enlarged, have been 
stained with Lugol’s iodine solution; the evidence of bluish discoloration after the 
application of dilute sulfuric acid indicates regions that are rich in starchy components—
in these cases, amyloid (Figure 1.8C and 1.8D) [17, 89].   
Cardiac deposition of AL is usually observed within the myocardium as 
evidenced by thickening of the interventricular septum, and the distribution in the liver is  
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Figure 1.7: Basic mechanism of AL amyloidosis (Taken from [1]). 
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Figure 1.8: Clinical manifestations of AL amyloid in various tissues. (A) Kidney, (B) 
Gastrointestinal tract, (C) Heart, (D) Liver and (E) Spleen (All images adapted from [17] 
except the spleen which came from [89]). 
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generally localized to the space of Disse between the hepatocytes and sinusoids [17, 
89].  Amyloid deposition in the spleen often appears similar to the kidney with the 
formation of dense, white material (Figure 1.8E); typically, the area around the follicles 
is the primary region of splenic deposition, but the amyloid can infiltrate further into the 
red pulp as well. Patients with renal or cardiac AL amyloidosis have the poorest 
prognoses with a median survival of one year, or less [90-93].  This is likely due to 
dysfunction caused by the disruption of sensitive tissue architecture in these organs in 
response to small amounts of amyloid, leading to progressive organ failure, co-
morbidities and ultimately death.  Therapeutic approaches for AL amyloidosis typically 
involve targeting the amyloidogenic plasma cell clones with chemotherapy which 
reduces the production of free IgLCs; this treatment, in rare cases, has been shown to 
improve cardiac and renal function even without the resolution of amyloid deposition, 
but the approach is not curative [17, 94-96]. 
 
2.3. Transthyretin amyloidosis – ATTR 
 Certain potentially amyloidogenic proteins contain heritable (familial) mutations 
which cause the protein to be either kinetically or thermodynamically less stable than 
the native, non-mutated variant.  This is the case in patients with familial amyloid 
polyneuropathy (FAP) which is associated with the deposition of mutant transthyretin 
(TTR)—a homotetrameric protein that binds and transports thyroxine and retinol in the 
circulation [97-100].  The crystal structure of human transthyretin has been determined, 
and it includes 4 units comprising primarily beta sheets with one helix per unit (Figure 
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1.9).  Unlike AL amyloidosis, the amyloid precursor protein, TTR, is not secreted by 
plasma cells; instead, TTR is produced exclusively by the liver.  It is worth noting that, in 
addition to the familial form of ATTR, certain patients (normally > 60 years of age) 
present with a non-heritable form of the disease associated with the aggregation of 
“wild-type” protein [101].  This disease, formerly known as senile systemic amyloidosis 
(SSA), has recently been given the name wild-type TTR (wt-TTR) by the amyloidosis 
nomenclature committee which was announced at the XIVth International Symposium on 
Amyloidosis. 
More than 100 point mutations have been characterized in TTR and most result 
in destabilization of the natively folded protein and/or cause dissociation of the TTR 
tetramer [102]—the critical event that leads to formation of the unstable structural 
conformation and precedes fibril formation [99, 103-106].  ATTR is a progressive, 
eventually fatal, disease that is typically characterized by sensory, motor, and 
autonomic neuropathy in addition to cardiomyopathy; thus, with its phenotypic 
variability, the disease may be difficult for physicians to recognize and properly manage 
[107-110].  In fact, under-diagnosis and misdiagnosis is quite common in these patients, 
which results in years of inappropriate treatment and increased likelihood of irreversible 
damage to the affected tissues [111].  The genetic inheritance of TTR-FAP is autosomal 
dominant; the variant TTR protein circulates from fetal life into adulthood, but no 
amyloid forms until later in life which suggests the importance of host factors, such as 
immune surveillance, in disease progression [111-113].  The clinical manifestations of 
ATTR-FAP paint a grim picture of diverse complications including peripheral neuropathy 
which initially affects the lower limbs.  With time, numbness and discomfort make  
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Figure 1.9: Crystal structure of homotetrameric transthyretin. The structure shown 
includes all 4 units of TTR which is almost entirely made of beta sheets (PDB accession 
number: 1DVQ).  
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walking more difficult.  Some amyloid may accumulate locally which can cause carpal 
tunnel-like symptoms.  The autonomic nervous system can also be affected which leads 
to gastrointestinal complications.  Additionally, amyloid can infiltrate cardiovascular 
structures including atrial and ventricular myocardium; this causes thickening of the left 
and right ventricular walls.  In some cases, heart failure progresses due to amyloid-
associated restrictive cardiomyopathy [111, 114, 115]. 
TTR amyloidosis is the most common form of familial amyloidosis.  Some 
germline mutations that are commonly observed clinically include Val122Ile, Ile68Leu, 
Thr60Ala and Leu111Met which generally result in cardiomyopathy as the predominant 
feature, and Val30Met, the most common TTR mutation, is primarily associated with 
peripheral neuropathy [111, 116].  Due to its heritability and late onset, there are 
populations around the world associated with higher prevalence of the disease [117-
119].  For instance, in Portugal, Sweden, Japan and Brazil, the Val30Met mutation is 
predominant making this mutation the most frequently seen world-wide [120-122].  A 
region in northern Portugal is estimated to have an incidence of 1 in 538 individuals with 
the Val30Met mutation [123].  In the US African American population, the most 
commonly seen mutation is Val122Ile which has an incidence of approximately 4 
percent in this population [124, 125].   
Of the approximately 120 TTR mutations that have been characterized, only 13 
have been deemed as non-amyloidogenic [111, 114, 126]; this, as one might expect, 
results in remarkable variability in the disease presentation in these patients.  Given the 
high incidence of cases in various regions around the world, there are likely many cases 
of ATTR that are not recognized or misdiagnosed [111, 127, 128].  Knowledge of the 
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disease and detection strategies to diagnose TTR amyloidosis sooner would benefit 
patients worldwide. 
 
2.4. Reactive amyloidosis – AA 
 Amyloid that results secondary to a chronic inflammatory stimulus or infection is 
known as secondary, reactive (AA) amyloidosis [9].  As described in a seminal review 
by Röcken and Shakespeare, diseases that can cause AA amyloidosis include: 
rheumatic diseases (arthritis); idiopathic disease (sarcoidosis, Crohn’s disease and 
ulcerative colitis); inherited diseases (familial Mediterranean fever); infectious diseases 
(tuberculosis) and some malignant tumors (mesothelioma and Hodgkin’s disease) [9, 
129, 130]. 
AA amyloidosis is initiated by the production of serum amyloid protein A (SAA), 
which is the precursor of amyloidogenic protein, AA; SAA is produced principally by 
hepatocytes in the liver under the influence of certain pro-inflammatory cytokines such 
as IL-6 and TNF-α [131-133].  There are two types of SAA acute phase proteins, SAA1 
and SAA2 in humans [9].  Both types are synthesized by the liver in response to an 
acute phase inflammatory response.  During this response, the serum concentrations of 
these two proteins can reach 1-2 mg/mL which is 1000-fold higher than normal  
[9, 132, 133].  Once synthesized, 80% of SAA1 and SAA2 proteins bind to lipoproteins 
with approximately 90% complexing with high-density lipoprotein (HDL). The SAA 
bound to HDL is trafficked through the blood prior to uptake by certain tissues—
predominantly the spleen, liver or kidneys—where there are macrophages known to 
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express receptors for SAA-HDL [9, 134-136].  The cellular compartment for the 
displacement of SAA from HDL following receptor-mediated endocytosis is unknown, 
but data suggests that it may occur in the late endosome as was demonstrated with 
SAA conjugated with a fluorophore and monitored with scanning confocal microscopy 
[135].  In response to the acidic environment, SAA leaves the HDL particle and 
undergoes proteolysis to form AA fragments which are typically N-terminal fragments 
spanning the first 66 – 76 amino acid residues of the 122 amino acid protein [137].  The 
pathogenetic pathway of AA amyloidosis was summarized by Röcken and Shakespeare 
(Figure 1.10) [9]. 
In the acute inflammatory state, SAA (and perhaps any AA amyloid that forms) is 
degraded, but in individuals with chronic inflammatory disorders, fragments of SAA 
persist, undergo fibrillogenesis and lead to amyloid deposition in a wide variety of 
tissues [138].  Interestingly, the proteolytic digestion of SAA in vivo resulted in products 
of varied amino acid length depending on which protease was used [139-141].  It has 
been postulated that certain cleavage sites are protective and, once cleaved, render the 
products incapable of forming amyloid fibrils [141, 142].  More specifically stated, 
cleavage at the N-terminal of SAA has been shown to prevent amyloid formation while 
C-terminal cleavage can yield potentially amyloidogenic protein fragments [9, 143].  
Figure 1.11 illustrates various possible outcomes of SAA proteolysis. 
The deposition of AA amyloid in man is thought to initially occur in the spleen 
(mediated by the perifollicular macrophages), followed by the liver and the kidneys 
before involving the vasculature and other visceral organs [9].  The most prominent 
clinical feature of the disease is renal involvement (> 90% of patients), which results in  
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Figure 1.10: Mechanism of AA amyloidogenesis.  This diagram illustrates the 
biological processes involved in the development of reactive amyloidosis beginning with 
the necessary inflammatory stimulus and ending with fibrillogenesis (Taken from [9]). 
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Figure 1.11: Possible outcomes of SAA proteolysis leading to fibril formation.  (A) 
Site of SAA cleavage dictates amyloidogenic potential. The pathogenic SAA fragments 
that have been identified contain intact N-termini which suggests that cleavage in this 
region may be protective against fibril formation [143].  (B) Cleavage of SAA post 
fibrillogenesis.  This outcome demonstrates that cleavage at this point in the pathogenic 
mechanism of fibrillogenesis may rid deposits of redundant peptides [144-146].  (C) 
Cleavage of SAA during the formation of fibrils.  It is thought that cleavage during fibril 
assembly may assist in the process because it facilitates the removal of protein regions 
that might be hindering fibril formation [9].  (D) Cleavage after fibril formation.  After 
fibrils have assembled, cleavage may have no effect, or it could result in complete 
degradation of the protein into amino acids [9] (Image taken from [9]).  
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proteinuria [147].  Cardiac AA amyloidosis, albeit rare in humans (~ 2% of patients), can 
disrupt tissue architecture and lead to restrictive cardiomyopathy and organ failure 
[148].  Gastrointestinal involvement, which presents as diarrhea and malabsorption, is 
also observed in ~ 20% of patients [149].  AA amyloidosis, unlike the other types of 
amyloidosis previously discussed, can be reversed if the serum concentration of SAA is 
substantially decreased, i.e. to < 10 µg/mL.  Thus, if the underlying inflammatory cause 
of increased SAA levels is treated, the progression of AA amyloidosis can be delayed, 
halted, or even reversed [9, 150, 151].  While the incidence in man is typically low, 
experimental animal models of AA amyloidosis are one of the primary models used for 
researching amyloid diseases.  
 
 
2.5. Other types of amyloidosis 
In addition to the major forms of visceral amyloidosis mentioned above, there are 
other diseases associated with amyloid formation (see Table 1.1). For patients that 
must undergo long-term kidney dialysis, usually for 10 years or longer, an accumulation 
of β2-microglobulin (β2m) leads to dialysis-related amyloidosis (DRA) [1, 152].  Under 
normal physiological conditions, β2m is synthesized by all nucleated cells and 
associates with major histocompatibility complex class I (MHC I) which assists in the 
binding and presentation of short peptide sequences to appropriate CD8+ T-
lymphocytes as part of an immune response [152-154].  The average life-time of MHC 
class I molecules varies from seconds to days [155, 156], but at the time of their 
degradation, the β2m component is released into circulation [157].  Nearly all of the β2m 
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is filtered through the kidney glomeruli and then reabsorbed by the proximal tubular 
cells where endocytosed β2m is degraded [152, 158, 159].  Consequently, less than 
0.1% of the filtered β2m appears in the urine [160].  In patients that must undergo long 
term dialysis, the glomerular filtration rate is hindered due to renal dysfunction, and as a 
result, the serum concentration of β2m remains elevated.  The dialysis membrane 
molecular weight cut off is near or below the molecular weight of β2m; thus, the protein 
accumulates in vivo despite the renal filtration assistance of dialysis [152].  This 
sustained elevated concentration of β2m (60-fold higher than healthy individuals) 
ultimately leads to DRA which tends to target cartilage associated with osteoarticular 
tissues leading to bone destruction (See Figure 1.12) [161-163].  
Another amyloid-associated disease is type II diabetes (T2D) in which there is an 
accumulation of the amyloidotic islet amyloid polypeptide (AIAPP; also known as 
amylin) [164].  The deposition of AIAPP solely in the Islets of Langerhans in the 
pancreas is a pathological characteristic of T2D [31].  Human IAPP (hIAPP) is stored in 
the β-cell secretory granules, in association with insulin [165] and is released in 
response to events that lead to insulin secretion [166, 167].  While hIAPP it is a highly 
fibrillogenic protein, in non-diabetic individuals, it is normally soluble and unfolded in its 
native state [164].  Given its propensity to form fibrils, hIAPP must be protected in non-
diabetic individuals in order to circumvent inevitable aggregation [164].  Association with 
insulin is thought to be the primary factor in the inhibition of hIAPP fibril formation as 
evidenced by several studies demonstrating the inhibitory effect of insulin on 
fibrillogenesis [164, 168-172].  Thus, the insulin dependency of individuals with T2D 
may predispose them to conditions in which IAPP is not fully protected from  
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Figure 1.12:  Mechanism of β2m pathogenicity leading to dialysis-related 
amyloidosis.  This illustration demonstrates how individuals on dialysis can develop an 
over-accumulation of β2m which aggregates and forms amyloid deposits.  The amyloid 
leads to the destruction of joints and osteoarticular tissues (ITaken from [161]). 
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aggregation.  It has been determined that AIAPP in the islets is not the cause of T2D, 
but it is widely accepted that amyloid formation leads to pancreatic β-cell dysfunction 
and cell death—a manifestation that leads to the loss of islet β-cell mass and insulin 
deficiency [31, 33, 173-175].  The normal physiological roles of IAPP have not been fully 
elucidated, but they may include controlling gastric emptying, maintaining glucose 
homeostasis, suppressing glucagon release and controlling satiety [31, 164, 176, 177].  
Studies to determine whether or not the deposition of amyloid leads to islet β-cell death 
have been conducted.  The data indicate that it is the oligomeric intermediate species 
that form prior to fibril elongation that are more cytotoxic in vitro [174, 178].  The 
addition of fully formed AIAPP fibrils to islet cells in culture did not induce apoptosis, but 
there was evidence of amyloid on the viable cells; in contrast, addition of an aqueous 
solution of hIAPP to islet cells resulted in apoptosis, and electron microscopy revealed 
the presence of nonfibrillar IAPP oligomeric species that had disrupted the cell 
membranes and permeated the cells [33, 174].  These data suggest that oligomers, 
formed prior to, but on the pathway to, fibril formation are more cytotoxic than the fibrils 
themselves; this is analogous to the pathology seen in Alzheimer’s patients [10, 37, 
179].  Several hypotheses have been offered to explain why islet amyloid forms in 
individuals with T2D, the simplest of which is that there is an increased production of 
IAPP as a result of increased secretory demand on the β-cell due to insulin resistance 
[177, 180].  This overproduction may lead to intracellular IAPP aggregation and 
extracellular amyloidogenesis [181, 182] as is the case with elevated SAA yielding AA 
amyloid deposition (see Figure 1.10).  Additionally, Montane posits that there may be 
defects in the β-cell handling of IAPP due to impaired β-cell function associated with 
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T2D [177, 183].  More specifically, the granules within β-cells—where IAPP is produced 
and harbored until secretion—may not possess mature functionality under secretory 
stress.  Indeed, the pH of β-cell granules under secretory stress is elevated which 
favors aggregation [177, 184].  While the mechanisms of AIAPP fibrillogenesis are not 
fully understood, two recent hypotheses have been outlined in the literature (Figure 
1.13A and 1.13B); in addition to these, a compilation of “proposed mechanisms of IAPP-
induced toxicity during amyloid formation” is also presented (Figure 1.13C) [31, 185-
192].  Regardless of the pathway, AIAPP is associated with β-cell loss in individuals 
with T2D.  Early detection of amyloid deposition could benefit T2D patients by 
implementing therapies sooner and sparing excessive loss of β-cells; thus, it may be of 
clinical import to develop non-invasive imaging strategies to detect and monitor AIAPP 
in patients.  
 Perhaps the most well recognized amyloid-associated disorder is Alzheimer’s 
disease (AD).  The amyloid pathology with AD is localized to the brain and cerebral 
vasculature and arises from the misfolding of the Aβ peptide—arising from the 
proteolytic cleavage of the amyloid precursor protein (APP) [32, 179].  Under normal 
conditions, Aβ peptide cleaved by certain secretase enzymes remains soluble, is 
released into the cytosol and plays a role in nuclear signaling and induction of 
transcription and gene expression [193, 194]; however, in patients with AD, the peptide 
fragments [e.g. Aβ(1-40) or Aβ(1-42); [195, 196]]  adopt conformations that are rich in β-
sheets (Figure 1.14A) rendering them more prone to aggregate and form extracellular 
amyloid plaques in the brain and vasculature [32, 197-199].  An example of amyloid 
plaques in brain tissue can be seen in Figure 1.14B; these plaques have been stained  
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Figure 1.13:  Proposed methods of AIAPP toxicity leading to β-cell death and 
amyloid formation associated with type 2 diabetes.  (A)  Intracellular amyloid leads 
to apoptosis forming an amyloid seed propagating extracellular deposition [adapted 
from [164]]. (B)  Metabolic stress leads to β-cell dysfunction causing amyloid deposition 
[adapted from [177]].  (C)  List of other possible mechanisms leading to AIAPP-induced 
cellular toxicity (compiled from [31]).  
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Figure 1.14:  Crystal structure of Aβ(1-42) peptide fragment and demonstration of 
the fragment within amyloid plaques of a sample of AD brain tissue.  (A) Crystal 
structure of the β-sheet rich, fibrillogenic Aβ(1-42) peptide (PDB accession number 
2BEG).  (B) Immunohistochemistry of AD brain tissue with anti-Aβ(1-42) antibody.  The 
tissue specimen demonstrates the presence of Aβ(1-42) peptide within amyloid plaques 
(arrows) (Image adapted from [200]). 
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with an anti-Aβ(1-42) antibody indicating the presence of this fibrillogenic peptide within 
the AD amyloid deposits.  There are two types of AD; one is a rare hereditary condition 
(< 3% of cases), in which APP is mutated leading to altered metabolism of the protein 
and an increase in Aβ peptide concentration.  The other form of AD is more commonly 
seen; it likely involves the sporadic overproduction of aggregation-prone Aβ peptides 
and/or the reduced degradation and clearance of these species [32, 34].  According to 
the amyloid cascade hypothesis of AD, which suggests that AD is a result of Aβ amyloid 
accumulation in the brain, the formation of β sheet-rich Aβ peptide and fibrillogenesis 
are the first events that start the pathological changes which lead to dementia [201, 
202].  Much focus has been directed toward understanding the pathogenesis of AD due 
to its devastating clinical and socio-economic impact.  It was estimated that “in 2012, 
more than 15 million family members and other unpaid caregivers provided an 
estimated 17.5 billion hours of care to people with AD and other dementias—a 
contribution valued at more than $216 billion” [203].  Investigation of the disease has 
now led many researchers to believe that it is the oligomeric species, which result from 
the association of multiple improperly folded Aβ peptides, that are more toxic to 
microglial cells than amyloid plaques [38] and are the underlying causative agent of the 
disease [36, 39, 40].  Given this, many therapeutic approaches involving the 
development of monoclonal antibodies targeted towards the Aβ peptide monomer in 
addition to a variety of Aβ dimers and oligomers produced prior to amyloid deposition 
have been investigated [38, 204]; however, treatment of the disease still remains a 
challenge [38]. 
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 Prion diseases, also known as transmissible spongiform encephalopathies 
(TSE), are fatal neurodegenerative disorders of the central nervous system (CNS) and 
are either inherited, arise sporadically or are acquired from an infection [205-207].  
Several prion diseases are known to affect humans while others are typically seen in 
other mammals.  The most common human TSE are Creutzfeldt-Jakob disease, 
Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia disease [208].  A 
less common TSE, one of the few acquired human diseases that make up 5 percent of 
all TSE cases, is called Kuru which was found associated with villages in Papua New 
Guinea [209].  The clinical features of TSE include widespread neuronal loss, 
astrocytosis, spongiform changes within the gray matter and amyloid plaque deposition 
in the blood vessels of the central nervous system which, in humans, presents with loss 
of motor coordination, neurophysiological deficits and dementia due to synaptic 
dysfunction [207, 210-213].  The pathogenicity of these diseases initiates with the 
misfolding of the inherently circular prion protein (PrPc)—a glycosylphosphatidylinositol 
(GPI)-anchored cell surface glycoprotein with no certain function that is abundantly 
expressed by neurons in the CNS [214-216].  The pathogenic form of this protein 
(PrPSc) is rich in β-sheet which increases its likelihood to associate with other misfolded 
prion proteins resulting in the deposition of fibrillar protein aggregates - amyloid [217].  
Numerous mutations in the PrPc gene account for the inheritable forms of these 
diseases, and it is thought that the transformation of the protein into the PrPSc isoform 
occurs spontaneously under the influence of the mutation [217, 218].  As with other 
neurological forms of protein-misfolding diseases, the intermediate species that develop 
as the protein progresses to amyloid plaque deposition may be the cytotoxic agents that 
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result in synaptic dysfunction and neuronal loss [217, 219, 220].  Perhaps the most 
remarkable feature of TSE was the identification that it was a “transmissible” condition – 
indeed, it was originally thought that the pathologic aggregates that could induce 
pathology in another human carried some sort of biological information akin to DNA.  
However, this phenomenon has since been explained by the ability of amyloid fibrils to 
seed and induce amyloid formation due to the presence of a preformed template (the 
seed or nucleus).  It is now widely accepted that seeding with preformed PrPSc fibrils is 
the underlying mechanism for transmissibility.  This observation has led to the finding 
that other forms of amyloidosis are also transmissible both naturally and experimentally 
– AA in goats [28] and in mice [221, 222], ApoA2c in mice [30] and Aβ in mice [223]. 
 
2.6. Non-human amyloid-associated diseases 
 Protein-misfolding diseases are not restricted to humans; they can affect other 
mammals as well [206, 207].  As previously stated, certain TSE are pathogenic in 
animals; Scrapie which affects goats and sheep, bovine spongiform encephalopathy 
(BSE) which is also known as “mad cow” disease [224] and chronic wasting disease 
(CWD) which affects both deer and elk are the most common [225]. 
 In addition to TSE, animals can also develop AA amyloidosis which likely 
progresses, as it is seen in many cases in humans, coincident with chronic 
inflammation.  Tissue samples from several different animals including, but not limited 
to, dogs, cats, ducks, guinea pigs, cheetahs, tigers, gazelles, rabbits, bats, chickens 
and hamsters have demonstrated presence of the disease [9, 226-228].  The 
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mechanism by which the amyloid forms in these animals is thought to follow the same 
progression as that seen in Figure 1.10—the proposed mechanism for human AA 
amyloidosis. 
 The islet amyloid polypeptide that is associated with T2D is present in many 
animals, but it is not always an amyloidogenic protein [229].  In addition to humans, cats 
and monkeys contain versions of IAPP with mutations in the central region of the protein 
that make them more likely to misfold leading to amyloid deposition and T2D [164, 229]; 
the appearance of a proline residue in the sequence of rat and pig IAPP renders these 
proteins non-amyloidogenic [229] unless, in the case of rats, they are genetically altered 
to express human IAPP [230-232].  Studies have been conducted comparing the IAPP 
homology between cats and humans which reveal that cat IAPP is not as amyloidogenic 
as human IAPP [233], but both can misfold and lead to AIAPP amyloidosis. 
 Given that there are naturally occurring animal models of protein misfolding 
disorders including TSE’s, AA amyloidosis and T2D, the use of these disease models 
provides a tractable in vivo system in which amyloid-seeking agents can be evaluated 
for efficacy.  These disease model systems are invaluable to investigators who are 
developing diagnostic and therapeutic agents for the treatment of amyloidosis.  They 
provide important test beds prior to seeking FDA approval of new drugs before 
translation into human clinical studies.   
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3. Diagnosis 
 
3.1. Pathobiology 
 Amyloidosis is considered an orphan disease (not including AD or T2D), which 
accounts for approximately one per thousand deaths in developed countries [8]; 
however, since it is not a clinical condition that physicians commonly see and typically 
involves multiple tissues in the disease presentation, missed or delayed diagnoses often 
occur [8].  While there is a considerable challenge in making an accurate diagnosis of 
any type of amyloidosis, it is important to strive for the development of tools, such as 
imaging agents, to foster earlier and more complete diagnoses; appropriate treatment 
plans being implemented sooner could provide better prognoses for affected individuals. 
 The realm of diagnostic tools for amyloidosis has somewhat expanded over the 
last decade, but the most widely used method for recognition of the pathology relies 
heavily on the oldest technique, i.e. histological examination of biopsied tissues [1, 8, 
17].  Unlike other protein aggregates, the fibril composition of amyloid enables its 
binding to Congo red (CR)—a histological dye that, according to recent work, utilizes 
both hydrophobic and electrostatic interactions to bind parallel to fibrils that contain β-
strands along the edge or in the middle of a β-sheet [21, 234].  A proposed localization 
of Congo red within amyloid fibrils was shown in Figure 1.3B.  When viewed 
microscopically with cross-polarized light, the fibrils show green birefringence which is 
indicative of amyloid deposition within the tissue (see Figure 1.3A).  Examination of CR-
stained tissues has been the gold standard for amyloid detection for more than 50 
years, but this technique has its challenges and limitations; it requires proper application 
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of the stain along with other chemicals and skilled interpretation for accurate results [1].  
Additionally, the test requires adequate amounts of amyloid and sufficiently thick tissue 
sections—without these, the sensitivity of the test falters [8].  According to Pepys, the 
British National Health Service National Amyloidosis Center sees more than 1100 
patients with known or suspected amyloidosis annually; thus, they have reviewed 
thousands of CR biopsies.  He states that they continue to see both false positive and 
false negative CR diagnoses from many hospitals around the world which further 
elucidates the challenges that physicians face when diagnosing the disease [8].  
Experiments have shown that CR can bind many “native proteins including cellular prion 
protein [235], elastin [236], RNA polymerase [237] and human prostatic phosphatase 
[238]” [234]. In addition, CR lacks secondary structure specificity which may suggest an 
explanation for the false-positive results that are commonly obtained [234].  While 
observing positive CR-stained tissues may provide a diagnosis of amyloid, the type of 
amyloid cannot be determined without further testing.  
 Once it has been detected, classification of the amyloid is a necessity for each 
individual patient so that the origin and possible pathogenesis of the amyloid disease 
can be recognized and appropriate therapeutic regimens implemented [239-243].  
There are different approaches to amyloid typing including the macro- and micro-
extraction of the amyloid protein from tissues and immunohistochemical analysis of 
formalin-fixed paraffin-embedded tissue samples [241]. The former has been performed 
on autopsy-derived amyloid-laden tissues by multiple centrifugations as described by 
Pras et al. [244].  This macroextraction method of separation and purification yielded 
approximately 1100 mg of amyloid protein within the resultant supernatants from 20 g of 
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amyloid-laden tissue which differed from the normal tissue controls in which no 
detectable protein was recovered by adhering to the same protocol [244]. The 
microextraction of amyloid proteins has also been performed on biopsy-derived tissue 
specimens [245-247] and formalin-fixed tissues [248]; once extracted, the derived 
proteins can be identified by amino acid sequencing or mass spectrometry [249, 250].  
In addition to protein extraction and sequencing, amyloid classification can be 
determined with immunohistochemical techniques in which amyloid-specific antibodies 
to some of the most common amyloid proteins (e.g. AA, ALκ, ALλ, ATTR) are applied to 
fixed tissues [251-256].  This approach is relatively inexpensive [241], but it has 
limitations including the lack of appropriate antisera to conduct the studies [254].  
Murphy et al. explains that “commercially available reagents are prepared against the 
native form of the amyloidogenic precursor” and may, therefore, not be suitable for 
amyloid binding [254].  As was previously demonstrated in the proposed mechanism of 
nucleation-dependent fibrillogenesis (see Figure 1.4), the process introduces 
conformational changes to the precursor protein.  Due to the lack of standardization of 
the reagents used for amyloid typing and the lack of regularization of the processing of 
the tissue sample, results from immunohistochemistical analysis may be inconclusive; 
however, if the appropriate antibody is available and stains amyloid within the sample 
strongly and uniformly, it is likely diagnostic [241]. 
 Given that these methods of amyloid characterization may render inconclusive 
results, Murphy et al. explored the use of mass spectrometry to identify amyloid type 
within biopsy samples and fat aspirates [254].  The application of tandem mass 
spectrometry (MS/MS) to various samples of amyloid-containing biopsies or fat 
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aspirates that had previously been characterized (e.g. ALλ, ALκ, AA, ATTR) yielded 
fragmentation indicative of each of the amyloid types studied; a limitation to this 
procedure is the amount of material needed for MS/MS analysis—additional biopsy 
samples were often necessary [254]. 
 Whether it be due to: the untrained observer’s inability to detect scant amyloid 
birefringence; the difficulty associated with discerning between amyloid-associated 
congophilic material and native tissue components with cross-polarized birefringence 
when attempting amyloid detection; the lack of appropriate sample preparation or 
amyloid stains for amyloid characterization; or the limited availability of material 
necessary for MS/MS amyloid typing, there is an extreme challenge associated with 
detecting and characterizing amyloid deposition by these methods.  Therefore, other 
techniques need to be developed and validated. 
 
3.2. Imaging 
 In most instances, patients with amyloidosis begin their clinical path by seeing 
physicians who do not specialize in the treatment of the disease (most often 
oncologists, cardiologists and nephrologists).  Consequently, accurate diagnosis of 
amyloidosis can take more than 18 months and usually requires consultation at one of 
the amyloid treatment centers such as the Mayo Clinic, Rochester.  Therefore, more 
effective approaches need to be implemented for routine detection and diagnosis of 
amyloid in the general clinical arena.  To this end, dedicated efforts have been made in 
the realm of medical imaging for the facile detection of amyloid diseases.  Advances in 
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molecular imaging can help provide these patients with a non-invasive alternative for 
disease detection—prior to advances in the field of imaging, biopsy-derived histological 
test results were the only means of detecting the disease. Some of the imaging 
modalities that have been utilized for the detection of amyloid include magnetic 
resonance imaging (MRI), ultrasound (US), optical imaging (OI), computed tomography 
(CT), positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). 
3.2.1. Modalities 
CT and MRI—anatomical imaging modalities 
While anatomical imaging such as CT, MRI and US should not be used alone as 
diagnostic tools for amyloidosis, they can provide valuable information about the 
anatomic consequences of amyloid deposition.  For instance, abnormalities present in 
CT/MRI/US can offer guidance as to where biopsies should be taken if amyloid disease 
is suspected [257-259].  Additionally, the presence of abnormalities can help discern the 
type of amyloid disease.  If, upon CT examination, pulmonary deposits are detected, 
there is greater likelihood that the amyloid disease in question is AL and not ATTR or 
AA because, unlike AL, these amyloidoses rarely affect the lungs [260]. 
CT is an imaging modality capable of visualizing the anatomical characteristics of 
an individual (spatial resolution of clinical scanners is 0.5 – 1.0 mm) without having to 
collapse a 3D structure into two dimensional images like conventional radiography [261, 
262].  The principles behind this imaging system rely on the ability of X-ray beams to 
physically traverse the cross-section of an object, be attenuated by the object and then 
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be detected [263].  Multiple projections are necessary to reconstruct a representative 
3D image.  As the X-rays travel through diverse types of material, they become variably 
attenuated; for instance, water, bone, muscle and air attenuate X-rays differently.  Each 
attenuation is assigned a linear attenuation coefficient (μ) which is a measurement 
reflecting the degree to which the X-ray intensity was reduced by a certain material. 
These values are used in the formula below to determine the CT number, known as the 
Hounsfield unit (HU), associated with the materials detected in the CT acquisition [264]: 
𝐶𝑇 𝑛𝑢𝑚𝑏𝑒𝑟 =  (𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟) ∕ 𝜇𝑤𝑎𝑡𝑒𝑟 
The assigned CT numbers represent a range of gray values which are used to 
generate an image (i.e. the HU of water is 0 and air is -1000).  The materials of lowest 
density appear darker; air will look black in the image.  More dense materials will appear 
lighter with bone looking white in the image (Figure 1.15).  In some clinical cases, only 
certain regions of patients are of interest, and to efficiently visualize those regions, the 
HU window can be set to only display a particular range of values—alteration of the 
window width.  This is an advantage of CT imaging and image analysis, as compared to 
MRI or 2D X-ray, because it can improve lesion detection and diagnostic accuracy [265-
267].  Additionally, CT imaging is often much faster than MRI imaging which is 
beneficial for the patients and their level of comfort.  While CT provides much more 
information than X-ray radiography, this imaging modality exposes individuals to more 
radiation [268].  To address this concern, faster multidetector CT scanners with the 
automatic exposure control have been implemented into many systems [268, 269]. 
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Figure 1.15:  CT image demonstrating visualization of air and bone in a patient.  
Air within the lungs of this individual is black which is assigned the HU value of -1000 
(red arrow); bone, a more dense material, appears white which has the HU value of 
1000 (green arrow).  This is an unpublished image generated in Dr. Wall’s lab at the 
University of Tennessee Medical Center, Knoxville, TN. 
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MRI is a non-invasive method for examining the tissue architecture that does not 
rely on an internal or external source of radiation.  This imaging modality takes 
advantage of the magnetic properties within the body’s composition, especially those 
associated with the nuclei of hydrogen atoms.  With the Earth’s magnetic field, atoms 
align, but once the body is subjected to the presence of another magnetic field, like that 
within an MRI system, the atoms move to align with the new magnet—this can be 
manipulated and measured to form an image.  MRI can provide exquisite soft tissue 
imaging and is advantageous in that it does not require much energy absorbance.  MRI 
has been used to image patients with amyloidosis, but most often, the anatomical 
imaging reveals tissue abnormalities that may have resulted due to amyloid deposition, 
not the presence of amyloid itself.  The observed abnormalities, however, can guide the 
biopsy which will confirm, after histological examination, if amyloid is present in the 
tissue abnormality. Typical amyloid-associated MRI findings include myocardial and 
interventricular thickening associated with cardiac amyloidosis in patients with AL or 
ATTR [270, 271].  Additionally, patients with ATTR occasionally undergo MRI analysis 
to visualize neuronal amyloid deposits around the leptomeninges and brain stem [272].  
In rare cases, patients with localized amyloidosis develop focal deposits known as 
amyloidomas; this pathology can be well visualized with MRI [273, 274].  When 
investigating cardiac abnormalities that are possibly attributed to amyloid deposition, 
post-contrast MRI has been shown to display “global, subendocardial late gadolinium 
enhancement” which is characteristic of cardiac amyloid, but this abnormality can be 
challenging to detect when amyloid has infiltrated the interstitium or when arrhythmias 
degrade the quality of the image [275-278].  Ultimately, MRI can assist in the 
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visualization of pathological sequelae arising from amyloid deposition, can assist in the 
detection of rare, focal amyloidomas and can display contrast-enhanced abnormalities 
indicative of cardiac amyloidosis.  However, it cannot provide information about the 
whole body distribution of amyloid itself. 
PET Imaging 
 In recent years, much effort has been directed toward the implementation of 
molecular imaging technologies for the quantitative detection of amyloid in patients.  
The goal of these protocols is to create images that capture the in vivo whole body 
distribution of the amyloid, to assess the molecular-based characteristics of diseases 
and to monitor therapeutic responses in both humans and animals [261].  PET imaging 
involves the detection of positron-emitting radionuclides; positrons are particles that 
have the same mass as electrons but the opposite charge and are emitted by proton-
rich nuclei such as Fluorine-18 (18F), Carbon-11 (11C) and Iodine-124 (124I) [261, 279].  
These radionuclides are conjugated to tracers that are injected into or inhaled by the 
patient, and it is the distribution of the radiotracer that is imaged with PET.  The signal 
that is detected with PET imaging is generated by the annihilation of a positron/electron 
pair which usually emits a 511 keV coincident gamma photon pair in opposite directions 
at 180° [261].  The line that could be drawn to connect the two detected gamma 
photons is called the line of response (LOR).  Numerous photon pairs are detected by 
the 511 keV-sensitive crystal scintillation detectors which are typically positioned 
cylindrically around the imaged subject.  The scintillation material is able to emit visible 
light when it absorbs energy from charged gamma rays [280-282].  The positron and 
electron do not always annihilate and create a 180° coincident event, also known as a 
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true event; some annihilations result in skewed emissions called scatter events or 
random events (Figure 1.16).  Scatter events arise when the emitted photons, either 
both or just one, undergo Compton scattering—a photon encounters an electron 
causing the electron’s energy to be released and the photon’s direction to be changed 
[283]—prior to their detection.  Thus, the lack of 180° opposing deflections does not 
generate a LOR that accurately pinpoints the origin of emission (Figure 1.16A).  
Random events occur when photons from distinct nuclei are generated and detected 
simultaneously, but the LOR between the two detections is not indicative of the origin 
from which either photon was emitted (Figure 1.16B).  For an image to be processed, 
the detected photon energy which has been transformed into light energy by scintillators 
must be converted into electronic signals; this is accomplished with photomultiplier 
tubes (PMT) [280].  The sensitivity of PET imaging, which is greater than that of 
SPECT, is reliant upon both geometric and intrinsic detection efficiencies; the former 
pertains to the placement of detectors as close to the subject as possible to lessen the 
likelihood that any photons are emitted and not captured.  The latter pertains to the 
material used within the detectors—thicker, denser materials will be more likely to stop 
511 keV gamma rays, allowing for their detection.  The use of PET imaging provides a 
unique capability for in vivo monitoring of the biodistribution of radiolabeled materials in 
real time—an acquisition known as dynamic PET imaging.  Analysis of dynamic data 
can generate time activity curves (TAC) which can elucidate the biokinetic properties of 
radiotracers in the subject.  The high sensitivity of PET imaging makes it a desirable 
modality for disease detection in both preclinical and clinical studies, but it has 
limitations.  The noncolinearity of annihilation photons and the range of positron  
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Figure 1.16:  Types of coincidence events associated with PET photons (Image 
taken from [261]). 
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emissions hinder the system’s ability to distinguish and detect subtle differences in 
molecular signals from miniscule structures (generally < 4 mm), known as the spatial 
resolution, of PET [261, 284].  Recent advances in Alzheimer’s disease molecular 
imaging utilize PET to image the radiotracer, Amyvid™, in amyloid-laden regions of the 
brain that may be indicative of the disease (which will be discussed in a later section) 
[285]. 
SPECT Imaging 
In addition to PET molecular imaging, SPECT imaging is also used to non-
invasively detect diseases and clinical manifestations.  SPECT is the most common 
molecular imaging modality in the clinic and requires the use of an injectable tracer 
which has been radiolabeled with isotopes that emit gamma ray photons.  Some of the 
most commonly used gamma ray-emitting SPECT radionuclides are iodine-125 (125I), 
iodine-123 (123I) and technetium-99m (99mTc).  Unlike PET imaging, where detection of 
the radionuclide is dependent upon the formation of a LOR generated from two high 
energy positrons through electric collimation, with SPECT, the one photon emission 
associated with each event must be detected through what is termed physical or 
geometric collimation [261, 284].  The collimators within a SPECT imaging system are 
usually made of a dense material such as tungsten or lead.  They contain a 
configuration of pinholes through which photons that will contribute to the image enter; 
those that do not go through the pinholes will not be detected [261].  The pinholes, in 
combination with a position-sensitive detector, determine the LOR affiliated with photon 
emissions in SPECT systems.  Much like that seen with PET systems, not all events 
that are recorded by the camera are true events that should contribute to the image; 
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events are considered true if the LOR that is drawn between the point of interaction with 
the detector and the photon emission location passes through a collimator pinhole [286].  
Scatter events occur when photons enter the pinholes from skewed directions thus 
creating false events.  With both PET and SPECT imaging modalities, scattered 
photons generate what is referred to as “background noise” within the image—this 
“statistical uncertainty” creates a haze and reduces the image’s contrast resolution [261, 
287, 288].  The data from SPECT systems are acquired much like that seen in PET 
systems, but, instead of the detector elements being placed in a ring around the imaged 
subject, the detectors are on plates (one plate is required, but two plates increase the 
sensitivity of the system) which rotate around the individuals to generate 3D images.  
Pre-clinical and clinical SPECT imaging systems offer different advantageous properties 
as compared to PET.  These include a range of radionuclides with longer physical half-
lives than those routinely used in PET protocols, which may better estimate the 
biokinetics of radiotracers, and the ability to perform multiple energy studies 
simultaneously [280].  The latter refers to studies in which more than one radiotracer 
can be introduced into the imaged subject; the tracers are individually labeled with 
different radionuclides (i.e. 123I with 99mTc or 125I), and since the energies associated with 
these radionuclides do not overlap (99mTc has an energy of 140 keV and 125I has an 
energy of 20-35 keV), the two tracers can be discerned within the individual 
simultaneously [289].  This capability provides a means of comparing two imaging 
agents, perhaps the gold standard agent and a novel agent, under the same 
physiological conditions within the same individual; it also allows visualization of two 
different physical processes, such as the measurement of blood flow, metabolic rates or 
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protein binding, amidst the detection of other characteristics simultaneously [289-294].  
The ability to detect and acquire multiple measurements within an individual subject with 
SPECT imaging circumvents the questionable reproducibility of in vivo conditions that 
arise with sequential imaging acquisitions when concurrent dual energy studies are not 
feasible.  For example, an individual, amyloid-laden mouse which was simultaneously 
administered the gold standard amyloid imaging agent, SAP, radiolabeled with 125I, and 
an amyloidophilic, synthetic peptide, p5, radiolabeled with 99mTc, can be seen in Figure 
1.17 [293].  This study illustrated a direct comparison of two radiotracers—insight into 
the relative efficacy of either (i.e. comparative effectiveness) can be ascertained with 
SPECT dual energy imaging in a single subject. 
Dual Modality Imaging 
 In many instances, CT imaging is informative as a singular modality; however, 
recently, CT is used in conjunction with PET and SPECT to provide enhanced 
capabilities.  This approach yields images that provide anatomical reference to the 
radioactivity introduced by the PET or SPECT imaging agent.  A review by Schöder et 
al. on the subject refers to this system as “an imaging technology that combines high-
quality PET and CT in a single device and provides simultaneous structural and 
biochemical information under nearly identical conditions” [262].  Without an anatomic 
frame of reference, the precise location of radiotracers in vivo is not evident, and thus, 
the image may be misinterpreted.  Studies have been conducted to assess the value of 
the dual modality system in which individual modalities and combined PET/CT 
modalities were used to detect pathology; results in each study show that the use of 
PET/CT enhanced detection of disease [262, 295, 296].  In addition to the benefit of  
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Figure 1.17: Dual energy SPECT imaging with 125I-SAP and 99mTc-p5 in an 
amyloid-laden mouse.  The use of two radiotracers allowed for simultaneous imaging 
of both SAP and peptide p5 in a single mouse.  (A) In vivo distribution of 125I-SAP.  The 
radioactivity has localized to amyloid in the liver and spleen of this AA mouse with slight 
accumulation of free iodide in the thyroid.  (B)  In vivo distribution of 99mTc-p5 in the 
same mouse.  The image demonstrates accumulation of radiotracer in the liver, spleen, 
kidneys, pancreas and intestine.  Direct comparison of SAP and p5 suggests that p5 
targets more of the amyloid load in this mouse.  (Adapted from [293]).  
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anatomical reference, CT can be used to provide attenuation correction to the PET 
image data which results in better image quality and a reduction in whole body scan 
time by at least 40% [279] . Without attenuation, the uncorrected PET image can form 
“a rim of apparently increased activity along the periphery of the body and relatively 
lower tracer uptake in organs in the center of the body” [262].  Thus, attenuation 
correction is necessary in order to provide more accurate image display and 
interpretation. 
 Nowadays, all clinical and preclinical PET imaging is performed by using dual 
modality PET/CT systems.  SPECT/CT systems have also been implemented to 
address many of the same concerns that single modality PET imaging faces.  As stated 
by Mariani et al., “the main advantages of SPECT/CT are represented by better 
attenuation correction, increased specificity and accurate depiction of the localization of 
disease” [297].  Additionally, dual SPECT/CT imaging improves visualization of 
functional and metabolic information that is provided with nuclear medicine tests which 
monitor molecular changes that may not be observed with anatomical tests such as CT 
or MRI alone [297-299].  To demonstrate the advantage of anatomic localization using 
SPECT/CT, the same data presented in Figure 1.17 is displayed in Figure 1.18 as a 
SPECT/CT dual modality image. 
3.2.2 Tracers 
 Molecular imaging in the form of PET or SPECT relies on the use of radiotracers 
which have been developed to target disease and metabolic functions.  I will focus 
exclusively on those that relate to amyloid imaging.  These agents can be categorized 
into one of the following types: small molecules, antibodies and proteins or amyloid- 
59 
 
 
 
 
 
 
 
Figure 1.18:  Dual modality SPECT/CT images.  Co-registration of the CT data with 
the SPECT data (B and C) provides anatomical reference for the distribution of 
radiotracers.  Thus, the labeled tissue accumulation shown (A and C) are more readily 
interpreted (Image taken from [293]). 
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associated materials.  The tracers have been radiolabeled with positron emitters such 
as 18F, 124I, 11C or gamma emitters such as 123I or 99mTc for PET or SPECT detection, 
respectively. 
3.2.2.1. Small molecules 
 Due to its immense socio-economic impact, much clinical focus has been 
devoted to the molecular imaging of amyloid associated with Alzheimer’s disease (AD) 
which has been determined to be one of the “defining neuropathologic findings” of the 
disease [300].  The greatest risk factor for AD is advanced age, and with enhanced 
medical discoveries leading to longer life-spans, there is greater likelihood that more 
individuals will become afflicted with the disease [179, 301, 302].  According to the AD 
organization’s annual review, it is estimated that 5.2 million Americans have AD; this 
estimate can be broken down into approximately 5 million that are over the age of 65 
and 200,000 individuals under age 65 that have developed the disease with earlier 
onset [303, 304].  The report also indicates that “one in nine people age 65 and older 
(11 percent) has the disease”; this estimation is based on the U.S. population records 
projected by the 2013 U.S. Census Bureau [304].   
The pathological, extracellular deposition of amyloid in the brain parenchyma and 
cerebral vasculature of AD patients and patients with mild cognitive impairment (MCI) 
results from the accumulation of misfolded beta-amyloid peptide fragments as amyloid 
[32].  The discovery of extensive and site-specific amyloid in AD patients warranted the 
development of an amyloid-seeking agent which could aid in detection of the disease. 
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The first amyloid imaging agent to be approved by the FDA for clinical 
assessment of the amyloid load in patients suspected of AD is Amyvid™ (formerly 
known as Florbetapir or AV-45; Avid Radiopharmaceuticals/Eli Lilly, Indianapolis, IN).  
Several multicenter trials have been conducted in which Amyvid™ was administered to 
patients with AD and patients with MCI along with a group of healthy controls (HC) [305-
307].  PET/CT imaging was performed after ~ 50 – 70 minutes post injection of the 
radiotracer.  The results from these studies indicated that the accumulation, determined 
visually and quantitatively using standard uptake values (SUV), in cortical regions was 
higher in AD and MCI patients than that seen in HC.  While these findings were 
encouraging for both physicians and patients affected by AD, there are limitations to its 
clinical use.  The quantitative information collected from each of these scans must be 
interpreted by a skilled and trained reader in order to get credible results; it has been 
reported that the discernment between AD/MCI patient data and HC data could be 
simplified if efforts are made to improve the spatial resolution of the images and if 
appropriate training is offered for nuclear medicine physicians [305].  News reports have 
indicated an additional limitation on the clinical use of Amyvid™ because of the 
decision, one that took many months to reach, by the Centers for Medicare and 
Medicaid Services (CMS) to not cover the drug’s use for β-amyloid PET imaging for the 
diagnosis and treatment of neurodegenerative disorders [308, 309].  According to the 
detailed memo provided by the CMS, there was a lack of sufficient evidence to support 
the use of PET imaging with AmyvidTM; however, there was a realization that the drug 
may be beneficial in specific cases in which the goal would be to exclude AD as a 
diagnosis (e.g., in patients with fronto-temporal dementia) [310].  They also believed 
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Amyvid™ could facilitate clinical studies seeking better treatment and prevention 
strategies (i.e., used as an endpoint in clinical trials).  While there are positive results for 
Amyvid™’s ability to detect amyloid plaques within the brain, there is a lack of evidence 
that the radiopharmaceutical could be used for the whole body detection of systemic, 
visceral amyloid.  A recent study using AmyvidTM to detect systemic amyloid deposition 
revealed that distribution of the radiotracer provided target-to-background ratios 
indicative of amyloid pathology in only the heart of amyloid patients [311].  Given that it 
was a pilot study, they were unable to calculate the specificity, sensitivity or diagnostic 
accuracy of the imaging agent, and they were unable to discern the whether the amyloid 
was AL or ATTR in those patients with positive images.  Additional, multicenter studies 
are being performed to further assess Amyvid’sTM utility as a visceral amyloid imaging 
agent [311].  
 Another small molecule used for β-amyloid detection is known as Pittsburgh 
compound B (2-[4´-(methylamino)phenyl]-6-hydrobenzothiazole; PiB).  The molecule 
also binds to Aβ amyloid in the brain parenchyma and blood vessel walls of AD patients 
[312-317].  Initial studies with the PiB used carbon-11 as the radionuclide.  While 11C-
PiB has been shown to detect β-amyloid, the positron emitter hinders the effectiveness 
of 11C-PiB due to its very short half-life (20.4 min)—essentially, in order to use the 
molecule, the in vivo image acquisition must be performed in an institution with a 
cyclotron for radioisotope preparation and immediate use [317, 318].  To circumvent the 
inconvenience of the short half-life of carbon-11, PiB has been radiolabeled with 
fluorine-18 (T1/2 = 109.8 min); this molecule, recently approved by the FDA, is known as 
18F-Flutemetamol (or clinically Vizamyl™: GE Healthcare, Arlington Heights, IL).  
63 
 
Studies in clinical trials have shown that the fluorinated molecule performs similarly to 
the parent 11C-molecule and additionally provides wider accessibility for both clinical 
and research purposes [317].   
However, it suffers from the same regulatory limitations imposed on AmyvidTM.  
Recent data indicate that 11C-PiB, because of its retention by amyloid, can also be used 
to image cardiac amyloid deposits associated with both ATTR and AL amyloidosis 
[319].  This group concluded that the molecule could image cardiac amyloidosis within 
the myocardium of affected patients, but there was reversibility in the binding which 
would suggest early time point imaging in future studies [319].  Notably, the amyloid in 
other visceral organs was not imaged using this tracer.  Studies using 18F-Flutemetamol 
for imaging cardiac amyloidosis have yet to be published. 
 Many other small molecules have been utilized as amyloid-imaging agents also.  
These include 99mTc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-
DPD) and 99mTc-labeled hydroxymethylene diphosphonate (99mTc-HDP).  These 99mTc-
labeled phosphate derivatives were developed decades ago as bone seeking agents to 
be used in nuclear medicine planar, gamma scintigraphy as a means of detecting bone 
abnormalities such as skeletal metastases and benign bone disease [320-322].  
Calcifications that present in some amyloid deposits—especially those seen in the heart 
of patients with ATTR and those with SSA (wild type ATTR)—may explain the uptake of 
these tracers in cardiac amyloid [323].  Myocardial involvement associated with TTR 
amyloidosis, both mutant and wild type TTR amyloid, has been imaged with 99mTc-DPD; 
positive image data correlated with high amounts of amyloid fibrils [323-325].  The same 
tracer used in AL patients with cardiac amyloid deposition gave negative image data 
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[323, 324].  Thus, this imaging agent may be used to discern between ATTR and AL 
cardiac amyloid.  A recent study using 99mTc-HDP concluded that scintigraphic analysis 
with this tracer may be able to detect cardiac amyloidosis in ATTR patients, and like 
DPD, the amount of uptake correlated with the severity of amyloid deposition [326]. 
 These small molecules have been shown effective in certain types of amyloid 
diseases, but they are not suitable for whole-body detection of amyloid in the case of 
systemic disease.  Thus, the small molecules available for amyloid detection do not 
address all clinical needs. 
3.2.2.2. Antibodies and proteins 
 In addition to small molecules, certain antibodies and proteins have been 
developed as amyloid-targeting agents.  Two antibodies that have been explored as 
therapeutic and/or diagnostic (“theranostic”) agents for amyloidosis are 11-1F4 [327-
329] and 2A4 [330, 331].  Initially developed as therapies for the disease, these 
antibodies have since undergone PET and SPECT imaging studies to assess their 
efficacy for amyloid detection in vivo.  In addition, the most commonly used protein that 
has been evaluated as an amyloid-imaging agent is aprotinin [332].  It was shown to be 
efficacious as an amyloid imaging agent, but, as with other tracers, there are limitations 
associated with its use. 
 The monoclonal antibody (mAb) 11-1F4 was generated using human light chain 
amyloid-related aggregates and recognizes an epitope common to fibrils associated 
with ALκ and ALλ  [327, 328, 333].  Initial studies conducted with 11-1F4 revealed its 
ability to expedite resolution of subcutaneous (sc) human AL in “amyloidoma”-bearing 
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mice; these studies involved formation of a palpable sc AL amyloidoma by injection of 
~100 mg of amyloid extract derived from autopsy tissue specimens [327].  After iv 
injection of a total of 600 μg mAb 11-1F4 (administered over a 12 day period), the 
amyloidomas in treated mice, by day 15, were reduced in size as compared to control 
mice which received equivalent amounts of an isotype matched control antibody or were 
left untreated altogether [150].  Furthermore, iv administration of radioiodinated 11-1F4 
into mice with an AL amyloidoma and PET/CT imaging showed co-localization of 124I-
11-1F4 radiotracer in the amyloid xenograft [328, 329] as shown in Figure 1.19.  Given 
the potential therapeutic and diagnostic potential of the mAb, an FDA-approved Phase 1 
exploratory investigational new drug (eIND) trial to study the efficacy of 124I-11-1F4 as a 
systemic amyloid targeting agent was initiated.  The results of this study indicated that 9 
of the initial 18 enrolled patients with known amyloid deposition demonstrated uptake of 
124I-11-1F4 in the liver, lymph nodes, intestines, bone marrow and spleen as shown in 
PET/CT images  [329].  A representative patient from this study can be seen in Figure 
1.20 where the image revealed uptake of the mAb in the amyloid-laden liver. For all 
imaged patients, the renal and cardiac deposits were not visualized, however.  The lack 
of uptake in these affected organs was thought to be due to the absence or 
inaccessibility of the mAb’s epitope.  The conclusion from this study was that imaging 
with 124I-11-1F4 could be a good predictor of patients that may benefit from a passive 
immunotherapeutic approach with this mAb (i.e., as a preliminary patient stratification 
tool before recruitment into an 11-1F4 therapy protocol). 
 The other mAb that has been generated to possibly assist in the detection and/or 
therapeutic removal of amyloid deposits is known as 2A4 [330, 331].  This mAb was  
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Figure 1.19: Co-localization of mAb 124I-11-1F4 with a sc AL amyloid xenograft as 
evidenced by PET/CT.  The image shows uptake of the radiotracer within the AL 
amyloidoma which is located between the scapulae of the mouse.  This finding led to 
further development of the radiotracer as a potential imaging agent in patients with AL 
amyloidosis.  (Adapted from [328]). 
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Figure 1.20: The mAb 124I-11-1F4 can image amyloid-laden liver in an AL patient.  
The mAb was administered 5 days prior to imaging.  As shown, 124I-11-1F4 
accumulated in the hepatic amyloid of this patient.  (Taken from [329]). 
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developed to bind the carboxy-terminal epitope (amino acid sequence His-Glu-Asp-Thr; 
HEDT) which was created following proteolysis of serum amyloid A protein (SAA), the 
precursor protein for AA amyloidosis.  The antibody does not recognize native SAA 
which contains 103 amino acids; it was shown to bind the -HEDT epitope of the cleaved 
SAA fragment (~ 75 residues) associated with AA amyloid fibrils [142, 330, 334, 335].  
When radiolabeled with iodine-125 and injected into AA amyloid-laden mice, 125I-2A4 
co-localized with the amyloid deposits as evidenced by SPECT imaging (Figure 1.21A) 
and microautoradiography [330].  Surprisingly, further preclinical studies with this 
antibody indicated that it is also capable of in vitro binding to amyloid fibrils composed of 
immunoglobulin light chains associated with AL amyloidosis [331].   
Furthermore, in vivo analysis revealed that administration of 125I-2A4 to mice 
bearing sc human AL amyloidomas resulted in preferential SPECT imaging of the 
amyloid mass (Figure 1.21B), and treatment of these mice with the mAb expedited 
resolution of the amyloidomas when compared to control mice which received an 
isotype-matched antibody.  Thus, preclinical studies provided evidence that 2A4, 
because of its ability to selectively bind amyloid in vivo, could be a valid agent for 
imaging and immunotherapy in patients with AL amyloidosis in addition to its diagnostic 
utility for AA amyloidosis [330, 331].  A humanized GMP version of the murine mAb 2A4 
was generated, known as NEOD001 (Prothena; Dublin, Ireland),  is currently in a Phase 
1 clinical trial investigating the maximum tolerated iv dose in AL amyloidosis patients 
[336] (NCT01707264). 
The protein that has been investigated most thoroughly as a potential amyloid 
imaging agent is 99mTc-labeled bovine aprotinin (Trasylol), a protease inhibitor.  Since  
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Figure 1.21: SPECT/CT imaging and ARG of both AA and AL amyloid with mAb 
125I-2A4.  (A) Distribution of 125I-2A4 in an AA amyloid-laden mouse.  SPECT/CT 
imaging showed uptake of the mAb in the liver and spleen of an AA mouse.  The black 
silver grains in the ARG of both liver and spleen tissues coincide with the birefringent 
regions in consecutive tissue slices stained with CR indicating co-localization of mAb 
with AA amyloid.  (B)  Uptake of 125I-2A4 in a sc human AL amyloidoma.  The 
SPECT/CT indicates radiotracer in the AL amyloidoma (arrow), and ARG/CR 
comparison confirmed co-localization of mAb with AL amyloid (Images adapted from 
[330, 331]). 
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amyloid deposits are known to contain antiproteinases such as α1-antichymotrypsin 
[332, 337, 338], it was hypothesized by Aprile et al. that aprotinin may react with this 
component of amyloid deposits [332].  There is evidence that this protein accumulated 
in the renal cortices as part of natural catabolism; thus, initial investigations with the 
imaging agent focused on the detection of extra-abdominal AL amyloid deposition by 
planar scintigraphy [332, 339-342].  Cardiac amyloid involvement in the 24 AL patients 
participating in this study was imaged in all patients with known myocardial deposition; 
additional amyloid deposits were also imaged in the lung, thyroid, salivary glands and 
tongue leading to the conclusion that 99mTc-aprotinin could be a cost-effective approach 
to imaging extra-abdominal amyloid involvement in AL patients [332].  A more recent 
study conducted in 2003 showed similar results in 23 patients with known or suspected 
AL amyloidosis; uptake of 99mTc-aprotinin was, again, visualized in the heart and other 
organs previously mentioned.  Of note, this study included a patient which showed 
positive myocardial uptake of the radiotracer but had no clinical signs of cardiac 
involvement; thus, 99mTc-aprotinin was able to detect “clinically silent” amyloid pathology 
in an individual [343].  Conclusions from this study revealed that 99mTc-aprotinin may be 
useful for detection of extra-abdominal amyloid lesions, but, due to renal excretion, “it is 
not suited for detection of amyloid deposits in kidneys or bladder” [343].  Other 
limitations include the inability of the radiotracer to reveal amyloid within the central or 
peripheral nervous system and nonspecific binding in the liver.  While aprotinin has 
been used by several institutions world-wide, it has been suspended from clinical use in 
the United States due to adverse effects seen in studies utilizing the drug to reduce 
bleeding during heart surgeries [344]. 
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 Thus, 11-1F4 and aprotinin have been developed for imaging amyloid deposition 
in patients, but there are limitations to each of their use—namely, the antibody has not 
shown efficacy in detecting cardiac or renal amyloid, and aprotinin, which has shown 
merit in cardiac amyloid detection, can no longer be used in the United States. 
3.2.2.3. Visceral amyloid-related agents 
 Given the need for amyloid imaging agents, some investigators have explored 
the use of radiolabeled amyloid components as a strategy to detect the deposits.  There 
are two amyloid-associated agents that have been utilized: serum amyloid P component 
(SAP), which is found ubiquitously in amyloid deposits and β-2-microglobulin (β2M), 
which is found in amyloid fibrils related to dialysis-associated amyloidosis. 
 Of all the imaging agents developed for amyloidosis, SAP has been most widely 
investigated and utilized clinically, albeit exclusively in Europe (UK, Italy and the 
Netherlands).  As previously stated in section 1.2.3, SAP is a 250 kDa glycoprotein that 
is associated with all types of amyloid deposits with the exception of Aβ plaques in the 
brain.  In an individual with no amyloid, SAP circulates in the plasma at ~ 20 mg/L; the 
concentration of SAP is increased in the amyloid, and there can be 20,000 mg of SAP 
within the deposits as well as free SAP in circulation [8].  SAP binds to the fibrillar 
component of amyloid deposits in a calcium dependent manner [8].  Given this, the 
abundance of SAP associated with amyloidosis patients has been exploited as a means 
of amyloid detection.  It was first introduced as a potential imaging agent by Hawkins et 
al. when they discovered that 123I-SAP targeted amyloid after iv injection in a murine 
model of AA amyloidosis as evidenced by planar scintigraphy [65].  The imaging agent 
was introduced into patients with amyloidosis in a study conducted by Hawkins, 
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Lavender and Pepys in which 50 biopsy-proven patients were enrolled (25 AL and 25 
AA patients) [345].  The protocol for this study included iv administration of 123I-SAP into 
patients and control individuals which was then followed by whole body scintigraphic 
imaging 24 hours post injection.  This landmark study revealed that 123I-SAP imaged 
amyloidotic organs in all confirmed patients, and uptake was also seen in 6 individuals 
whom had negative biopsies prior to the study.  These patients either underwent 
subsequent biopsies or tissue was analyzed at autopsy, and amyloid disease was later 
confirmed in all 6 patients [64].  The control individuals showed no uptake of the tracer.  
A representative image of a patient with AL amyloidosis alongside an image of a healthy 
control can be seen in Figure 1.22.  The image shows uptake of the tracer in the liver, 
spleen and bone marrow of the AL patient while the healthy control reveals evidence of 
radiotracer in the blood pool and tissues involved with hepatobiliary clearance.  The 
specificity of 123I-SAP localization to amyloid deposits was confirmed at autopsy in 6 
patients [64].  Additionally, the investigators found that the “density of amyloid 
deposition demonstrated histologically in the various tissues corresponded exactly to 
the quantity of tracer present in the in vivo images” [345].  This study indicated that, 
although the tracer cannot provide convincing images of cardiac amyloid, 123I-SAP can 
be used as a diagnostic tool for amyloidosis and as a method to ascertain disease 
progression or regression for AL and AA patients [346].  With the success of this tracer, 
scintigraphic imaging with 123I-SAP has been incorporated into the clinical management 
of many patients at multiple institutions in Europe [56, 64, 345, 347-350]; the tracer, 
however, is not FDA approved and cannot be used as a means of determining amyloid  
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Figure 1.22:  123I-SAP planar scintigraphy acquired 24 h pi in an AL patient and a 
healthy control.  The image on the left shows uptake of the radiotracer in AL amyloid-
laden tissues such as the liver, spleen and bone marrow of a patient. (Image taken from 
[351]). The distribution of 123I-SAP (and free 123I-iodide) in a healthy individual is shown 
on the right to account for non-specific accumulation of the radiotracer at 24 h pi. 
(Image taken from [352]. 
 
74 
 
distribution for patients in the US.  An alternative whole-body imaging agent is needed 
for patients that cannot undergo an SAP imaging acquisition. 
 The final amyloid component that has been developed as an imaging agent for 
amyloidosis detection is 111In- or 131I- β2M.  Patients that have undergone chronic 
dialysis for longer than 10 years are at risk of developing dialysis related amyloidosis 
(DRA) which involves an over-abundance of circulating β2-microglobulin rendering it 
amyloidogenic (Aβ2M) [161, 353].  The amyloid is typically deposited in soft tissues 
surrounding joints but can also affect the gastrointestinal tract, lungs and heart [1].  It 
has been reported that the relatively safe methods of amyloidosis diagnosis—Congo 
red histological analysis of a fat aspirate or rectal biopsy—fail in the cases of DRA [354-
359]; additionally, the method that can, indeed, detect Aβ2M involves examination of 
amyloid within synovial fluid invasively extracted from joints such as the knee, ankle, 
wrist or shoulder [354, 358, 360].  As an alternative to these invasive strategies, imaging 
agents for Aβ2M detection have been investigated.  While 123I-SAP can detect some 
amyloid deposits in long-term hemodialysis patients, accumulation in other sites such as 
joints in the hips and shoulders were not accomplished with this tracer [361].  Studies 
conducted by Floege et al. demonstrate that scintigraphy with radiolabeled β2M could 
adequately visualize Aβ2M amyloid deposition in patients with confirmed DRA; patients 
that underwent hemodialysis but had no evidence of amyloid deposition were also 
administered the tracer, and no uptake was detected [361].  They used either 131I- β2M 
or 111In- β2M to assess amyloid deposition, and they determined that the 111In- β2M 
provided improved image contrast and sensitivity along with reduced radiation 
exposure.  This imaging agent could offer a non-invasive approach to diagnosing DRA 
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in patients with end-stage renal failure [360], but it is not applicable to other forms of 
systemic amyloidosis. 
 
4. Preclinical evaluation of amyloidosis 
 
4.1. Model systems 
Based on the previous description of amyloid-specific radiotracers, there is a 
clear need to develop alternatives, particularly for whole body imaging in the US.  To 
discover and optimize new amyloid-targeting imaging agents, preclinical models of the 
disease have been developed.  Proper assessment of novel techniques and reagents 
must be performed prior to their introduction into a clinical setting; this section discusses 
many of the model amyloid systems, both in vitro and in vivo, that are utilized by 
investigators and employed in this thesis for studying new potential imaging agents for 
amyloidosis. 
4.1.1. Synthetic fibrils 
Given that all types of amyloid deposits contain proteinaceous fibrils, one of the 
earliest model systems that has been developed for in vitro studies of amyloidosis is 
synthetic fibrils.  The use of synthetic fibrils gives insight into the structural, biochemical 
and biophysical properties of protein polymerization, or fibrillogenesis, and has been 
employed to study numerous types of protein fibrils [81, 182, 362, 363].  This model 
system can elucidate protein-protein interactions in a simple, non-biological 
environment—an advantage and limitation of this method.  A certain dye, known as 
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thioflavin T (ThT), is a fluorescent marker that binds to all amyloid fibrils; upon binding, 
the emission intensity of ThT at 490 nm, as measured with a fluorimeter, increases by 
orders of magnitude which indicates the presence of fibrils or the process of fibril 
formation if measurements are taken over time [364, 365].  This type of assay can also 
be used to evaluate potential inhibitors of synthetic fibril formation [366].  Additionally, 
the in vitro formation of amyloid-like fibrils facilitates high resolution structural studies of 
the fibrils and the intermediates that exist on the pathway of fibrillogenesis.  Techniques 
such as X-ray diffraction [367], solid state nuclear magnetic resonance [368, 369] and 
cryo-electron microscopy [370] have been performed on various amyloid-like synthetic 
fibrils—processes that would not be amenable using tissue amyloid extracts due to the 
heterogeneity and complexity associated with such samples.  Synthetic fibrils composed 
of the variable domain of λ6 light chains, e.g. Vλ6Wil, are generated [81] and used 
routinely in our laboratory. 
4.1.2. Tissue extracts 
 Since there are more components to amyloid deposits than solely the fibrils, 
amyloid extracts derived from tissues provide a more complex model system of the 
disease.  Tissue extracts derived from autopsy materials (livers and spleens), of 
patients with AL amyloidosis have been used in characterization studies of potential 
amyloid-binding agents [363, 371].  Patient amyloid extracts are often prepared using 
techniques which removed extraneous materials leaving amyloid fibrils, proteoglycans 
and minimal SAP components within the samples [244].  In contrast, tissue amyloid 
extracted from patient material or from mouse organs (e.g., with AA or ApoA2c 
amyloidosis) yields homogenate samples which contain all the essential amyloid 
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components mentioned above, but they might be complicated by the presence of other 
polymers such as intracellular materials.  When compared to synthetic fibrils, the use of 
tissue extracts provides an ex vivo environment that more closely resembles the 
composition of amyloid material in vivo.  This model system is amenable to 
characterization studies which assess the binding affinity of certain amyloid-targeting 
probes—namely those to be utilized in vivo as amyloid imaging agents (as is presented 
in this thesis).  Specificity of such agents can be established using this amyloid 
substrate by various techniques such as sodium chloride (NaCl) titrations (to assess the 
strength of electrostatic interactions) and heparinase treatments (see later sections).  
Heparinase treatment has been applied to AL patient extracts to remove the HSPG 
component and determine if amyloid-binding agents can interact with amyloid in the 
absence of this prevalent component [363].  These studies were used to elucidate the 
heterogeneity of patient AL extracts as indicated by the vastly differing binding abilities 
of a single agent on diverse ALλ and ALκ preparations.  These component-specific 
studies would not be possible without access to “complete” amyloid present in extracts; 
synthetic fibrils alone would not be as informative for analyzing amyloid-peptide 
interactions.  The amyloid extract model system can help characterize amyloid-targeting 
agents, but the possible hindrances that exist in vivo, such as tissue vascularity and 
competing “sinks” for the agent, are absent in this system; thus, positive findings ex vivo 
may not fully translate to the in vivo system—something I explore in this thesis. 
4.1.3. Mice 
 Experimental in vivo models of amyloidosis are the most informative system for 
evaluating amyloid-targeting agents and/or potential therapeutics.  Given that there are 
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several amyloidoses which are known to affect various tissues, many mouse models 
have been developed to facilitate the investigation of these diseases; however, the 
repertoire is incomplete.  Although there are several mouse models of Alzheimer’s 
disease which deposit localized Aβ amyloid, they are beyond the scope of this thesis.  
The following section discusses mouse models of visceral amyloidosis (e.g., AA, 
ApoA2c, ATTR, Aβ2M and AL). 
The most historically used model is that of AA amyloidosis which relies on the 
induction of amyloid deposition by the injection of compounds including casein [372], 
silver nitrate [373] and lipopolysaccharide [374]—all of which stimulate the production of 
pro-inflammatory cytokines, such as IL-1 and IL-6, and the subsequent secretion of SAA 
[27].  The repeated induction of an inflammatory stimulus causes an overproduction of 
SAA ultimately leading to AA amyloidosis.  This model has been used extensively to 
study the disease and is believed to mimic amyloid distribution seen in patients with AA 
amyloidosis [375], but in the absence of the stimulus, amyloid deposition can resolve 
spontaneously with time [27, 376]; thus, there are limitations to the types of studies 
which can be conducted.   
An alternative model for AA amyloidosis is a transgenic mouse which 
constitutively expresses human IL-6 leading to the overproduction of SAA.  The 
transgenic mouse strain, B6(C)-Tg(H2-Ld_IL-6)Kish(H2/huIL-6), was developed at the 
National Institutes of Health as a model for studying myelomas and plasmacytomas 
[377, 378].  The C57BL/6 mouse germ line was modified by the introduction of human 
IL-6 cDNA with transcriptional control mediated by the murine major histocompatibility 
complex class I (H-2Ld) promoter.  These mice (H2/IL-6) were crossed with mice of 
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BALB/c genetic background [379], and after more than 20 generations had been 
performed, spontaneous AA amyloidosis was detected in the spleen, liver, tongue, 
heart, intestines and kidneys by 8 to 9 months of age [378].   
The amyloid deposition associated with both mouse models of AA could be 
induced by injection of AEF [380, 381], but the transgenic model circumvents the need 
for repeated inductions of inflammatory stimuli, and it provides a system to study early-
onset, spontaneous, chronic AA disease which has proven suitable for both amyloid-
targeting and therapeutic studies. 
As an experimental model for mouse senile amyloidosis,—a disease which 
demonstrates progression in an age-associated manner—transgenic mice were 
developed that overexpress apolipoprotein A-2c (ApoA2c) under the cytomegalovirus 
immediate early gene enhancer/chicken beta promoter on the apoA-II gene [382].  The 
ApoA2c protein self-associates to form amyloid fibrils (AApoA2c) in these mice as they 
age.  Other allelic variants of this gene, namely ApoA2a and ApoA2b, are unable to 
form amyloid fibrils in transgenic mice [383].  An abundance of ApoA2c in combination 
with administration of pre-formed AApoA2c fibrils (8 to 10 μg) generated severe 
amyloidosis which can be observed in the testes, liver, kidneys, heart, lungs, spleen, 
tongue, stomach and intestine [382].  While the human form of AApoA2c amyloidosis is 
extremely rare (< 10 cases described in the literature), this model of the disease offers 
another in vivo system in which potential amyloid-targeting agents can be evaluated, 
particularly in the heart where significant amyloid is observed. 
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Mouse models of human ATTR amyloidosis have been produced, but “they have 
not been as successful as investigators would wish” [384].  These models involve the 
expression, as transgenes, of both mutant and wild-type human TTR genes, and while 
deposition does occur in some tissues, the model does not consistently generate 
amyloid deposits; additionally, the deposition does not recapitulate the neuropathology 
seen in patients [384].  Some studies involve the introduction of TTR genes into C57Bl/6 
x DBA/2 F1 mice in which the inserted human genomic DNA contained all elements 
known to regulate tissue specific expression; this technique, however, led to deposition 
in organs that are not known to synthesize the protein [385].  Later studies found that 
approximately 80 % of transgenic mice modified with wild type human TTR older than 
18 months of age developed non-fibrillar deposits; the remaining 20% of these mice 
developed lesions consistent with the human condition [386].  A model utilizing insertion 
of human genomic DNA from a patient with FAP confirmed these same findings in that 
mice most commonly generated what was considered to be “non-fibrillar, amorphous 
aggregates” as indicated by the presence of human TTR with immunohistochemical 
analysis and a lack of Congo red staining in histological examination [384].  In mice 
where amyloid is deposited, the hepatic and cardiac deposits are similar to those seen 
in patients; additionally, the late onset of the disease is analogous with the age-
associated manner of disease progression that affects patients [387-390].  Overall, 
these studies suggest that since there is inconsistent amyloid deposition in mice, this 
system may be most useful for only evaluating TTR aggregates which may form prior to 
amyloid deposition. 
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 As previously stated, patients that undergo long-term hemodialysis are at a risk 
of developing DRA by the deposition of amyloidotic β2M [391, 392].  Studies indicate 
that murine β2M is not amyloidogenic; thus, a transgenic model generated to 
overexpress human β2M (hβ2M) in mice with β2M knockout background has been 
developed [393, 394].  The concentration of hβ2M in mouse plasma measures 100 
times greater than that seen in normal human plasma, and it is more than 4 times that 
measured in long-term dialysis patients [394].  In regard to these plasma levels, the 
mice are similar to patients seen clinically.  The amyloid deposition that is associated 
with patients, however, was not observed in the transgenic mice; even by 2 years of 
age, there was no birefringent material detected in the mice when tissues were 
examined with Congo red stain [394].  The model may provide information on the 
diseased state of animals with elevated hβ2M levels, but the lack of amyloid deposition 
makes it unlike the human condition.  These data also imply that certain pro-amyloid 
host factors may be present in man but lacking in mice. 
 Given that AL is the most common form of amyloidosis in humans, a mouse 
model of the disease for experimental studies of potential amyloid-targeting agents for 
detection or therapy would be of great value.  Investigators have used different 
approaches to reproduce the disease in mice, but a model that closely resembles the 
pathology seen clinically is still lacking.  One model involved the intraperitoneal injection 
of various amounts of Vλ6 Bence Jones protein (BJP; extracted from AL patient urine) 
into C3H/HEJ mice [395].  These mice received multiple injections over several weeks.  
It was found that a single injection of 300 mg BJP was unsuccessful at producing 
amyloid deposits in mice euthanized 48 hours post injection; similarly, repeated 
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injections of 100 mg over 2 to 5 weeks, which was the equivalent of 900 to 2200 mg of 
protein, resulted in no amyloid deposition [395].  Slight renal deposition was detected 
only after mice had received ~ 5300 mg BJP over a 12 week period.  Since this requires 
large amounts of patient material, they employed a strategy that had been previously 
used to accelerate the induction of renal casts in mice receiving BJP—dehydration of 
the mice (48 hour without water prior to BJP injection) increased the extent of deposition 
[395, 396].  Amyloid deposition occurred in mice that were dehydrated for 24 hours prior 
to each of ten 200 mg injections of BJP over an 8 week period (2 g BJP total)—
renovascular deposits within vessel walls and the interstitium were Congo red positive.  
This model proved to be useful for the investigation of amyloidogenicity of certain BJP, 
but as previously stated, there is a need for large amounts of patient materials which is 
not ideal for an experimental animal model since a limited amount of patient-derived 
BJP may hinder experimental protocols.  Additionally, the repeated injection of BJP in 
immunocompetent mice could result in a mouse-anti-human immunological response 
[397].  The administration of AL patient-derived BJP into mice was used in another 
model in which the light chains were injected (1 mg per day) through the mouse penile 
vein; renal tissues were examined for amyloid deposition at various time frames, up to 
14 days, post-injection [398].  This model was generated as a means to investigate 
mesangial glomerular amyloid deposition that contributes to the renal failure seen in AL 
patients. By 12 h pi of patient light chains, mice had extracellular deposition of amyloid 
fibrils; at 7 d pi, amyloid deposition was clearly evident, but by 14 d pi, amyloid 
formation was abundant as evidenced by transmission electron microscopy and 
polarized Congo red stain.  As stated by Teng et al., this model system “is potentially a 
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significant scientific advance toward future development of new therapeutic avenues to 
ameliorate the progressive renal failure which represents the typical clinical course of 
patients with AL amyloidosis with renal involvement” [398].  Since the aforementioned 
AL mouse models involve the introduction of potentially limited patient-derived 
materials, and there is potential for a mouse immune response to injected materials, the 
use of this model for long-term, in vivo AL studies may be challenging.  To circumvent 
these obstacles, a transgenic mouse model was generated by insertion of cDNA from a 
λ6 AL patient who had amyloid involvement in the heart, liver, kidney, spleen and 
adrenals [397].  While the transgenic mouse was able to produce human light chains, 
Congophilic amyloid material was only found in the lumen of gastric glands of the 
stomach.  The amyloid was of light chain origin, but the clinical manifestation of AL 
amyloid is not typically localized to the stomach nor presents with this type of 
distribution.  This transgenic mouse model is useful for AL amyloid detection which is 
amenable to potential oral therapeutics [397], but it is not representative of the disease 
state which affects humans.  
4.1.4. Naturally occurring disease models 
 For certain amyloid diseases, there are naturally occurring animal models.  As 
previously mentioned, AL is the most common amyloid disease to affect humans.  In 
other mammals, however, AA amyloidosis is the most common form of the disease.  
Two of the most widely recognized naturally occurring models are in Chinese Shar pei 
dogs and Abyssinian cats.  AA amyloidosis in the former, which presents much like an 
inherited disorder known as familial Mediterranean fever (FMF) in humans, causes renal 
disease; however, the gene responsible for FMF differs from that seen in dogs [399, 
84 
 
400].  Studies suggest that Chinese Shar pei dogs with renal amyloidosis in 
combination with recurrent fever of unknown origin may be useful as a naturally 
occurring model of human disease due to the common organ distribution [400].  In 
Abyssinian cats, renal medullary and glomerular amyloidosis along with papillary 
necrosis has been observed as a result of familial predisposition; studies suggest that 
this amyloid is AA and that these animals may be a naturally occurring model of familial 
secondary amyloidosis or FMF leading to papillary necrosis [399-402]. 
 In addition to naturally occurring cases of AA amyloidosis, feline diabetes mellitus 
is another common naturally occurring model of amyloidosis in that there is deposition 
of IAPP detected in the pancreatic tissue, most commonly within the islets of 
Langerhans, of cats [403-405].  It has been postulated for years that AIAPP could play a 
significant role in the impairment of islet cells in individuals with Type 2 diabetes 
mellitus; islet amyloid deposition occurs in more than 90% of humans with the disease 
and more than 65% of adult diabetic cats [166].  Given that diabetic cats generally 
exhibit the same amyloid distribution detected in human pancreatic tissue, this naturally 
occurring animal model may prove valuable for investigating IAPP amyloid-targeting 
agents and can be used to evaluate in vivo efficacy and toxicology. 
 
4.2. Preclinical amyloid-targeting agent: Peptide p5  
Since the clinically available amyloid-targeting agents discussed above (Section 
3.2.2) have limitations to their use, much focus has been directed toward the preclinical 
development and translation of novel agents.  For example, the camelid antibody, B10, 
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has been shown to target a particular epitope on Aβ and AL fibril fragments through an 
electrostatic interaction by using in vitro binding studies [362, 406, 407].  In addition, we 
have shown that the small chain variable fragment (scFv), NS4F5, which interacts with 
a unique hypersulfated form of HS, also preferentially binds amyloid deposits as 
evidenced by SPECT/CT imaging [49, 71-73, 408].  These preclinical agents have 
demonstrated the utility of electrostatic interactions for targeting amyloid deposits.  They 
also have limitations to their use.  For example, B10 has not been shown effective as a 
pan-amyloid binding agent [362], and the amyloid-NS4F5 interaction was transient, and 
this probe was incapable of detecting amyloid at 4 h pi [73].  These limitations led to our 
further investigation of synthetic peptides as an alternative amyloid-targeting agent. 
Since the HSPG in amyloid appears to have sulfation patterns more like heparin 
[7] and is distinct from the HS in all other tissues and organs, recent studies have 
focused on the idea of amyloid-targeting through GAG involvement and have explored 
the use of heparin-binding peptides for amyloid detection [409].  The attention shifted 
from scFv to peptide development because “peptides can be chemically synthesized, 
are rapidly cleared from the circulation when not bound to target, are relatively small, 
can penetrate blood vessel walls and are generally nonimmunogenic” [409-413].  Seven 
heparin-binding peptides were radiolabeled with 125I and investigated by small animal 
SPECT imaging, biodistribution measurements and micro-autoradiography in H2/IL-6 
AA mice (previously described in section 4.1.3).  These peptides, referred to as p1 
through p7 in the comparative study, all exhibited a polybasic amino acid motif but 
revealed variable affinities for AA amyloid in vivo, as evidenced by SPECT/CT, 
biodistribution measurements and microautoradiography studies [409].  The lead 
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candidate peptide after image analysis at both 1 hour post injection and 4 hours post 
injection was peptide p5—a 31 amino acid peptide whose parent structure, referred to in 
the literature as K8, was initially synthesized for heparin neutralization [414].  The 
polybasic sequence of p5 includes a heptad repeat Lys-X-X-Lys-X-X-X (where X is Ala 
or Gln) which provides a +8 net positive charge and was predicted to adopt an α-helical 
conformation.  Interestingly, the secondary structure prediction illustrated that the basic 
lysine residues aligned to one face of the helix as seen in Figure 1.23.  Previous circular 
dichroism studies with K8 indicated that the peptide is, indeed, α-helical in the presence 
of heparin [414].  These experimental data, together with the predicted structure of the 
peptide, led to the hypothesis that the binding of p5 with HSPG in amyloid deposits may 
be the result of an electrostatic interaction between the polybasic surface of the α-
helical peptide and the enhanced sulfation pattern uniquely seen in amyloid-associated 
HSPG.  Microautoradiography of tissue samples obtained after the comparative peptide 
SPECT imaging study revealed that p5 preferentially bound amyloid as evidenced by 
the co-localization with amyloid in multiple organs (Figure 1.24).  This specificity has 
been further demonstrated by staining amyloid with biotinylated p5 in formalin-fixed 
tissue sections from patients with e.g., ALκ, ALλ, ATTR and Aβ [409]. 
 Given the amyloid-targeting specificity of peptide p5 in the aforementioned 
SPECT imaging study of AA mice, a dual energy SPECT/CT comparative effectiveness 
imaging analysis was performed by comparing p5 and the clinically available agent, 
SAP.  This study allowed for the direct comparison of p5 distribution with SAP 
distribution in the same H2/IL-6 AA mouse [293].  SAP was radiolabeled with 125I and 
injected into the lateral tail vein of mice; at 22 h pi, 99mTc-p5 was injected into the same  
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Figure 1.23:  Predicted structure of peptide p5.  Structure was generated by I-Tasser 
[415], and images were adapted from [416]. 
 
 
 
 
Figure 1.24:  Microautoradiography (ARG) of 125I-p5 distribution in various AA 
mouse tissues and Congo red (CR) histological confirmation of peptide co-
localization with amyloid.  (Image taken from [409]). 
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mice.  They were euthanized and imaged at 24 h pi of 125I-SAP (adhering to clinical 
protocol) and 2 h pi of 99mTc-p5 [293].  The resulting images reveal that both SAP and 
p5 were able to localize to hepatic and splenic amyloid, but p5 bound to pancreatic and 
intestinal amyloid more effectively than SAP (Figure 1.25).  Conclusions from this 
comparison suggest that p5 was a valid alternative to SAP and could fill a clinical need 
for patients in the United States. 
Additional studies with p5 have been conducted to show that the amount of 125I-
p5 that localizes to amyloid-laden mouse tissues after injection correlated with the 
amount of amyloid within the tissue [417].  This study compared amyloid load assessed 
by quantification of Congophilic, birefringent material in tissue sections with 125I-p5 
uptake, i.e. biodistribution measurement (percent injected dose of peptide/gram of 
tissue), of the same tissue.  The amount of peptide p5 uptake and birefringent material 
correlated linearly with a correlation coefficient of > 0.7 and a p value less than 0.00001 
[417], which indicated that p5 could not only detect amyloid deposition but that it could 
do so in a quantifiable manner. 
 While the initial hypothesis implied that peptide p5 binds to amyloid-associated 
HSPG, recent work has demonstrated that heparinase-treated, human AL amyloid 
extracts could still exhibit an interaction with p5.  This study compared p5 binding to 
various AL patient amyloid extracts before and after heparinase treatment utilizing an ex 
vivo binding assay [363].  The data indicated that binding of p5 to many of the extracts 
was decreased, but not completely abolished, after the removal of the HSPG sulfate 
groups, suggesting that p5 may have another target in amyloid deposits.  This was 
confirmed when the peptide was shown to bind synthetic AL amyloid fibrils composed  
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Figure 1.25: Dual energy SPECT/CT images illustrating 99mTc-p5 and 125I-SAP 
distribution in an individual AA mouse.  (A, B and E) Distribution of 99mTc-p5.  There 
was uptake in the liver (L), spleen (Sp) pancreas (P) and intestines (I).  The stomach 
(St) and thyroid (T) were devoid of radiotracer.  (C, D and F) Distribution of 125I-SAP.  
The image revealed uptake in the liver and spleen.  The stomach showed no uptake of 
radiotracer, but the thyroid sequestered free 125I-iodide as a result of radiotracer 
dehalogenation.  These images depict that radiolabeled p5 provided more information to 
the whole body amyloid burden than radiolabeled SAP.  (Image taken from [293]). 
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exclusively of rVλ6Wil [363].  Furthermore, Scatchard analyses supported the “multiple 
target” hypothesis of p5 revealing that the peptide, in the presence of tissue amyloid 
homogenate, has 2 binding sites which are, hypothesized to be HSPG and fibrils [371]. 
Although the peptide has proven efficacious at targeting amyloid in multiple 
systems and in various studies, certain biological parameters of p5, specifically the 
kinetics of the radiotracer in vivo and the stability of peptide-amyloid interaction, were 
undeterminable using the methods mentioned in previous studies.  To gain insight into 
the biodistribution and pharmacokinetics of p5 in diseased and healthy animals, 
dynamic PET imaging acquisitions were performed, and the time activity curves 
generated from the data illustrated that the peptide is rapidly cleared from the blood 
pool in both WT and AA mice.  The accumulation of 124I-p5 in amyloid-laden liver and 
spleen began abruptly after blood pool clearance and remained stable throughout the 2 
h duration of the acquisition; in healthy mice, at ~ 7 min pi, the radiotracer uptake 
peaked in the kidneys then washed out leaving no accumulation of intact 124I-p5 in any 
tissues—only free isotope was detected in the stomach and thyroid due to 
dehalogenation in the kidneys.  The kinetic profiles of diseased and healthy mice were 
drastically different which could facilitate diagnosis of amyloidosis (Figure 1.26).  
Additionally, this study revealed that the dehalogenation of p5 in the absence of amyloid 
target was important and could be beneficial for imaging renal amyloid.  The stability of 
p5 binding was also assessed, and there was evidence of 125I-p5 bound to amyloid in 
SPECT/CT images acquired at 72 h pi (Figure 1.27).  With such stability comes the 
advantage of waiting “extended periods of time post injection without the loss of positive 
signal” [416].  This allows for clearance of background noise and enhances the  
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Figure 1.26: 124I-p5 PET dynamic time activity curves.  The radiotracer distribution 
throughout a 2 h acquisition in AA mice (blue) and WT mice (red) is shown.  Notice the 
rapid blood pool clearance (heart) in both diseased and healthy mice.  Additionally, 
there was evidence of radiotracer clearance through the kidney in WT mice which led to 
stomach and thyroid accumulation.  The liver and spleen of diseased mice showed 
rapid 124I-p5 accumulation.  These distinct kinetic profiles could identify diseased mice.  
(Image adapted from [416]). 
 
 
Figure 1.27:  SPECT/CT images revealing the stability of 125I-p5 binding to 
amyloid.  AA mice were administered 125I-p5 and imaged multiple times pi.  The images 
indicate radiotracer stability in amyloid-laden tissues for at least 72 h. (Image taken from 
[416]). 
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likelihood of the critical detection of small deposits that form in early stages of the 
disease—a valuable property of an imaging agent for any disease but especially 
valuable for the under-diagnosed, yet deadly, amyloidosis.  
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Chapter 2 
Project Rationale and Summary 
 
 The systemic amyloidoses are particularly devastating diseases which are 
thought to be clinically underdiagnosed due to their heterogenous nature and the, often 
times, inconclusive presentation of clinical symptoms.  With the most common forms of 
systemic amyloidosis, namely light chain amyloidosis and hereditary or wild type 
transthyretin amyloidosis, renal and cardiac pathological involvement contribute to the 
most ominous prognoses for patients.  Since these organs are typically affected in the 
later stages of the disease, it is of the opinion of many researchers and clinicians that 
early diagnosis could lead to the implementation of appropriate treatments and, thus, 
better prognoses for patients.  Currently, the accepted method of amyloidosis detection 
and diagnosis involves histological (Congo red) evaluation of biopsy-derived tissue 
samples – an invasive procedure prone to clinical complications.  The use of Congo red 
for amyloid detection in tissue samples has been employed for decades, but for 
untrained observers, the samples can be difficult to interpret.  Additionally, this method 
is subject to sampling error and cannot offer insight into the whole body distribution or 
the extent of amyloid deposition in an individual.  Therefore, a more facile, non-invasive 
method of amyloid detection would be valuable to both physicians and patients. 
 While histological examination of tissue specimens remains the gold standard for 
disease diagnosis, efforts directed toward the development of amyloid-targeted imaging 
agents have been made.  The following imaging agents are clinically available or are in 
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human clinical trials for systemic amyloidosis: 123I-SAP, 99mTc-aprotinin, 99mTc-
DPD/HDP, 11C-PiB, 18F-PIB, 18F-florbetapir, and 124I-11-1F4.  These agents, however, 
all have limitations which include the lack of availability in the United States, the inability 
to detect cardiac amyloid deposits, isotope half-life constraints and inconsistent findings, 
i.e. the inability to detect all known amyloid-laden organs in a patient.  Given these 
restrictions, the development of novel amyloid-imaging agents is of clinical import. 
 Since the composition of amyloid deposits contains a unique, hyper-sulfated form 
of heparan sulfate proteoglycan which “looks” biochemically and electrochemically 
similar to heparin, we have investigated a series of heparin-binding peptides as 
potential amyloid-targeting and imaging agents.  These studies elucidated positive 
binding characteristics of one peptide in particular, known as p5.  This peptide has been 
shown in vivo to preferentially co-localize to amyloid deposits found in the murine H2-
IL6 model of AA amyloidosis, and comparative studies of p5 and SAP in this mouse 
model indicate that the peptide may be a valid imaging agent for AA amyloidosis.  
Histological examination of the peptide on tissue samples of various other visceral 
amyloid diseases—ALκ, ALλ and ATTR—demonstrated co-localization of the peptide 
with these forms of amyloid also.  Since there are no well-defined experimental or 
naturally-occurring animal models of AL or ATTR in which to further validate the 
peptide, another murine animal model of amyloidosis, an ApoA2c transgenic model, 
was used for additional ex vivo and in vivo testing of p5. 
Although the peptide p5 has been shown to interact with multiple types of 
amyloid including human AL, AA and ATTR as well as murine AA, p5 was not detected 
in ApoA2c tissue homogenates in an ex vivo peptide-binding assay.  This lack of 
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interaction was also seen in vivo where radiolabeled p5 peptide was incapable of 
binding and imaging amyloid in ApoA2c mice.  This conundrum led us to develop other 
synthetic peptides as prospective imaging agents, based on the structure of the parent 
p5 peptide. 
 In order to optimize peptides as agents for enhanced ApoA2c amyloid-targeting, 
multiple p5 variants were synthesized that focused on biochemical characteristics that 
govern amyloid detection.  Initially, the modification consisted of substituting all lysine 
residues with arginine residues to potentially increase the α-helicity of the peptide and, 
in turn, the strength of amyloid binding.  Next, extended peptides with four additional 
basic amino acid residues were created with the hypothesis that an increased net 
positive charge would enhance the peptide-amyloid interaction, which is principally 
electrostatic in nature.  A peptide with an N-terminal polyethyleneglycol (PEG) 
modification was synthesized to investigate the supposition that extended half-life via an 
increase in size would improve amyloid binding and coverage.  Finally, peptides with the 
incorporation of non-natural D-amino acids at the N-terminal were also developed and 
tested to hypothetically extend the half-life without altering the size of these amyloid-
targeting agents and, thereby, permit greater amyloid uptake. 
The work described in this thesis investigates these peptide variants for their 
ability to bind amyloid in both the AA and ApoA2c mouse models.  Surprising findings 
seen using the p5 peptide and peptides evaluated herein indicate that amyloid is a 
complex pathology and that it may be unreasonable to speculate that one peptide could 
detect all amyloid types.  Nonetheless, peptides optimized for the detection of certain 
amyloid diseases could be of clinical import for diagnosing the diseases and monitoring 
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responses to appropriate therapies.  An optimized peptide would be invaluable and 
permit earlier detection of amyloidosis. 
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Chapter 3 
 
Materials and Methods 
 
3.1 Peptides and proteins 
 
 The peptides used in the following studies were synthesized by Keck 
Laboratories (New Haven, CT) and RS Synthesis (Lexington, KY).  A table of the 
peptides along with their sequences, molecular weights and net charges is included 
(Table 3.1).  Synthetic recombinant Vλ6Wil fibrils were produced as described [81] by 
expression in E. coli.  The pelB leader resulted in accumulation of the protein in the 
periplasmic space from where it was isolated by osmotic shock and purified by reverse 
phase HPLC using a C8 solid phase matrix with a gradient of acidified acetonitrile as 
the mobile phase. 
 
3.2 Reagents 
 
Ascorbic acid ................................................................ Sigma Aldrich (St. Louis, MO) 
Blue dextran ................................................................. Sigma Aldrich (St. Louis, MO) 
Chloramine T ................................................................ Sigma Aldrich (St. Louis, MO) 
Heparinase I ................................................................. Sigma Aldrich (St. Louis, MO) 
Iodogen ........................................................................ Pierce (Rockford, IL) 
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Table 3.1:  Physical properties of synthetic peptides 
Peptide Amino Acid Sequence 
Molecular 
Weight 
(Da) 
Net 
Charge 
(+) 
p5 GGGYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q 3257.7 8 
p5R GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR Q 3481.8 8 
p5R+14 
GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR QAQRA 
QRAQA RQARQ 
5102.6 12 
p5+14 
GGGYS KAQKA QAKQA KQAQK AQKAQ AKQAK QAQKA 
QKAQA KQAKQ 
4766.4 12 
PEG-p5R+14* 
PEG-GGGYS RAQRA QARQA RQAQR AQRAQ ARQAR 
QAQRA QRAQA RQARQ 
~ 25,000.0 12 
p43** AQAYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q 3356.8 8 
p50 AQAYS KAQKA QAKQA KQAQK AQKAQ AKQAK Q 3356.8 8 
*The polyethyleneglycol modification is 20 kDa. 
**Those in red are D-type amino acids. 
The molecular weights and net charges were calculated using ProtParam [418]. 
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Isoflurane ..................................................................... Abbott Laboratories (Chicago, IL) 
Leupeptin ..................................................................... Thermo Scientific (Rockford, IL) 
Lyophilized gelatin ........................................................ Bio-Rad Labs (Hercules, CA) 
NaCl ............................................................................. Fisher Scientific (Fair Lawn, NJ) 
NaN3 ............................................................................. Sigma Aldrich (St. Louis, MO) 
NuPAGE™ LDS sample buffer 4X ............................... Novex (Carlsbad, CA) 
NuPAGE™ sample reducing buffer 10X ...................... Invitrogen (Carlsbad, CA) 
Phenylmethylsulfonyl fluoride ....................................... Sigma Aldrich (St. Louis, MO) 
Phosphate buffered saline ............................................ Sigma Aldrich (St. Louis, MO) 
Sodium metabisulfite .................................................... JT Baker (Phillipsburg, NJ) 
Tween-20 ..................................................................... Fisher Scientific (Fair Lawn, NJ) 
 
3.3 Mice 
 
Transgenic mouse models of AA and ApoA2c amyloidosis were used in the 
following studies.   
The H2-IL6 mouse model of AA amyloidosis was generated by the incorporation 
of human interleuken 6 (IL-6) cDNA into the C57BL/6 germ line with transcriptional 
control mediated by the murine major histocompatibility complex class one promoter (H-
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2Ld).  These transgenic mice were then mated with BALB/c mice for >20 generations. 
The overabundance of constitutively expressed IL-6 in these mice led to spontaneous 
AA amyloidosis by 8 to 9 months of age [379].  A breeding pair of H2-IL6 mice on the 
BALB/c background were kindly provided by Dr. Michael Potter from the Laboratory of 
Genetics at the National Cancer Institute of the National Institute of Health, Bethesda, 
MD.   
An experimental model of senile ApoA2c amyloidosis was generated by the 
overexpression of apolipoprotein A-2c, controlleded by the cytomegalovirus immediate 
early gene enhancer/chicken beta constitutive promoter [382].  Production of high 
concentrations of the amyloidogenic ApoA2c protein, in combination with an iv injection 
of preformed AApoA2c fibrils (amyloid enhancing factor (AEF): 10 – 100 µg), yielded 
severe systemic amyloidosis.  The initial breeding pair was kindly provided by Dr. 
Keiichi Higuchi from the Department of Aging Angiology at the Shinshu University 
School of Medicine, Matsumoto, Japan. 
Wild type BALB/c mice from Charles river or non-transgenic H2/IL-6 littermates 
were used as controls in these studies.  
All animals were housed in microisolator cages and provided food and water ad 
libitum.  The University of Tennessee Medical Center vivarium is an IAAALAC-
accredited facility, and all procedures described in this thesis were conducted in 
accordance with Institutional Animal Care and Use Committee (IACUC) approved 
protocols and in accordance with the Guide for the Care and Use of Laboratory Animals 
(8th Edition, National Academic Press, Washington, D.C. 2011). 
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3.4 AL amyloid extract preparation 
 
 Human AL amyloid was extracted from autopsy-derived tissues, both liver and 
spleen were used for this purpose.  The water floatation method used to separate 
amyloid proteins from unwanted tissue was previously described [244]. Briefly, 
approximately 20 g of tissue and 400 mL of 0.15 M NaCl were homogenized using a 
Polytron homogenizer (Binkmann Instruments, Westbury, NY) and then centrifuged at 
10,000 rpm (~ 15,000 x g) for 30 minutes.  The pellet was then mixed with 400 mL of 
0.15 M NaCl, and then homogenized and centrifuged, again, as described above.  This 
was repeated six or seven times; the supernatant from each centrifugation was 
discarded because it contained unwanted soluble proteins and non-amyloid tissue 
components.  After serial homogenization in 0.15 M NaCl the final pellet was 
resuspended in 300 mL of distilled H2O followed by further homogenization and one 
hour centrifugation (25,000 rpm).  This step was repeated using 200 mL of distilled H2O 
for two more consecutive runs; the final run was performed with 70 mL of distilled H2O 
for 3 hours at 10,000 rpm.  The supernatants from the final four centrifugation steps 
were pooled and contained the amyloid material.  The pooled amyloid suspension was 
lyophilized using a VirTis system (Gardiner, NY) and stored at room temperature in 
glass vials until used.  This material was supplied to me by the Human Immunology and 
Cancer Program at the University of Tennessee Graduate School of Medicine. 
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3.5 Radiolabeling peptides with Iodine-125 or Iodine-123 
 
 Several methods of radioiodination have been reported [419, 420], but the 
method used for our in vivo and ex vivo studies with iodine-125 (125I) or iodine-123 (123I) 
utilized the oxidative property of chloramine T [328, 421] to incorporate the radioiodide 
into the phenol ring of  tyrosine residues within the peptide sequence.  The radiolabeling 
procedure was described previously [328, 363, 409, 416].  Briefly, and with slight 
modification, a 5-mL Sephadex G-25 resin-packed column (GE Healthcare, 
Buckinghamshire, UK), with glass wool as a stopper was equilibrated with at least two 
bed volumes of carrier protein solution (0.2 µm pore size-filtered 0.1% gelatin in 
phosphate buffered saline [PBS], pH 7.2).   Peptides were dissolved in H2O to obtain a 
stock solution of ~ 1- 2 mg/mL, and for radiolabeling, ~50 μg of peptide (25 – 50 µL) 
was used in each reaction.  The peptide was added to 5 μL of NaPO4 buffer (pH 7.6) in 
a 1.5 mL-volume microfuge tube.  The 125I (Perkin Elmer, Waltham, MA) or the 123I 
(Nordion, Ottawa, ON, Canada) was then added to the reaction mixture—amounts of 
radioiodide varied with the planned experiment.  For example, in vivo imaging 
experiments required more radiolabeled peptide and, therefore, more radioactivity than 
ex vivo tissue binding assays (described in Section 3.9).  The purchased isotope 
contained ~ 1 mCi of radioactivity per 10 μL of 125I or 123I. Therefore, between 5 (500 
µCi) and 25 μL (2.5 mCi) was used for radiolabeling peptides for ex vivo and in vivo 
experiments, respectively.  Next, 10 μL of 2 mg/mL chloramine T dissolved in distilled 
H2O was added to initiate the labeling reaction.  As an oxidative agent, chloramine T 
was able to assist in the iodination of peptides by oxidizing iodide (I-) into iodine 
monochloride which was highly reactive and bound covalently to the aromatic rings 
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present in tyrosine side chains [422].  The iodination reaction was complete within one 
minute of chloramine T addition [328]; however, any residual reaction was quenched by 
the addition of 10 μL of 2 mg/mL Na2S2O5 (sodium metabisulfite) dissolved in distilled 
water. Thirty microliters of blue dextran exclusion marker (MW ~ 2x106) and 50 μL of 
carrier protein solution were added to the reaction mixture prior to chromatographic 
separation of free radioiodide. The reaction mixture was introduced onto the Sephadex 
G-25 column and elution buffer (0.1% gelatin in PBS) added drop-wise to the column.  
Once the blue dextran reached the column tip, 10 “30 second fractions” (~ 200 μL) were 
collected into plastic tubes to ensure that the radiolabeled peptide was collected.  A 
constant flow rate was maintained by continuous manual addition of carrier protein 
solution to the top of the column.  A small amount (~ 1 μL) of each fraction was 
transferred into a glass tube and the radioactivity measured using a gamma scintillation 
counter (Packard Cobra II, Perkin Elmer, Waltham, MA) set to detect either 125I or, using 
a larger energy detection window, 123I.  The fractions containing the majority of 
radioisotope (generally 3 fractions) were pooled and used for experiments.  The 
radiolabeling efficiency (i.e. the yield of radioiodinated peptide relative to the starting 
material) was typically > 50%.  
 
3.6 Radiolabeling peptides with Iodine-124 
 
 The method used for radiolabeling with iodine-124 (124I: IBA, Richmond, VA) 
used the same principles as those mentioned with 125I/123I radiolabeling; however, it was 
possible that stock solutions of 124I from the manufacturer contained oxidized iodine (I2), 
104 
 
instead of iodide (I-).  Therefore, 124I reactions were reduced prior to the oxidation step 
and reaction with the peptide [416].  The protocol began with the addition of 10 μL of 0.5 
M NaPO4 buffer at pH 7.6 to a 1.5 mL microfuge tube.  The radioisotope was then 
added in an amount appropriate for the planned experiment—these were usually in vivo 
studies so the number of mice to be used was an important consideration.  The stock 
solution was decay-corrected for 1 mCi per 10 μL; therefore, volumes between 10 - 50 
μL were generally used.  To reduce the 124I2 to 124I-iodide, 1 μL of 2 mg/mL fresh 
ascorbic acid in PBS, pH 7.2, was added.  The peptide, 50 μg dissolved in H2O (10-25 
μL), was brought up to 100 µL by the addition of PBS and was then added to the 
reaction mixture.  At this point, oxidation of the radioisotope was achieved by addition of 
7 μL of 1 mg/mL Iodogen dissolved in 100 % acetonitrile.  Two minutes were allotted for 
the reaction.  To fully quench the reaction, 50 μL of 2 mg/mL ascorbic acid was then 
added.  Approximately 20 μL of blue dextran exclusion marker and 50 μL of filtered 
0.1% gelatin in PBS were added to the reaction mixture before being introduced to a G-
25 size exclusion column (Section 3.5). 
Fractions were manually collected after the blue dextran marker reached the 
column tip. The first fraction was collected for 30 sec and the following three fractions 
collected for 1 min each.  Another 30 sec fraction was collected and the remaining 
volume discarded once it eluted.  The radioactivity of the fractions were measured with 
a dose calibrator (Capintec, Inc., Ramsey, NJ) set to detect 124I.  The majority of the 
radiolabeled product was within the 2nd and 3rd “one-minute” fractions, but the 4th 
fraction also often contained a salvageable amount of radiolabeled peptide product. The 
radiolabeling efficiency of this protocol was also typically 50%. 
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3.7. Radiolabeling peptides with Technetium-99m 
 
 To conduct SPECT imaging studies which utilize multiple radiotracers (i.e. dual 
energy SPECT imaging), 99mTc-radiolabeling [293] of one of the tracers was necessary.  
The technique used to radiolabel with 99mTc yielded incorporation into the peptides. 
To prepare for this technique, ~ 1 mg of SnCl2 and ~ 1 mg of cysteine were 
weighed in separate 1.5 mL microcentrifuge tubes (Fisher Scientific, Pittsburgh, PA).  A 
5 mL Sephadex G-25 column was poured as described in Section 3.5.  In the assigned 
reaction mixture tube, 20 μL of 0.15 N NaOH was added prior to the addition of ~ 20 μg 
of CGGY-p5 peptide.  To the tube containing SnCl2, 1 N HCl was added to yield a 100 
mg/mL suspension which was then diluted 100-fold by the addition of ultra-pure water.  
A 1:10 dilution of this solution in water yielded a final concentration of 0.1 mg/mL in Sn 
in 0.01 N HCl.  The cysteine was made up to 1 mg/mL by addition of PBS.  The 99mTc 
solution was supplied by the Nuclear Medicine department at the University of 
Tennessee Medical Center in Knoxville, Tennessee.  An appropriate amount of 99mTc 
was added to PBS in a separate tube.  At this point, there were 4 separate tubes: 1) 
SnCl2 solution; 2) Cysteine solution; 3) 99mTc solution; 4) the reaction mixture containing 
the peptide. 
Approximately 2 μL of the SnCl2 solution was applied to side of the reaction tube 
just above the peptide mixture.  The entire 99mTc solution was then added to the 
reaction tube, and the 2 μL of SnCl2 washed into the reaction mixture.  The reaction was 
allowed to take place for ~ 1 min at room temperature prior to the addition of 1 μL of the 
cysteine solution which quenched the reaction.  To the mixture, 2 drops of carrier 
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protein solution (0.1 % filtered gelatin in PBS) and ~ 20 μL of blue dextran solution were 
added.  The reaction mixture was then passaged through the Sephadex G-25 size 
exclusion column, and 4 fractions were collected once the blue dextran reached the 
glass wool at the tip of the column: fraction 1 was collected for 30 seconds and fractions 
2 – 4 were collected for 1 minute.  The radioactivity in these was measured using the 
Capintec (99mTc setting), and those with the majority of radiolabeled peptide were 
pooled for further use. 
 
3.8. Radiochemical purity testing 
 
 For all radiolabeled peptides, it was necessary to ensure that the product was 
radiochemically pure, i.e., that there was little free radioisotope present.  To do this, one 
μL of a 1:100 dilution of the radiolabeled peptide in PBS or 0.1% gelatin solution was 
analyzed using 10 % acrylamide SDS-PAGE gel electrophoresis (Novex, Carlsbad, 
CA).  To the peptide was added 7.5 μL of NuPAGE™ LDS sample buffer (4X) and 10 
μL of distilled H2O, and the solution was then boiled for 10 min. A second sample of 
peptide, prepared by addition of 7.5 μL of SDS buffer, 10 μL of distilled H2O and 2.5 μL 
of NuPAGE™ sample reducing buffer (10X), was also boiled for 10 min.  Approximately 
10 µL of both reduced and non-reduced peptide samples were loaded onto the gel.  If 
the sample was pure and did not contain aggregates or contaminants, both the reduced 
and non-reduced preparations migrated similarly through the gel (if the peptides 
contained no cysteine residues).  Electrophoretic separation was achieved with an 
FB200 system (Fisher Scientific, Dubuque, IA) set at a constant voltage of 200 V and a 
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current of ~ 1.0 Ǻ for 30 min.  To visualize the peptides, the gel was removed, covered 
with plastic wrap, and placed on a phosphor imager screen (Cyclone Storage Phosphor 
System, Perkin Elmer, Shelton, CT) for up to 1 h depending on how much radioactivity 
was in the loaded sample (samples with greater radioactivity required less exposure 
time).  In certain cases when very little radioactivity was loaded onto the gel, the 
exposure time was extended beyond 1 h with only slight increases in non-specific 
background occurring.  Image analysis, i.e. measurement of radiochemical purity, was 
performed using the OptiQuant software package (Packard, Downers Grove, IL).  If 
more than one band was observed, there may be aggregates or contaminants in the 
preparation.  Free radioisotope, when present, was seen at the gel “running” front.  In 
general, the radiochemical purity of the peptides used in these studies was > 95 % 
[328].  This procedure can be used for quality assurance of peptides labeled with many 
radioisotopes, i.e. 125I, 123I, 124I and technetium-99m (99mTc), but the half-life of the 
radioisotope should be taken into consideration so that this assay is performed in a 
timely manner. 
 
3.9. Tissue homogenate preparation 
 
 Preparation of the tissue homogenates used in all ex vivo peptide binding assays 
followed a procedure that has been reported [371].  The procedure remains unmodified 
for most experiments.  To begin, mouse tissues, namely liver, spleen, heart and lung, 
from two or three amyloid-laden mice (AA amyloid or ApoA2c amyloid) as well as 
control (healthy mice) were harvested at necropsy.  A portion of tissue from each mouse 
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was combined to yield a “pooled sample” and placed within a pre-weighed 50 mL plastic 
conical tube (Fisher Scientific, Pittsburgh, PA).  The total combined amount of each 
tissue was ~ 200 mg – 1500 mg net weight (depending on the tissue) and a 10-fold 
volume of PBS added to the sample.  To reduce the risk of tissue proteolysis, serine 
protease inhibitors, leupeptin and phenylmethylsulfonyl fluoride (PMSF), were included 
at 100 μg/mL each.  The solution was then mixed vigorously (speed 6) with 3 x 10 s 
bursts using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY) before 
being centrifuged at 4,000 x g for 10 min. The supernatant was discarded, and the pellet 
was resuspended in another 10-fold volume of PBS with 0.05 % Tween-20 (PBST) to 
prevent the homogenized material from sticking to the sides of the tube and 0.05 % 
NaN3 to inhibit bacterial growth. This solution was then homogenized a second time (as 
described above), before being stored at 4 °C for use in ex vivo peptide binding assays. 
This same procedure was used for healthy, amyloid-free (WT) tissues. 
 
3.10. Ex vivo peptide binding assays 
 
For these binding assays, tissue homogenates prepared from: AA, ApoA2c, or 
WT mice; human AL amyloid extracts, or; synthetic recombinant λ6 Wil variable domain 
(rVλ6Wil) fibrils were used. The general procedure for all materials was the same, but 
some parameters were unique. The method for tissue homogenate (specifically AA 
liver) binding assays and AL extract/rVλ6Wil fibril binding assays have been described 
in the literature [363, 371].   
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 3.10.1. Tissue homogenates 
 
  For an ex vivo peptide binding assay using tissue homogenate as the substrate, 
50 μL of the tissue homogenate was centrifuged at 21,000 x g for 3 min in a 1.5 mL-
volume microfuge tube.  This was done in duplicate (i.e., 2 samples per peptide).  The 
resultant supernatants were discarded and the pellets resuspended in 400 μL PBST.  A 
1:100 dilution of radiolabeled peptide in either 0.1 % gelatin/PBS or PBST was added to 
the tissue samples.  Twenty microliters of peptide (~ 200,000 counts per minute [cpm] of 
radioactivity) were added and the samples rotated for 1 h (Tube Rotator, Scientific 
Equipment Products, Baltimore, MD) at room temperature.  Samples were then 
centrifuged at 10,000 x g for 3 min; the supernatants, which contained unbound peptide, 
were carefully aspirated and placed in glass tubes, and the pellets were resuspended 
gently by hand in 400 μL PBST and washed by centrifugation, as described above. 
Supernatants from the second wash were added to those previously collected, 
and pellets were resuspended in 800 μL PBST and transferred into glass tubes.  The 
radioactivity in both the pooled supernatant samples (free peptide) and the pellet 
samples (bound peptide) were measured using a gamma scintillation counter with a 1 
min acquisition time and an energy window optimized for detection of 125I.  The 
percentage of radiolabeled peptide bound to the pellet was determined using the 
following formula: 
% 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑏𝑜𝑢𝑛𝑑 =  [𝑃𝑒𝑙𝑙𝑒𝑡
𝐶𝑃𝑀
𝑃𝑒𝑙𝑙𝑒𝑡 𝐶𝑃𝑀 + 𝑆𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 𝐶𝑃𝑀
]  ∗ 100 
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3.10.2. AL extracts and rVλ6Wil fibrils 
 
For ex vivo peptide binding assays using human AL amyloid extracts and 
rVλ6Wil fibrils, the protocol was essentially the same as described in Section 3.10.1 with 
the following modifications. The amount of amyloid extract or fibril used was 25 μL (~ 25 
µg of protein).  Since this procedure used half the reaction volume of the tissue 
homogenate protocol, only 10 μL of a 1:100 dilution of radiolabeled peptide (~100,000 
cpm) was added to all samples prior to their 1 h rotation at room temperature.  The 
samples were washed by centrifugation at 15,000 x g for 10 min because the pellets 
formed in this assay were not as “tightly packed” as tissue homogenates when using the 
standard protocol of 10,000 x g for 3 min. Increasing the speed and time of the 
centrifugation for the human AL extracts and rVλ6Wil fibrils yielded a more reliable 
(“stable”) pellet for the assay.  The reactivity in the supernatant and pellet fractions was 
measured as previously described, and the percent of radiolabeled peptide bound to the 
extract or fibril was determined (Section 3.10.1). 
 
3.11. Assessment of relative peptide affinity to amyloid using NaCl titration 
 
 Since the binding of poly-basic peptides to amyloid is thought to be due to 
principally electrostatic interactions of the peptide with the negatively-charged sulfate 
moieties presented by the hyper-sulfated heparan sulfate proteoglycans associated with 
amyloid, the peptide binding assay was modified slightly to determine a measure of the 
relative affinity of peptide for the substrate (e.g., tissue amyloid, AL extract or rVλ6Wil 
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fibrils).  This was achieved by performing the binding reaction in increasing 
concentrations of NaCl which will perturb the electrostatic binding interactions. 
The protocol was altered, from that described above (Section 3.10.2) after the 
initial centrifugation; the pellets were resuspended in either 0.25, 0.5, 0.75, 1.0 or 2.0 M 
NaCl instead of PBST. The volumes of each NaCl concentration were, as before, 400 
μL for tissue homogenates and 200 μL for AL extracts or rVλ6Wil fibrils.  The addition of 
NaCl at this step was designed to perturb the binding of radiolabeled peptide to the 
substrate during the 1 h incubation.  All wash and resuspension steps after the rotation 
used PBST, and the protocol was performed as described (Sections 3.10.1. and 
3.10.2).   
 
3.12. Imaging acquisitions 
 
 To assess the in vivo amyloid-targeting peptides, SPECT, dynamic PET and CT 
small animal imaging were performed.    All imaging data were acquired using the 
Inveon trimodality SPECT/PET/CT platform with the Inveon Acquisition Workplace 
software version X (Siemens Preclinical Solutions, Knoxville, TN). 
3.12.1. SPECT imaging 
SPECT imaging was used for visualization of 125I- or 99mTc-radiolabeled tracer 
distribution in mice.  The imaging protocol for the studies described herein has been 
previously reported [371, 416] with only slight modifications tailored to each study. The 
basic protocol included injection of the radiotracer (i.e., 125I-peptide, 125I-SAP, 99mTc-
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peptide) iv in the lateral tail vein of amyloid-laden or WT mice.  At the appropriate time 
post injection (dependent upon the radiotracer used), mice were euthanized, by 
isoflurane overdose, for post mortem imaging or anesthetized in an induction chamber 
with 3 % isoflurane in air at 2 L/min for live imaging.  For live imaging, paralube 
ophthalmic veterinary ointment (Dechra, Overland Park, KS) was applied to the eyes of 
the mice prior to positioning in a heated imaging chamber (M2M, Cleveland, OH) with a 
nose cone delivering 2 % isoflurane for the duration of the acquisition.  The Inveon 
imaging system acquired gamma photons (125I: 25 – 45 keV; 99mTc: 140 keV) at 60 
different projections, each acquired for 16 seconds, over 90 mm of scanner bed travel.  
To enhance the image resolution, the multi-pinhole (Mouse Whole Body) collimator 
[261] was used with a 30 mm radius of rotation.  SPECT data were reconstructed using 
a 3D ordered subset expectation maximization (OSEM) algorithm with 8 iteration and 6 
subsets.  The resulting image was displayed onto an 88 x 88 x 312 matrix with isotropic 
0.5 mm voxels. 
For studies utilizing two radiotracers in a single animal, a dual energy SPECT 
acquisition was performed.  This protocol has been described previously [293], but there 
were minor modifications for these studies.  Both radiotracers (e.g., 2 different peptides 
labeled with 125I and 99mTc) were injected simultaneously with similar amounts of 
radioactivity (~100 μCi / isotope).  After an appropriate uptake time (e.g., 2 h pi), mice 
were euthanized as described above.  The comparison of 2 radiolabeled peptides was 
achieved by performing 2 consecutive SPECT acquisitions (as described above).   
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3.12.2. Dynamic PET imaging 
 
 Dynamic PET imaging was used to visualize the biodistribution of radiolabeled 
peptides and to obtain their kinetic biodistribution in vivo.  The protocol has been 
outlined previously [416].  Mice were injected with 124I-labeled peptides following 
anesthesia and placement in the imaging chamber on the PET scanner bed—anesthetic 
delivery and mouse positioning were performed as described in section 3.12.1 for live 
SPECT imaging.  The data acquisition was initiated ~ 5 sec prior to injection of the 
radiotracer—this time delay was used to obtain the full kinetic biodisitrubtion of the 
radiolabeled peptide after injection. 
AA amyloid-laden or WT mice received ~ 20 μg of 124I-radiolabeled peptide (200 
– 400 μCi) in ~ 200 μL of sterile gelatin/PBS solution with 1 mM 
ethylenediaminetetraacetic acid (EDTA), which prevented blood coagulation upon 
injection.  PET data were acquired for either 60 or 120 min, depending on the study.  
The data were histogrammed for 124I with appropriate scatter and attenuation correction 
using a low resolution CT dataset (see section 3.12.3).  Reconstruction of the images 
was completed with the following binning parameters: 10 frames × 1 sec, 10 frames × 
30 sec, 30 frames × 114 sec and 60 frames covered the remainder of the data.  
Reconstruction was performed using a 3D OSEM with the Maximum A Posteriori (MAP) 
algorithm, and the image matrix was 256 × 256 × 159 with a pixel size of 0.0215 × 
0.0215 × 0.796 mm. 
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3.12.3. CT imaging 
 
 Low-resolution CT data were acquired in conjunction with both SPECT and 
dynamic PET image acquisitions, which provide anatomical reference correct for 
attenuation and scatter, respectively.  Images were acquired with an x-ray voltage 
biased to 80 kVp with an anode current of 500 μǺ .  Two bed positions were acquired to 
obtain a CT image of the entire mouse body.  Each acquisition comprised 121 
projections with a 225 ms x-ray exposure collected over 220° of continuous rotation 
around the imaged subject.  Low resolution (i.e., binning of 4) were used.  
Reconstruction of the data was performed with an implementation of the Feldkamp-
filtered back-projection algorithm onto a 224 × 224 × 635 matrix with isotropic 212.1 μm 
voxels. 
 
3.13. Image analyses 
 
 Both SPECT and dynamic PET data were analyzed with the 2D Inveon Research 
Workplace visualization software (IRW; Siemens Preclinical Solutions).  The methods of 
analysis for SPECT/CT data and dynamic PET/CT data were described by Martin et 
al.[416]. 
 3.13.1. SPECT/CT analysis 
 
 The SPECT data were automatically co-registered with CT data using IRW.  To 
obtain measurements of radioactivity (displayed as voxel intensities in arbitrary units), 
regions of interest (ROI) were manually drawn over multiple organs including the liver, 
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spleen, heart, lungs, leg muscle, stomach, pancreas, kidneys, intestines and bladder.  A 
3D ROI drawing tool (spherical or cubical) was used to encompass multiple CT slices of 
the organ.  This method provided a better representation of the radioactivity within the 
ROI.  The mean voxel intensity in the SPECT data associated with each ROI was used 
as a measure to compare radiotracer accumulation in each tissue and to compare the 
accumulation between amyloid-laden (AA or ApoA2c) and WT mice. 
 3.13.2. Dynamic PET/CT analysis 
 
 The 2D IRW software automatically co-registered PET data with CT data.  Prior 
to drawing ROI in the same manner as described in section 3.13.1, all image frames for 
the entire acquisition were summed.  The ROI for kinetic biodistribution analyses 
included the vena cava (a measure of blood pool), heart, liver, kidneys, stomach, thyroid 
and bladder of each mouse.  The software’s kinetic analysis tool generated time activity 
curves (TAC) for each ROI drawn.  The TAC data were fit to exponential equations 
using Prism version 6.0 (GraphPad Software Inc., La Jolla, CA). 
 
3.14. Necropsy 
 
 Mice were euthanized by isoflurane overdose in accordance with IACUC-
approved animal protocols and amyloid-laden and healthy tissues were harvested for 
tissue homogenate preparation, biodistribution measurements, histological examination 
and microautoradiography.  The tissues that were harvested for homogenate 
preparation (section 3.9) to be used in the ex vivo assay (section 3.10) were the liver, 
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spleen, kidneys, heart, lungs, intestines and pancreas.  These tissues were taken in full 
and stored in -20°C until used. 
 When performing experiments with radiolabeled peptides, tissues were 
harvested for biodistribution measurements and histological examination or 
microautoradiography (when 125I or 124I was used).  The tissues taken for these 
procedures were leg muscle, liver, pancreas, spleen, kidneys, stomach, ~ 2 inches of 
upper intestine (taken from the base of the stomach), ~ 2 inches of lower intestine 
(taken near the anus), heart, lung and, in some cases, tongue.  The contents of the 
stomach and intestinal samples were emptied prior to analyses.  A small portion of each 
tissue was used for biodistribution measurements, and the remainder of the tissue was 
placed in 10 % buffered formalin to be fixed for histology and microautoradiography.  
After use, the radioactive carcasses were held in a biohazard/radioactive freezer for 
radioisotope decay and disposal. 
 
3.15. Biodistribution measurements 
The amount of radioactivity within tissues was measured as described previously 
in several articles [378, 381, 409].  Samples of tissue, harvested at necropsy, were 
placed into tared plastic vials (Wheaton, Millville, NJ) and weighed.  The radioactivity 
(125I, 123I, 124I or 99mTc) in each sample was measured for 1 minute using a Wizard 3 
gamma counter (1480 Wallac Gamma Counter; Perkin Elmer, Boston, MA).  
Additionally, 10 μL of a diluted sample of the injected dose of radiotracer was added to 
2 separate vials and counted.  These were considered “decay-corrected” standards by 
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which to determine the number of counts equivalent to the injected dose.  The 
biodistribution data were determined with the following formula and the data expressed 
as a percent injected dose per gram (%ID/g): 
% 𝐼𝐷 𝑔⁄ =  (𝑐𝑜𝑢𝑛𝑡𝑠 𝑝𝑒𝑟𝑚𝑖𝑛[𝑐𝑝𝑚] 𝑡𝑜𝑡𝑎𝑙 𝑐𝑝𝑚⁄ ) × (100 𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡[𝑔]⁄ )  
 
3.16. Autoradiography and Histology 
 
 Confirmation of radiotracer localization to amyloid deposits in tissue sections was 
obtained by comparing microautoradiography and Congo red (CR)-stained histological 
tissue sections [378, 381, 409].  Tissues harvested at necropsy were fixed in 10% 
buffered formalin for at least 24 h prior to being embedded in paraffin blocks.  For 
autoradiography, sections ~ 4 – 6 μm thick were cut from the blocks and placed onto 
Plus™ microscope slides (Fisher Scientific, Pittsburgh, PA).  The slides were then 
dipped in NTB2 emulsion (Eastman Kodak, Rochester, NY) and stored in the dark for a 
predetermined amount of exposure time depending on the study [423]—tissue 
specimens taken from imaging experiments were typically stored for 4 days prior to 
development; studies of biodistribution only, that did not require as much radioactivity, 
were exposed to the photographic emulsion for 10 days prior to development.  The 
sections were then counter-stained with hematoxylin and eosin and examined with light 
microscopy.  Radiotracer accumulation was evidenced by the presence of black silver 
grains within the tissue sections. 
 Consecutive 4 – 6 μm-thick slices of the same paraffin-embedded specimens 
were then stained with freshly prepared alkaline CR solution.  For the detection of CR 
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birefringence, all sections were examined by light microscopy (DM500, Leica, 
Bannockburn, IL) using cross-polarized illumination.  Microscopic images were taken 
using a cooled, charge-coupled device camera (SPOT, Diagnostic Instruments, Sterling 
Heights, MI).  Some studies involved imaging CR fluorescence using epifluorescent 
illumination with a rhodamine (red) filter [416].  
 
3.17. Statistical analyses  
 Statistical analyses (e.g., unpaired/two-tailed/student t-tests and correlation 
analyses) were performed using the Prism software package (GraphPad, LaJolla, CA).  
Estimation of statistical significance was based on p < 0.05. 
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Chapter 4 
 
Peptide characterization studies 
 
4.1. Overview 
 
 The peptides to be studied in this thesis for amyloid binding were characterized 
using several in vitro and ex vivo studies.  Previously, circular dichroism of the peptide 
p5 revealed that it has a propensity to form an α-helix in a solution of more than 30% 
trifluoroethanol (TFE)—a chemical known to promote the formation of helical secondary 
structure [371, 424].  Additionally, the peptide from which p5 was derived, K8, was 
shown to adopt an α-helix in the presence of heparin [414].  These studies suggested 
that p5 adopts a secondary structure in the presence of its ligand (or “when bound to 
target”); the notion of helical peptide structure was reiterated in the predicted structure 
of the peptide [363, 371, 415].  A linear array of positive charges aligned to one face of 
the peptide was predicted by I-TASSER modeling; this structural property was thought 
to facilitate in p5-GAG interactions [371].  Given these structural properties which likely 
make the peptides more amenable to bind all amyloid, we characterized the interaction 
of peptides to a battery of amyloid-related substrates.  The ex vivo binding assays 
described in section 3.10 were used.  This chapter surveys the interactions of peptides 
p5, p5R and p5R+14 with various amyloid-laden materials including AL patient-derived 
amyloid extracts, recombinant Vλ6Wil fibrils, and AA or ApoA2c amyloid-laden mouse 
tissue homogenates.  Although AL and ATTR are the most common forms of human 
visceral amyloidosis, there are no good experimental models of these diseases; 
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therefore, we used murine models of AA and ApoA2c amyloidosis which represent the 
most widely studied models of visceral amyloidosis. 
 
4.2. AL extract binding studies with 125I-p5 
 Patient-derived AL amyloid extracts that contain fibrils, HSPG and numerous 
accessory molecules were used to study peptide binding.  The study outlined below was 
recently published in Biochemical and Biophysical Research Communications [363].  
Briefly, 9 patient samples derived from either the liver or spleen of confirmed AL amyloid 
patients was evaluated; additionally, the collection included both ALκ and ALλ amyloid 
types so as to not bias the study to one isotype of AL fibril.  Radioiodinated p5 was 
incubated with approximately 25 μg of amyloid extract (which contains HSPG and fibrils 
but only negligible amounts of SAP and no DNA components) and a peptide binding 
assay performed (Section 3.10.2).   
Results 
As seen in Figure 4.1, results of this study indicated that the reactivity of p5 with 
the extracts was quite variable (% peptide bound to the amyloid pellet ranged from 2% 
to 74%).  Since amyloidosis in patients is such a heterogenous disease in terms of 
amyloid load per organ [1, 19], the inconsistent amyloid-binding was not entirely 
unexpected; however, as evidenced by Alcian blue measurements, these extracts 
contained sulfated GAGs, a major ligand of p5, making the near lack of p5 binding, in 
some cases, perplexing.   
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Figure 4.1:  125I-p5 binding to AL extracts.  The heterogeneity of AL patient-derived 
extracts was demonstrated by the variable reactivity of 125I-p5 with the extracts in the 
peptide binding assay.  There was a wide range of peptide reactivity in the nine samples 
tested. (L) liver, (S) spleen.   
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Therefore we used the GAG-clearing enzyme, heparinase I, to remove the 
heparan sulfate GAGs [363].  We posited that without the hypersulfated GAGs, a known 
target of p5, there would be diminished binding in all of the samples.  Heparinase I was 
added to each AL extract prior to performing the ex vivo peptide binding assay.  We 
observed a decrease in p5 binding to all samples; however, there was still significant 
binding.  This finding suggested that there must be another component in the amyloid 
extracts to which p5 can bind.  In the heparinase-treated samples, a positive linear 
correlation was found between p5 binding and ThT fluorescence (a measure of the 
fibrils) in the 5 samples which exhibited the highest ThT measurements (Figure 4.2).  
These data suggested that, in the absence of HSPG, there was a positive correlation 
with p5 binding relative to the fibril content.  Thus, we hypothesized that p5 may also be 
able to interact directly with AL amyloid fibrils. 
It is known that synthetic fibrils display an electronegative surface to which the 
primarily positive antigen binding site of camelid antibody, B10, can interact [362, 407].  
Furthermore, the polybasic nature of p5 with a predicted linear array of positively-
charged amino acids positioned on one face of the peptide may render the peptide 
capable of also binding fibrils.  This was tested using synthetic rVλ6Wil fibrils, which 
lack GAGs and other amyloid associated proteins, in the peptide binding assay.  Our 
data showed that p5 interacted with synthetic fibrils with ~ 80% peptide bound (Figure 
4.3).  Therefore, p5 was shown to interact with both the HSPG and the fibril components 
of AL amyloid, and our studies demonstrated that: 1) amyloid is an extremely 
heterogenous material; and 2) p5 can recognize two of the primary components in 
amyloid deposits. 
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Figure 4.2: Positive correlation of 125I-p5 binding and ThT fluorescence in 
heparinase-treated samples.  The five AL extracts with the highest ThT measurement 
showed a positive correlation with 125I-p5 binding after heparinase treatment. This 
proposed that peptide p5 may bind to amyloid fibrils directly. (Image adapted from 
[363]). 
 
 
Figure 4.3:  125I-p5 binds to synthetic recombinant Vλ6Wil fibrils.  The binding of 
125I-p5 to heparinase-treated AL samples and Vλ6Wil fibrils supported the interaction of 
this peptide with fibrils directly. (Image taken from [363]).  
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4.3. Peptide binding to amyloid-laden tissue homogenates 
Mouse tissue homogenates were used to assess peptide binding with a more 
“complex” amyloid system which includes HSPG, fibrils, SAP, as well as DNA and other 
cellular debris that was not fully separated from the amyloid in the tissue homogenate 
preparation.  One of the experiments routinely performed when screening new peptides 
for amyloid binding was an ex vivo binding assay utilizing liver homogenate from H2-IL6 
transgenic mice with confirmed AA amyloidosis. The assay was performed as described 
in section 3.10.1.  The peptides tested were: the parent peptide, p5; an arginine 
derivative of the peptide, termed p5R; and an extended version of p5R, known as 
p5R+14.  The arginine variant of p5 was analyzed because literature suggested that 
arginine has a higher propensity to form an α-helix which may enhance binding with 
amyloid [425].  Thus, it was hypothesized that p5R would exhibit greater binding to AA 
amyloid-laden tissue when compared to p5.  The extended version of these peptides, 
p5R+14, combined both the higher propensity to form an α-helix with an additional 14 
amino acids that included four more arginine residues making the resultant net charge 
+12 instead of +8 as seen with p5 and p5R.  It was postulated that, due to these two 
properties (enhanced helicity and increased charge), p5R+14 would bind more 
effectively than p5R.  The reasoning behind this stemmed from a recent study which 
investigated the in vivo binding efficacy of a 24 amino acid p5R variant with a +6 
charge.  Data suggested that this shortened p5R peptide did not bind to amyloid as well 
as the intact peptide [371].  Therefore, we hypothesized that an increase in peptide 
charge may enhance amyloid binding.  Based on this hypothesis, we expected to see 
the following peptide pattern relative to their binding to amyloid-laden tissue 
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homogenates: p5 < p5R < p5R+14.  For these studies, we used organs from the H2/IL-6 
and ApoA2c transgenic mice. 
Results 
 Our studies indicated that all 3 peptides were able to bind to AA amyloid-laden 
homogenates from liver, spleen, kidney, pancreas and intestines in a peptide binding 
assay (Figure 4.4A).  The lung had much less binding with all peptides, but this was 
expected because very little, if any, AA amyloid forms in the lungs.  The heart revealed 
increasing binding from p5, to p5R, to p5R+14, but even with the p5R+14, there was 
less interaction than with all other tissues—again, due to the scant deposits in this 
tissue.  The differential binding of the peptides (p5 < p5R < p5R+14) was also seen in 
the kidney and the intestines (Figure 4.4A).  Thus, with some tissues, the expected 
pattern of peptide binding, based on our conceptual model, was observed, but this was 
not the case for all tissues studied.  The liver and spleen generally have more amyloid 
relative to the other tissues (Congo red scoring of these 2 tissues was typically 3+ to 4+ 
on a scale of 0 – 4+) which could explain the higher percentages with all peptides in 
these tissues (nearly all were > 50%).   
The binding of these peptides to WT tissues revealed that, in all tissues, the 
p5R+14 peptide had the most non-specific binding (Figure 4.4B).  In some tissues, 
namely the pancreas and the intestine, p5R also displayed more off-target binding than 
that seen with p5.  The greater net positive charge associated with p5R+14 may have 
enhanced its affinity for other components within the homogenates, possibly the 
negatively charged DNA.  Regardless, all peptides exhibited much greater binding to  
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Figure 4.4:  Peptide binding to tissue homogenates.  (A) Peptide reactivity with AA 
tissues.  (B) Non-specific binding of peptides to WT tissues.  (C) Peptide reactivity with 
ApoA2c tissues.  In all graphs: 125I-p5   ,125I-p5R    and 125I-p5R+14   . 
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the highly AA amyloid-laden homogenates, suggesting that each of these are capable of 
specifically interacting with ex vivo AA amyloid deposits. 
Given these findings for the 3 peptides, they were further tested in the same 
assay to determine their efficacy in binding to ApoA2c amyloid-laden mouse tissues 
(Figure 4.4C).  The distribution of amyloid in these tissues varies slightly from that seen 
in AA mice; the main difference is that there is much more amyloid deposition in the 
lung and heart relative to AA tissues.  The data indicated that p5 and p5R interacted 
much more weakly with ApoA2c amyloid in this system relative to the binding with AA 
amyloid.  The spleen, a site known to be largely affected with ApoA2c amyloid, 
exhibited minimal binding with the p5 and p5R peptides.  In contrast, positive binding 
was seen in all ApoA2c tissues with p5R+14 (Figure 4.4C). 
 These findings suggest that AA and ApoA2c amyloids, although they do contain 
HSPG and fibrils, are remarkably physico-chemically different.  Given that the 
homogenized mixtures should, theoretically, expose the amyloid for binding with no 
hindrances to the interaction (e.g. access to the vasculature), the structural composition 
of the deposits themselves must be different—e.g. p5 and p5R do not recognize their 
targets within ApoA2c amyloid as compared to AA amyloid.  The ApoA2c tissues 
appear to require a peptide with higher net positive charge to achieve the best peptide-
amyloid interaction.  There are numerous reasons why this may be the case: ApoA2c 
amyloid may contain a ratio of the 2 known peptide targets, hypersulfated HSPG and 
fibrils, which makes certain peptides less effective at binding to this type of amyloid; the 
ApoA2c amyloid deposits may consist of more apolipoproteins than AA amyloid 
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deposits, hindering peptide reactivity; or ApoA2c fibrils may have a different charge 
motif than AA fibrils, thus, decreasing peptide binding. 
 This study led us to investigate the relative strength of binding between the 
peptides and certain AA and ApoA2c tissues. 
 
4.4. Binding studies in the presence of increasing concentrations of sodium 
chloride to assess the relative strength of electrostatic binding of peptides with 
amyloid 
 Since there were unexpected inconsistencies in binding between the peptides 
and the two amyloid types, sodium chloride (NaCl) titrations were performed to assess 
the strength of the electrostatic interaction between p5, p5R and p5R+14 with AA and 
ApoA2c amyloid.  The tissues used included AA liver and spleen and ApoA2c liver, 
spleen, heart and lung—all were known to contain considerable amyloid for their 
respective disease.  The pancreas and intestine were not used in these studies 
because of the inappropriate nature of the material after incubation with NaCl (i.e. the 
pellets were unable to be separated from the supernatants).   
The same peptide binding assay was used in these studies with only slight 
modifications.  For the NaCl titration studies, concentrations of NaCl (0.15 M (PBST), 
0.25 M, 0.5 M, 0.75 M, 1.0 M and 2.0 M) were used in the peptide-homogenate 
incubation step to attempt interference with the peptide-amyloid electrostatic interaction.  
Even though we observed that all peptides bound impressively to AA liver and spleen 
tissues, we hypothesized that it would take a higher concentration of NaCl to inhibit 
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binding by 50% in samples containing p5R+14 due to the +12 net charge on the 
peptide.  For the ApoA2c tissues, we hypothesized that the concentration of NaCl 
needed to interfere with binding would follow a similar pattern but would be less for all 
peptides when compared to the concentrations used in AA tissues—a hypothesis 
derived from the observation that the peptides interacted much less avidly with ApoA2c 
tissue in PBST as compared to AA. 
Results 
The data indicated that, with p5, binding to AA liver required ~ 0.4 M NaCl to 
inhibit 50% (IC50) of the maximum binding observed with PBST.  The IC50 for p5R with 
AA liver was ~ 0.9 M NaCl, and was > 2.0 M NaCl for p5R+14 (Figure 4.5).  The same 
pattern was observed with AA spleen with IC50 values for each peptide: IC50 ~ 0.5 M 
NaCl for p5, IC50 ~ 1.7 M for p5R and IC50 > 2.0 M NaCl for p5R+14 (Figure 4.5).  The 
NaCl titration on AA tissues indicated that there was an ionic interaction between the 
peptides and amyloid since binding decreased with increasing salt concentration.  
Additionally, the strength of the ionic binding for the tested peptides followed the 
expected pattern for AA tissues: p5 < p5R < p5R+14.  Interestingly, these data suggest 
that, for peptide p5R+14, binding other than electrostatic interactions may be occurring. 
  Titration of peptides on ApoA2c tissues demonstrated lower IC50 values for most 
samples, which was consistent with the decreased binding seen earlier.  For both p5 
and p5R, the IC50 for each of the 4 tissues tested was < 0.35 M NaCl.  However, for 
p5R+14, there was a much wider range of NaCl concentrations needed to interfere with 
tissue amyloid binding.  For the heart and liver, the IC50 of p5R+14 was < 0.4 M NaCl, 
whereas the spleen IC50 was 0.47 M, and the lung required a concentration >0.8 M  
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Figure 4.5: Peptide binding to AA tissues in the presence of NaCl.  The NaCl 
titration indicated that the peptides bind to AA liver and spleen with differing affinities.  
For this type of amyloid, peptide binding followed the hypothesized pattern: p5 < p5R < 
p5R+14.  
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NaCl.  These data, summarized in Figure 4.6, suggested that the peptides had a lower 
binding affinity for ApoA2c amyloid than AA amyloid, but of the 3 peptides, p5R+14 
exhibited the strongest binding to most tissues, consistent with our hypothesis.   
The differences observed in the NaCl titration reiterate that AA and ApoA2c 
amyloids, while comprised of similar components, are obviously “different”.  The varying 
degrees of peptide binding may be the result of differing amounts of HSPG or fibrils in 
the tissues and the different affinity that each peptide has for these components.  If 
peptides exhibit a greater affinity for HSPG but the composition of the deposit contains 
more fibrils than HSPG, the peptides would not be expected to bind as well to these 
samples.  Since p5 and p5R bind with much lower affinity than p5R+14, perhaps the 
former 2 peptides have a greater propensity for a target that is underrepresented in 
ApoA2c amyloid.  A report in 2013 by Wall et al. indicates that p5 and p5R both bind 
immobilized heparin, but p5R (~ 1.3 M NaCl) has a greater affinity than p5 (~ 0.9 M 
NaCl) [371].  
Affinity for immobilized heparin may suggest that p5 and p5R preferentially bind 
to HSPG in amyloid deposits.  All 3 peptides were subjected to a NaCl titration binding 
study with rVλ6Wil fibrils to directly compare their affinity for fibril-binding in the absence 
of HSPG. The titration revealed that p5R+14 expressed a much higher affinity for 
synthetic fibrils than the other two peptides (Figure 4.7); an IC50 of between 0.75 M and 
1.5 M NaCl was seen previously with p5 and p5R.  On the contrary, p5R+14 appeared 
to plateau at 2.0 M NaCl as evidenced by > 50% bound even in the presence of 4.0 M 
NaCl.  Thus, there was a very high affinity of p5R+14 for this synthetic fibril.   
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Figure 4.6: Peptide binding to ApoA2c tissues in the presence of NaCl.  (A) 125I-p5 
reactivity. (B) 125I-p5R reactivity. (C) 125I-p5R+14 reactivity.  The peptide reactivity with 
ApoA2c amyloid required a much lower concentration of NaCl than was seen with the 
AA tissues, but the same pattern was observed: p5 < p5R < p5R+14.  (Many thanks to 
Brianna Rader and Angela Lee for their assistance in obtaining the NaCl titrations). 
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Figure 4.7: Peptide affinity for recombinant synthetic Vλ6Wil fibrils measured by 
NaCl titration.  The peptides showed variable affinity for fibrils. Notice that p5R+14 
would require > 4.0 M NaCl for 50% binding inhibition. (Thank you to Mrs. Angela 
Williams for the historic p5 and p5R NaCl titration data).  
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Since the binding inhibition of p5R+14 plateaued, it was worth speculating that 
the binding may be more than simply ionic in nature.  To test this, we examined the 
binding of p5R+14 to rVλ6Wil in the presence of 4.0 M urea which should disrupt 
peptide-fibril hydrophobic interactions.  As shown in Figure 4.8, urea treatment resulted 
in a decrease in p5R+14 binding to rVλ6Wil fibrils by ~ 20% compared to fibril binding in 
PBST.  To ensure that the 4.0 M urea treatment reduced peptide-fibril interactions 
without diminishing fibril structure, four different concentrations of urea were added to 
plated fibrils alone; after 1 hour at room temperature, ThT fluorescence was measured 
at 490 nm.  The data indicated that there was no significant difference between the 
fluorescence emissions in any of the fibril samples, treated or untreated with urea 
(Figure 4.9); therefore, the fibrils were intact.  The data suggested that p5R+14 binding 
to fibrils may consist of both ionic and hydrophobic interactions; the two tested 
treatments were unable to completely inhibit binding, however.  These experiments 
could assist in explaining the various peptide-ApoA2c amyloid interactions.  In short, the 
molecular composition of ApoA2c amyloid may contain more fibrils with respect to 
HSPG, resulting in greater p5R+14 binding and decreased affinity of peptides p5 and 
p5R. 
 
4.5. Conclusions 
The studies presented in this chapter were designed to characterize the 
interactions of peptides p5, p5R and p5R+14 with synthetic and “native” amyloid and to 
assess the nature of those interactions.  The data support the thesis that peptides can 
be used to specifically target amyloid in various forms—patient extracts, tissue  
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Figure 4.8:  125I-p5R+14 binding to rVλ6Wil fibrils in the presence of both NaCl and 
urea treatments.  Peptide binding in PBS alone represented maximum binding.  After 
4.0 M urea treatment, ~ 20% of the maximum peptide reactivity with fibrils was lost.  As 
was previously determined, 4.0 M NaCl interfered with ~ 50% of the maximum binding.  
These treatments and the resultant peptide reactivity indicated that p5R+14 may use 
both hydrophobic and ionic interactions to bind to synthetic fibrils.  Neither treatment 
resulted in full interference of peptide binding, however. 
 
 
 
 
Figure 4.9:  Urea treatment of rVλ6Wil fibrils.  The one-way ANOVA test revealed 
that up to 4.0 M urea treatment resulted in no significant difference in fibril structure as 
measured by ThT fluorescence (p = 0.9649). 
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homogenates and synthetic fibrils.  The model systems used proved that the 
modifications made to p5 resulted in stronger amyloid binding (in most cases).  The 
data also indicated that AA and ApoA2c amyloids are structurally different regardless of 
the ubiquitous presence of fibrils and HSPG in both types of deposits.  The peptides did 
not behave identically in each of the model systems, which suggested that they may 
each prefer binding to HSPG or fibrils differentially.  These ex vivo studies were used to 
characterize how p5 and its variants interact with multiple amyloid types; this 
information was the foundation on which the following experiments were designed and 
conducted to examine amyloid-targeting with various peptides. 
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Chapter 5 
Dual isotope SPECT/CT imaging of peptides in ApoA2c mice 
 
5.1. Overview 
 In our laboratory, we have found that many peptides interact with amyloid 
materials in ex vivo assays.  The previous chapter indicated that peptides p5, p5R and 
p5R+14 bound with varied affinities to AA and ApoA2c amyloid extracts likely due to 
preferential interactions with GAGs and fibrils, but these data could not guarantee that 
similar peptide behavior would be observed in vivo since possible hindrances to 
peptide-amyloid reactivity (i.e. weak vascularization of amyloid-laden tissues and serum 
half-life of the peptide tracer) are factors that must be considered.  The literature 
provides data pertaining to the in vivo reactivity of the parent peptide, p5, in the 
transgenic H2/IL-6 model of AA amyloidosis [293, 409].  With this peptide, SPECT/CT 
imaging studies have been conducted and revealed positive and specific uptake in 
amyloid-laden organs; the murine model deposited ample AA amyloid in several 
tissues, and autoradiographs (ARG) showed preferential binding and co-localization of 
125I-p5 with amyloid deposits (see Figure 1.24; [409]).  To ascertain amyloid-reactivity in 
a different model of the disease, this chapter focuses on the in vivo analyses of peptides 
p5 and p5R+14 in transgenic ApoA2c mice.  To induce amyloidosis, the mice were 
injected with 50 μg of ApoA2c intestine-derived AEF at 14 weeks of age, and they were 
used at 12 weeks post AEF induction when sufficient amyloid was present.  Prior to this 
study, no in vivo small animal imaging of ApoA2c mice had been conducted or reported.  
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With that, we were uncertain which, if any, peptides would target amyloid in these mice 
such that the pathology could be visualized.  Given that p5 is the parent peptide to 
these studies and that it provided positive amyloid imaging in AA mice, we opted to 
investigate it first in this model of amyloidosis; additionally, we investigated p5R+14 
since it bound most effectively of all the tested peptides to ApoA2c tissue homogenates 
in the ex vivo binding assay (Figure 4.4C).  The method by which these 2 peptides were 
comparatively evaluated was dual-isotope SPECT/CT imaging; by radiolabeling the two 
peptides with different radioisotopes, in this case 99mTc and 125I, a direct comparison 
within a single mouse was possible.  This type of study was previously conducted in 
which peptide p5 and SAP were compared [293].  In addition to imaging, tissues were 
harvested in order to obtain biodistribution measurements for both radiotracers, and for 
the 125I-labeled p5R+14, ARG was performed to confirm peptide-amyloid co-localization. 
 
5.2. Dual-isotope SPECT/CT imaging of peptides in ApoA2c mice 
 As previously stated, radioiodinated p5 successfully imaged AA amyloidosis with 
significantly higher tissue biodistribution measurements compared to WT controls [423].  
Experimental conditions from those studies involved injection of the radiotracer and 
imaging using mice at approximately 3 – 6 weeks post induction of amyloidosis with AA 
spleen-derived AEF.  The transgenic model of AA amyloidosis yielded abundant 
amyloid deposition within this time frame.  For ApoA2c transgenic mice, however, 9 – 
11 weeks post AEF induction were required to yield a comparable amount of amyloid.  
For the peptide comparison study, p5R+14 was radiolabeled with 125I (Section 3.5), and 
peptide p5 was radiolabeled with 99mTc (Section 3.7).  For each radiotracer,         
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Figure 5.1: Quality assurance of radiolabeled p5 and p5R+14.  (A) Results of the 
SDS-PAGE radiopurity analysis for 99mTc-p5 and 125I-p5R+14.  Both the non-reduced 
and reduced samples of peptides are included.  The gel indicates that there was a small 
quantity of free 125I in the p5R+14 product and no detectable 99Tc in the radiolabeled p5 
product.  (B) Peptide binding assays demonstrating amyloid reactivity.  Both 
radiolabeled peptides show positive reactivity with AA liver homogenate and minimal 
reactivity with WT liver.   
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1 μL of 1:100 diluted product in 0.1% purified gelatin was tested for radiopurity with 
SDS-PAGE (Section 3.8).   Little free isotope was detected for either peptide (Figure 
5.1A).  To ensure that both radiolabeled peptides were amyloid-reactive, they were 
tested by binding to AA liver homogenate in the ex vivo (pull down) assay (Section 
3.10.1; Figure 5.1B), and both peptides were shown to be amyloid-reactive.  An 
approximately equal amount of radioactivity of each tracer (~ 200 μCi) was injected into 
the lateral tail vein of WT and ApoA2c mice (total volume ~ 200 μL per mouse).  Mice 
were euthanized at 2 h pi, and biodistribution of each radiotracer was established with 
SPECT/CT imaging.  The imaging protocol consisted of 2 consecutive SPECT 
acquisitions—the first to acquire only high energy (~ 140 keV) 99mTc photons and the 
second for low energy (~ 30 keV) 125I photons.  A single CT acquisition provided 
anatomical reference for both SPECT datasets.   
Since the peptide tracers were radiolabeled with different isotopes, both their 
catabolism and their distribution in mice were not expected to be equivalent (e.g. 
dehalogenation of only the radioiodinated peptide).  To determine the “background” in 
vivo distribution of radioactivity associated with these tracers, approximately the same 
activity equivalent was injected into healthy mice.   
Results 
SPECT/CT imaging of WT mice at 2 h pi revealed that 125I-p5R+14 underwent 
dehalogenation when it encountered deiodinase enzymes in both the liver and kidneys 
[416, 426]; this resulted in the release of radioiodide and its uptake in the stomach and 
thyroid.  In contrast, the 99mTc-p5 radiotracer accumulated in the kidneys and intestines 
as a result of peptide clearance (N.B. 99mTc is not prone to dehalogenation activity).  A 
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representative WT mouse demonstrating these two different radiotracer distributions is 
shown (Figure 5.2).  The bladder was emptied naturally when mice were euthanized 
prior to image acquisition and was not visible with either radiotracer in the image.   
Although peptide p5 has previously been shown to interact with AA amyloid in all 
affected organs such that whole-body amyloid burden could be visualized with 
SPECT/CT imaging [293], the visual biodistribution of p5 in ApoA2c mice provided 
much less information about the amyloid burden due to decreased reactivity with 
ApoA2c amyloid.  99mTc-p5 in the ApoA2c mouse revealed minimal uptake in amyloid-
laden tissues; the image was dominated by radiotracer accumulation in the kidneys in 
addition to hepatobiliary clearance evidenced by radiotracer in the intestines (Figure 
5.3).  For ApoA2c mice, renal amyloid pathology is typically less extensive than that 
seen in AA mice, and the kidneys are not considered a major organ for amyloid 
deposition [382]; thus, the enhanced renal uptake in ApoA2c mice is presumably 
associated with radiotracer clearance rather than amyloid-reactivity.  Since amyloid 
deposition within the intestines of ApoA2c is a common manifestation, the radioactivity 
displayed in the intestines of the ApoA2c mice could be considered amyloid-specific, but 
the biodistribution measurements suggested otherwise (Figure 5.4).  After the removal 
of feces from the upper and lower intestines, there was little 99mTc-p5 associated with 
these organs in ApoA2c or WT mice.  SPECT images of 99mTc-p5 distribution 
demonstrated similar patterns between diseased and healthy mice—this further 
suggested that presence of 99mTc-p5 in these tissues was associated with radiotracer 
clearance and not amyloid uptake.  Biodistribution measurements (reported as % ID/g) 
were made for the liver, spleen, upper/lower intestines, heart, kidneys, lungs and  
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Figure 5.2:  Dual energy SPECT/CT image representing the distribution of 125I-
p5R+14 and 99mTc-p5 at 2 h pi.  The standard distribution of 125I-p5R+14 is shown in 
blue and is present in the thyroid and stomach due to peptide dehalogenation.  The 
distribution of 99mTc-p5 is shown in orange and is seen in the renal cortices due to 
peptide clearance and, potentially, retention of the 99mTc nuclide in the proximal tubules.  
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Figure 5.3:  Dual energy SPECT/CT image demonstrating the distribution of both 
99mTc-p5 and 125I-p5R+14 in a representative ApoA2c mouse.  The image shows 
uptake of 99mTc-p5 (yellow-orange) in the kidneys and intestines which are both likely 
associated with peptide clearance.  Distribution with 125I-p5R+14 (blue) was more 
extensive and can be seen in the liver and heart.  Intestinal uptake may be associated 
with clearance or amyloid reactivity.  Accumulations in both the thyroid and stomach, 
however, are a clear result of radiotracer dehalogenation and free iodide sequestration.  
The image demonstrates that 125I-p5R+14 provided a more informative picture of 
amyloid deposition. 
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Figure 5.4:  Biodistribution measurements of 99mTc-p5 in ApoA2c and WT mice at 
2 h pi.  These measurements revealed that the uptake of radiotracer in each tissue did 
not differ between diseased and healthy mice.  Since the tracer was not dehalogenated, 
the route of clearance, the kidneys, displayed a much higher % ID/g than other tissues.  
The kidneys were plotted against the right axis due to their high level of uptake. 
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stomach of both ApoA2c and WT mice (Figure 5.4).  These quantitative measurements 
of tracer tissue distribution indicated that the difference in uptake of 99mTc-p5 between 
diseased and healthy mice was not significant in all tissues, with the exception of the 
observed renal activity.  Although not shown, SPECT/CT imaging of WT mice with free 
99mTc shows uptake in the renal cortices; therefore, it is likely that the radionuclide itself 
gets retained in the proximal tubules.  This suggests that the uptake observed with 
99mTc-p5 in ApoA2c mice was not amyloid-specific but was associated with peptide 
clearance and radionuclide retention. 
 Images and biodistribution measurements of 125I-p5R+14 in ApoA2c mice were 
quite disparate to those seen with 99mTc-p5.  The SPECT/CT imaging data revealed 
uptake of 125I-p5R+14 in amyloid-laden organs including the liver and heart (see Figure 
5.3).  There was also evidence of radiotracer dehalogenation with stomach and thyroid 
uptake of radioiodide.  As was stated before, the intestinal accumulation seen with 125I-
p5R+14 could have been associated with amyloid, or it might be associated with 
hepatobiliary clearance of the peptide.  It was more likely in this case, however, that the 
intestinal uptake was amyloid-specific because: 1) the biodistribution measurements 
obtained after imaging showed enhanced lower intestinal 125I-p5R+14 uptake compared 
to that seen in WT mice, and 2) the peptide would be dehalogenated in the liver and, 
therefore, not visible in the intestines.  A greater accumulation of 125I-p5R+14 was 
observed in most ApoA2c tissues (% ID/g) when compared to the WT tissues, but this 
finding was particularly noticeable in the spleen, lower intestines and lung, sites of 
significant ApoA2c amyloid accumulation (Figure 5.5).  To directly compare the uptake 
of both tracers in each of the tissues and accounting for any possible off-target binding,  
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Figure 5.5:  Biodistribution measurements of 125I-p5R+14 in ApoA2c and WT mice 
at 2 h pi.  A higher % ID/g of 125I-p5R+14 accumulated in most ApoA2c tissues (green) 
when compared to WT tissue (red) accumulation.  This was especially noticeable in the 
spleen, lower intestines and the heart. 
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the % ID/g of the tracers in each tissue was scaled by the average uptake obtained in 
the respective tissue within WT mice (i.e. ApoA2c mouse/mean WT).  These 
comparisons for each mouse independently revealed that 125I-p5R+14 dominated the 
accumulation profiles in most organs as compared to p5, due to its increased reactivity 
with ApoA2c amyloid (Figure 5.6).   
To further evaluate the accumulation of these two peptide radiotracers in ApoA2c 
mice, image analysis of the dual isotope acquisition was performed by drawing regions 
of interest over known ApoA2c amyloid-laden tissues such as the liver, heart and lungs.  
Although the uptake in these tissues was not clearly visible in each mouse, image 
analysis revealed a higher mean voxel intensity (reported as arbitrary units [au]) of 125I-
p5R+14 radiotracer in each of these organs when compared to 99mTc-p5 distribution 
(Figure 5.7).  Since the intestinal uptake visible in the images could not discern whether 
the radioactivity was associated with clearance or with specific amyloid-binding, the 
intestines were not included in the image analysis.  Image analyses confirmed the 
findings in the tissue biodistribution data—p5R+14 accumulated in ApoA2c amyloid-
laden tissues more effectively than p5.   
To ensure that the 125I-p5R+14 tissue uptake was amyloid-specific, portions of 
the harvested tissues were analyzed with microautoradiography (ARG).  Tissues were 
fixed in 10% buffered formalin for 24 h and developed after an emulsion exposure of 4 
days (Section 3.16).  Examination of the ARG revealed that 125I-p5R+14 co-localized 
with amyloid deposits (seen as CR birefringent material in consecutive slides; data not 
shown).  Although peptide p5R+14 clearly bound amyloid, there was evidence in the 
ARG that not all of the amyloid within certain tissues—namely the spleen and lung— 
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Figure 5.6:  Scaled comparisons of 99mTc-p5 and 125I-p5R+14 uptake in ApoA2c 
mice.   These graphs display the ratio of radiotracer uptake in ApoA2c tissues to the 
average uptake in respective WT tissues.  This accounts for any non-specific binding 
that biased radiotracer accumulation.  There was greater 125I-p5R+14 (red) than 99mTc-
p5 (blue) accumulation in most tissues but most notably in the lower intestines and 
spleen.  In ApoA2c # 3, both the liver and heart also showed enhanced accumulation of 
125I-p5R+14.  Error bars are not shown because these data are ratios. 
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Figure 5.7:  Image analyses revealed greater 125I-p5R+14 uptake in amyloid-laden 
organs.  These data were acquired by drawing ROI over the liver, heart and lung.  In 
each mouse, it was evident that a more 125I-p5R+14 (red) bound as compared to 99mTc-
p5 (blue).  Since intestinal activity could have been amyloid-specific or a result of 
clearance, this organ was removed from the analysis.  Error bars are not shown 
because these data represent individual animals. 
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was covered by silver black grains.  This meant that the amyloid deposits were not 
entirely targeted with the peptide.  Additionally, there was no reactivity with healthy 
tissue in the evaluated organ specimens (Figure 5.8).    
 
5.3. Conclusions 
Perhaps the most remarkable finding in these studies was positive cardiac 
imaging which was made possible with 125I-p5R+14 in ApoA2c mice.  We have 
observed that, unlike the AA model of amyloidosis which inconsistently develops small 
amounts of cardiac amyloid, the ApoA2c transgenic mice unfailingly generate a large 
amount of cardiac amyloid.  The biodistribution measurements associated with 125I-
p5R+14 in ApoA2c tissues yielded a diseased heart tissue:healthy tissue ratio of ~ 3 in 
one mouse.  This value was high enough to clearly visualize the radiotracer within the 
heart (see Figure 5.3).  Since cardiac amyloid is a particularly ominous manifestation in 
patients with amyloidosis, the ability of this radiotracer to visualize amyloid burden in 
this critical organ may be clinically relevant. 
 In summary, dual isotope imaging provided a facile method for assessing two 
different peptide radiotracers in individual mouse, thus subjecting them to the same in 
vivo conditions.  This direct comparison generated data suggesting that peptide p5 was 
not suitable for ApoA2c amyloid detection; peptide p5R+14, however, was able to detect 
ApoA2c amyloid effectively.  Both tissue biodistribution measurements and image 
analyses revealed that p5R+14 was superior to p5 in ApoA2c amyloid reactivity and that 
it could positively detect cardiac amyloidosis.  The previous chapter discussed ex vivo  
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Figure 5.8:  Autoradiographs of 125I-p5R+14 in ApoA2c tissues at 2 h pi.  These 
ARG indicate that peptide, seen as black silver grains, avoids reactivity with healthy 
tissue in these samples and preferentially binds to amyloid deposits. 
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findings which indicated that p5R+14 bound to ApoA2c tissue homogenates better than 
both p5 and p5R peptides; the translation of these findings in vivo was made credible 
through the dual isotope study.  Additionally, p5R+14 ARG and CR tissue examination 
confirmed that the peptide co-localized with amyloid in all tissues, but it also revealed 
that amyloid coverage did not reach entirety with the radiotracer which is the focus of 
the next few chapters.    
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Chapter 6 
Comparison of in vivo and ex vivo ApoA2c amyloid binding with p5R+14 
 
6.1. Overview 
 The in vivo reactivity of p5R+14 with ApoA2c amyloid was clearly established by 
using dual isotope imaging, tissue biodistribution and microautoradiography (Chapter 5).  
Autoradiographs of various tissues revealed that the peptide co-localized specifically 
with the amyloid deposits, leaving healthy tissue unaffected.  The amyloid reactivity in 
tissues with extensive, “waxy deposition”, however, was incomplete with p5R+14 (i.e. 
not all of the amyloid was decorated with peptide).  This effect was observed most 
commonly in the spleen.  There are a number of possible explanations for the lack of full 
amyloid coverage by 125I-p5R+14 in vivo: 1) There was a lower concentration of peptide 
binding sites in splenic amyloid compared to other tissues; 2) dense amyloid deposition 
rendered the peptide incapable of fully penetrating the pathological material; or 3) the 
binding site became buried in the thick amyloid depots which commonly form in the 
spleen.  Peptide reactivity with ApoA2c tissues in the ex vivo binding assays (Chapter 4) 
demonstrated that p5R+14 bound to amyloid-laden spleen with a greater percentage 
relative to its reactivity with most other tissues and the reactivity of other peptides with 
ApoA2c spleen.  Thus, the peptide binding site must be present in splenic tissue 
amyloid and is likely no less pronounced than in other tissues.  Since the much larger 
SAP radiotracer (MW 250,000 Da) could fully penetrate ApoA2c splenic amyloid in vivo 
(Figure 6.1), it seemed unlikely that the peptide would be incapable of doing the same.   
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Figure 6.1:  Autoradiograph of 125I-SAP in ApoA2c amyloid-laden spleen.  The 
black silver grains deposited perifollicularly in the splenic tissue sample demonstrated 
full ApoA2c amyloid coverage with 125I-SAP.  The healthy red pulp and white pulp were 
unaffected by the radiotracer which suggested that SAP preferentially bound amyloid in 
this tissue.  (Image provided by Dr. Jonathan Wall). 
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Therefore, it appeared most likely that the binding site for the peptide became buried or 
more inaccessible within in vivo conditions as the deposits grew denser over time.  If 
this were the case, p5R+14 reactivity with tissue amyloid in vivo may underrepresent 
the full burden of amyloid, especially if these tissues had developed extensive 
deposition.  This hypothesis was tested by performing a study that compared the in vivo 
reactivity of p5R+14 in ApoA2c mice using tissue biodistribution measurements with the 
ex vivo reactivity of the peptide in the pull down binding assay utilizing tissues harvested 
from the same mice.  To achieve this, the peptide was radiolabeled with I-123 for the in 
vivo biodistribution study because it has a half-life of only 13 hours which would allow 
for a full radioactive decay of the harvested tissues (10 half-lives as recommended by 
UT Radiation Safety) within 5 days.  These tissues could then be prepared as 
homogenates for the ex vivo assay.  In order to have enough material to homogenize, a 
sample of each tissue was not collected for ARG in this study.  Thus, the p5R+14 
peptide was tested under both conditions using the same tissues to determine if the 
under-representation of amyloid burden, when analyzed in vivo, was due to 
inaccessibility of the peptide binding site. 
  
6.2. Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice 
 To obtain in vivo measurements of peptide binding, p5R+14 was radiolabeled 
with I-123 as described in the methods chapter (Section 3.5) with the help of Dr. 
Stephen Kennel.  Radiopurity was assessed, and the peptide was evaluated in the ex 
vivo binding assay with AA liver (Figure 6.2).  Mice were injected with approximately 20 
μCi of radiolabeled peptide with an uptake time of 4 hours.  Mice were then euthanized  
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Figure 6.2:  Assessment of radiopurity and amyloid-reactivity of 123I-p5R+14.  (A) 
SDS-PAGE analysis of radiolabeled peptide.  The reduced and non-reduced samples 
migrated identically on the gel and revealed no oligomeric species within the product.  
Additionally, no free isotope was detected.  (B) Results of the ex vivo peptide binding 
assay.  The radiolabeled p5R+14 binds amyloid-laden tissue and yields low reactivity 
with healthy tissue. 
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by inhalation overdose of isoflurane, and tissues of interest (liver, spleen, kidneys, 
intestines, lungs and heart) were harvested for biodistribution measurements.  As 
indicated in Figure 6.3, there was a higher percent injected dose per gram in most 
ApoA2c tissues relative to the amount detected in an average of 2 WT mice for each 
tissue; however, the uptake (% ID/g) was, with the exception of the heart, not more than 
2 or 3-fold higher than the non-specific reactivity of p5R+14 with healthy tissue, and no 
measurement was higher than 7 %ID/g for any tested tissue.  With biodistribution values 
less than 7% in all examined tissues, it was unclear whether or not these ApoA2c mice 
had actually developed significant amyloid or if the pathological deposits were 
incompletely targeted.  Since samples were not harvested for Congo red histological 
examination, an additional study was performed to test for the presence of amyloid. 
 
6.3. 125I-p5R+14 binding assay on ApoA2c tissue homogenates 
As a means of confirming amyloid deposition and comparing in vivo peptide 
reactivity with ex vivo binding data, the harvested tissues were frozen for 5 days for 
radioactive decay (10 half-lives) and homogenates prepared for the ex vivo peptide 
binding assay (Section 3.10.1).  Each of 6 individual tissues from 3 ApoA2c mice and 2 
WT mice were homogenized as previously described (Section 3.9) and a pull down 
assay performed.  Peptide p5R+14 was radiolabeled with 125I for the ex vivo binding 
assays due to cost efficiency and radioisotope half-life (T1/2 = 59 days; the assays took 3 
weeks to complete).  Our data indicated that p5R+14 bound to all ApoA2c tissues (> 
20%) to a much greater degree than the non-specific binding associated with WT 
tissues (< 10%; Figure 6.4).  Given that the peptide can bind the amyloid-laden tissue 
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Figure 6.3:  Biodistribution measurements of 123I-p5R+14 in ApoA2c and WT mice 
at 4 h pi.  The radiotracer accumulation in various tissues harvested from 3 individual 
ApoA2c amyloid-laden mice is shown.  In addition, the mean plus SD of peptide 
accumulation obtained from 2 WT mice is included to represent any non-specific binding 
within the tissues.  Notice that the % ID/g for the liver, spleen, lung and heart of each 
ApoA2c mouse exceeded the average WT value.  The kidneys, a tissue less affected by 
ApoA2c amyloid, revealed similar values for diseased and healthy mice. After removal 
of the feces, the ApoA2c intestines did not appear to accumulate much more peptide 
than that seen with WT mice. 
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Figure 6.4:  Ex vivo assessment of 125I-p5R+14 binding to ApoA2c and WT 
homogenized tissues.  The tissues analyzed in this assay were harvested from the 3 
ApoA2c mice and 2 WT mice used in section 6.2.  The data indicate that there was 
greater peptide reactivity with all diseased tissues as compared to that seen in an 
average measurement of non-specific peptide binding to amyloid-free tissue 
homogenates. 
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from the healthy tissue for each organ as suggested by the percentage of radiolabeled 
peptide bound to the pellet in this assay, it seemed logical to assume that p5R+14, 
when exposed to the multitude of binding sites presented after tissue homogenization, 
can effectively target ApoA2c amyloid. 
 
6.4. Comparison of in vivo and ex vivo peptide binding data 
In order to directly compare the in vivo and ex vivo data, the amount of 
radioactivity (counts per minute; cpm) in each tissue was reported relative to the weight 
of the tissue.  In the ex vivo binding assay, approximately 5 mg of tissue and 100,000 
cpm were used in each sample.  Thus, if complete binding was achieved, 1 mg of tissue 
would bind 20,000 cpm.  For the biodistribution study, each tissue was weighed, and a 
percentage of the injected dose (measured in cpm) in the tissue was recorded.  With 
these data, the in vivo analyses could be directly compared to the data generated from 
the binding assay.  An example of the analysis can be seen in Figure 6.5, and the 
results from each individual mouse are presented in Figure 6.6.   
The direct comparison of p5R+14 binding to amyloid in vivo and ex vivo showed 
that the peptide underrepresented the amount of amyloid in half of the tested tissues—
notably the spleen, lungs and heart.  Since the tissues harvested at necropsy were to 
be homogenized and used as substrate for the ex vivo pull down assay, there was not 
enough of each sample to develop ARG.  Thus, we were unable to visually locate 
regions of amyloid in these specific tissues that were not completely targeted by the 
peptide radiotracer.  Previous studies utilizing p5R+14 in ApoA2c mice produced ARG  
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Figure 6.5:  Method for analyzing ex vivo and in vivo data with comparable 
peptide binding values.  Since there was a different amount of tissue used in the ex 
vivo binding assay (5 mg as compared to the whole organ used in the in vivo 
biodistribution measurements) and a different amount of radioactivity, the two methods 
were scaled by a theoretical maximum of counts bound to a certain weight of tissue. 
The example shown revealed a theoretical maximum of 2.7% binding in vivo for the 
amount of peptide that could bind to an equivalent piece of tissue ex vivo.  Additionally, 
non-specific binding to each tissue was accounted for by the subtraction of peptide 
reactivity observed with respective WT tissues.  All data were scaled according to the 
provided example in order to compare the datasets. 
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Figure 6.6:  Comparative analysis of ex vivo peptide-binding data and in vivo 
biodistribution data in 3 ApoA2c mice.  The ex vivo data (solid bars) are plotted 
against the left axis and in vivo data (striped bars) are plotted against the theoretical 
maximum axis on the right.  In all 3 mice, there was a good representation of the liver 
and intestines with both the ex vivo and in vivo data.  Since there is not typically a large 
amount of renal ApoA2c amyloid, the low kidney binding with both techniques was also 
expected.  In the spleen, lungs and heart, however, there was a consistent under-
representation of amyloid in the in vivo biodistribution analysis.  This suggested that, in 
these tissues, radiotracer accessibility to the amyloid may be hindered in vivo. 
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which demonstrated the lack of complete amyloid coverage in the spleen, lung and 
heart (Figure 6.7).  These observations further confirmed that peptide p5R+14 
quantitatively underestimated the ApoA2c amyloid burden in vivo. 
 
6.5. Conclusions 
The data presented here indicate that even though p5R+14 was the optimal 
agent for imaging ApoA2c amyloid, it bound to ApoA2c tissues more effectively in the ex 
vivo assay for many of the tested tissues—particularly the spleen, lungs and heart.  
These findings indicate that the peptide binding site within amyloid that is associated 
with these organs was more readily available in the homogenized tissue samples than 
in the pathological tissue deposits in situ.  Therefore, to enhance the reactivity of 
peptide with ApoA2c amyloid in vivo, a different peptide might be necessary.  According 
to the literature [371], comparison of peptides p5 and p5R (the variant of p5 with 
arginine residues substituted for all lysine residues) in a murine model of AA 
amyloidosis revealed that the arginine variant had a higher affinity for amyloid resulting 
in a “binding site barrier effect” which limited amyloid coverage by the peptide in tissues 
with extensive amyloid deposition [371].  Given that p5R+14 has twelve arginine 
residues, it may also suffer from a similar effect in the extensive ApoA2c amyloid 
deposits.  Additionally, it is worth considering that the biological half-life of a peptide is 
generally relatively short [410-412], due to its small size, which may have hindered the 
peptide’s ability to access the entirety of amyloid deposition due to its rapid catabolism 
and removal from the blood pool. To address this specific issue, we tested modified 
peptides which are discussed in the next chapter. 
164 
 
 
 
 
 
 
 
Figure 6.7:  ApoA2c amyloid deposits which were unidentified by the 125I-p5R+14 
radiotracer in various tissues.  Autoradiographs (ARG) of ApoA2c spleen, lung and 
heart demonstrated that the peptide, visualized as black silver grains, was incapable of 
fully targeting the entirety of amyloid deposition in these tissues.  The regions of amyloid 
are shown as bright red in the Congo red (CR) fluorescent images of splenic and 
cardiac tissue, and the amyloid within the lung tissue appears as birefringent greenish-
gold material in the center CR image.  The black arrows indicate regions of amyloid that 
are not fully covered with 125I-p5R+14 in these tissues. The white arrows indicate 
regions of amyloid which lack radiotracer co-localization. (Heart image was supplied by 
Dr. Jonathan Wall). 
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Chapter 7 
Assessment of modified peptides designed to enhance                     
quantitative ApoA2c amyloid detection 
 
7.1. Overview 
 It has been shown that peptide p5R+14 effectively binds to ApoA2c amyloid such 
that many amyloid-laden organs can be non-invasively visualized with SPECT/CT 
imaging.  Observations obtained from the in vivo vs. ex vivo amyloid binding experiment 
suggested that the peptide could not bind ApoA2c amyloid deposition in its entirety, 
however.  In mice with advanced deposition, tissues accumulated dense pathological 
deposits of amyloid that the peptide was unable to bind to or fully penetrate.  Thus, the 
representation of ApoA2c amyloid in vivo was underestimated with 125I-p5R+14, notably 
in the spleen, lung and heart.  While the peptide imaging agent may be effective at 
detecting amyloidosis, the lack of full amyloid coverage could be detrimental to the 
clinical use of this peptide in monitoring quantitative response to therapy aimed at 
clearing dense tissue amyloid deposits.  We hypothesized that this phenomenon may 
be likely due to: 1) the high affinity of p5R+14 for the amyloid resulting in a binding site 
barrier effect, or 2) the short half-life of the peptide in the circulation did not allow for 
complete uptake of the peptide by poorly “vascularized”, dense amyloid lesions.  To 
address these potential concerns, modified peptides were designed and tested in 
ApoA2c mice.  These peptides addressed issues pertaining to amyloid binding affinity 
and serum half-life in an attempt to enhance uptake by dense amyloid. 
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7.2. Studies using 125I-p5+14: A peptide addressing amyloid affinity and binding 
site barrier effects 
 A recent study using amyloid-reactive peptides suggested that enhanced affinity 
to the target resulted in a binding site barrier effect which hindered full amyloid coverage 
in extensive deposits [371].  This study utilized heparin-binding peptide, p5, and a 
variant of this peptide, p5R.  The latter peptide was modified to contain arginine 
residues in place of all lysine residues, resulting in a greater propensity of the peptide to 
adopt an α-helical secondary structure [371, 425].  Since the helical structure of peptide 
p5 has been postulated as an important property required for amyloid-binding [371, 
409], the potential for a more helical peptide, which could result in higher-affinity 
amyloid-targeting, was appealing.  The arginine variant, indeed, had a higher affinity for 
heparin and AA amyloid as evidenced by HPLC and ex vivo NaCl titration, respectively 
[371].  Additionally, p5R was shown to co-localize with congophilic material in a murine 
model of AA amyloidosis indicating preferential in vivo binding to amyloid.  
Autoradiographs with 125I-p5 or 125I-p5R in tissues harvested from AA mice, with “1+” 
and “4+” splenic amyloid burden, were compared (Figure 7.1).  Results of ARG studies 
indicated that, in mice with less amyloid, the peptides were equally efficient at 
quantitatively targeting all deposits, i.e. full coverage of the amyloid by peptide was 
achieved.  In mice with greater amyloid burden, however, the high affinity of peptide 
p5R hindered its ability to penetrate dense deposits, resulting in a “binding site barrier 
effect”; thus, the lower affinity peptide p5 was more effective at quantitative amyloid 
coverage in mice with extensive deposition [371].  These findings introduced the notion 
that enhanced affinity of a peptide may lead to a binding site barrier effect causing less  
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Figure 7.1:  Autoradiographs (ARG) indicating disparate AA amyloid targeting 
with two radiotracers.  These ARG demonstrate that amyloid coverage with peptides 
p5 and p5R decrease as the amount of amyloid within tissues increases.  The coverage 
in mouse tissue with little amyloid (AA +1) looks similar with both peptides.  Coverage of 
amyloid in tissue with more pathological deposition (AA 4+) revealed a pattern of p5 
distribution which appeared less dense than that seen with p5R, but the coverage 
seemed to be more complete.  The last row in the figure shows full amyloid coverage on 
the left (p5; black arrow) and incomplete coverage on the right (p5R; black arrow).  The 
black arrowhead points to a region near a blood vessel that contains dense peptide 
deposition—thought to be the presence of a “binding site barrier effect”.  (Image taken 
from [371]). 
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than complete target coverage.  Given that incomplete ApoA2c amyloid coverage was 
observed with p5R+14, a peptide with 12 arginine residues, we posited that substitution 
of these 12 residues with lysines, thus slightly reducing the amyloid affinity, may visibly 
increase in vivo amyloid coverage observed with ARG and increase radiotracer 
accumulation seen in biodistribution measurements and SPECT/CT image analyses. 
Results 
 For this study, peptides p5+14 and p5R+14 were both radiolabeled with 125I 
(Section 3.5) and tested for radiochemical purity and amyloid-reactivity (Sections 3.8 
and 3.10.1) prior to in vivo analyses.  Additionally, affinity of both peptides for rVλ6Wil 
fibrils was assessed by performing a pull down assay with NaCl titration.  It was 
determined that: there was no free isotope in the radiolabeled products; both peptides 
showed positive reactivity with AA amyloid liver; and a higher concentration of NaCl was 
required to interfere with rVλ6Wil fibril reactivity for peptide p5R+14 as compared to the 
lysine variant, which was expected (Figure 7.2).  The radiolabeled peptides were 
intravenously injected into the lateral tail vein of ApoA2c mice that had been induced 
with ApoA2c AEF ~ 12 weeks prior to the imaging study (n = 5 with p5+14 and n = 4 
with p5R+14).  Necropsies were performed on all mice at 2 h pi, and harvested tissues 
were analyzed by using tissue biodistribution measurements and microautoradiography 
(Sections 3.14 – 3.16). 
 The accumulation of the radiotracers in harvested tissues was reported as a 
percent of the injected dose per gram of tissue (Figure 7.3).  Results indicated that, on 
average, mice that received p5R+14 had greater accumulation of radioactivity in all 
tissues as compared to mice that received p5+14.  The hypothesis that a peptide with  
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Figure 7.2:  Assessment of radiopurity and amyloid-laden tissue and synthetic 
rVλ6Wil fibril reactivity.  (A)  Electrophoresis of radiolabeled peptides.  The SDS-
PAGE revealed that reduced and non-reduced samples migrated similarly.  Additionally, 
no free isotope was detected in the products.  (B)  Ex vivo peptide binding assay.  
Amyloid-reactivity as evidenced by enhanced binding to amyloid-laden liver compared 
to binding to WT liver.  (C)  NaCl titration with peptides on rVλ6Wil fibrils.  The titration 
indicated fibril reactivity with both peptides but higher affinity with p5R+14 compared to 
the lysine variant, p5+14. 
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Figure 7.3:  Biodistribution measurements 2 h pi of either 125I-p5+14 or 125I-p5R+14 
in ApoA2c mice.  The in vivo amyloid reactivity of both peptides showed that, in most 
tissues, there was greater 125I-p5R+14 accumulation than 125I-p5+14.  One mouse, 
however, appeared to have very little 125I-p5R+14 accumulation in any tissue.  This 
mouse (red bar in bottom graph) likely had less amyloid than the other mice since only 
the stomach had comparable uptake which was due to free iodide sequestration after 
peptide dehalogenation.  Each bar on the graphs represents individual mice; thus, no 
error bars are included. 
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less affinity may provide enhanced amyloid coverage did not hold true based on the 
biodistribution measurements alone—peptide p5+14 would likely have had greater 
accumulation if its lower affinity for amyloid improved coverage.  To confirm that the 
peptides were specifically associated with amyloid deposits in the tissues, ARG was 
performed.  The appearance of black silver grains seen in representative tissues 
confirmed that both peptides co-localized specifically with amyloid material, but p5R+14 
achieved enhanced amyloid coverage as compared to peptide p5+14 (Figure 7.4).  The 
binding site barrier effect was again present with p5R+14, but this peptide remained the 
most effective peptide for ApoA2c detection due to its high affinity for this type of 
amyloid. 
 These data suggested that the low affinity, lysine-rich peptide was less efficient 
than p5R+14 at detecting ApoA2c amyloid in vivo.  In these experiments, contrary to the 
hypothesis, the peptide with a lower amyloid affinity did not enhance target (amyloid) 
coverage.  Instead, the p5R+14 peptide that exhibited the binding site barrier effect in 
the lung and spleen was surprisingly the most effective at ApoA2c amyloid detection in 
vivo as evidenced by tissue biodistribution measurements and ARG.  Given these data, 
we turned our attention to the second hypothesis and attempted increasing the serum 
half-life of the peptide without altering the arginine amino acids responsible for the 
strong interaction with amyloid.  We posited that this peptide may achieve improved 
target coverage if it remained in circulation longer and was, therefore, “exposed” to the 
amyloid for longer periods. 
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Figure 7.4:  Autoradiographs demonstrating radiotracer accumulation in amyloid-
laden tissues.  ARG revealed that both peptides bound to amyloid within the tissues, 
but 125I-p5R+14 exhibited greater accumulation when compared to 125I-p5+14 as 
evidenced by the density of black silver grains within the amyloid deposits. 
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7.3. Studies using PEGylated 125I-p5R+14: A peptide to study the effects of longer 
serum half-life 
 As stated in Chapter 1 (Section 4.4), there are several advantages to using 
peptides as imaging agents: they can be chemically synthesized; they are generally 
non-immunogenic; they clear rapidly when not bound to target; they can penetrate 
vessels due to small size [409-413].  Given that peptides are relatively small biological 
agents, in comparison to other potential radiotracers (i.e. antibodies, scFv’s and 
proteins), their biological half-life is shorter compared to larger agents.  For example, 
when the ~ 3100 Da peptide, p5, was radioiodinated and injected into WT mice, it was 
determined that the effective half-life of the peptide was ~ 2 – 3 min [416].  In contrast, 
when healthy mice were injected with the 250 kDa SAP, the half-life was determined to 
be ~ 7.5 h [427].  While rapid clearance of unbound radiotracer can be considered 
advantageous in molecular imaging studies because it can improve the signal-to-noise 
ratio of images, the short half-life of peptides could potentially limit the extent of ApoA2c 
amyloid-binding.  The affinity of p5R+14 for ApoA2c amyloid in vivo and ex vivo 
surpasses all other tested peptides, but although it successfully detects deposits, it has 
not been shown to fully penetrate dense amyloid material.  Therefore, a true, 
quantitative representation of the amyloid load in a mouse (or a patient) injected with 
p5R+14 might not be achievable.   
In an attempt to extend the serum half-life of p5R+14—which may enhance the 
peptide’s ability to penetrate ApoA2c amyloid—we incorporated a 20 kDa 
polyethyleneglycol (PEG) moiety to the N-terminus of the peptide (synthesized by RS 
Synthesis, Lexington, KY).  This approach, also termed PEGylation, has been well-
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documented in the literature for its utility, safety and success in extending the half-life of 
various molecules including those already approved by the FDA and in clinical use [428-
431].  Since PEG is a “neutral, hydrophilic polyether”, it usually “exhibits little [immuno] 
reactivity” [432].  The incorporation of a PEG structure to an imaging agent, thus, yields 
a non-immunogenic, non-antigenic conjugate with an increased molecular weight which 
may alter its physicochemical properties and rate of catabolism within the organism; this 
may result in extended serum half-life [428, 432].  Without modification, peptide p5R+14 
had a molecular weight of ~ 4,500 Da; after N-terminal addition of PEG, the conjugate 
had a molecular weight of ~ 24,500 Da.  We tested both p5R+14 and the PEGylated 
p5R+14 (PEG-p5R+14) in vivo with expectation of detecting both enhanced serum half-
life and amyloid coverage with the latter peptide. 
Results 
 For in vivo studies, predetermined concentrations of the peptides to be studied 
(equal to 50 μg per peptide) were radiolabeled for comparable results.  To determine 
the appropriate concentration of PEG-p5R+14, a BCA peptide concentration analysis 
was conducted with the assistance of Mrs. Angela Williams.  Since the PEG portion of 
the conjugate contains no amino acids, it is not detected with this assay.  Thus, unless 
the PEG interfered with the analysis, the resulting concentration was likely a direct 
indication of the p5R+14 content.  The peptide portion of the conjugate is ~ 1/5 of the 
molecular weight; therefore, the calculated peptide concentration obtained from the 
analysis was multiplied by 5 which yielded a concentration of ~ 1 mg / mL.  For the 
following in vivo studies, ~ 50 μL (~ 50 μg) of PEG-p5R+14 was radiolabeled with I-125.  
The non-PEGylated p5R+14 (~ 50 μg) was also radioiodinated, and both peptides were 
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tested for radiochemical purity (Section 3.8) and amyloid fibril reactivity (Section 3.10.2) 
prior to their utilization in the following studies.  The SDS-PAGE analysis indicated that 
both peptides were similar in size—a finding that was initially puzzling since the 
PEGylated peptide should be 20,000 Da larger than the other.  It was concluded that 
the SDS buffer used in the gel electrophoresis did not interact with the neutral, PEG 
portion of the conjugated peptide; thus, the analysis only represented the polybasic, 
p5R+14.  No free iodide was detected, and the binding assay confirmed positive 
reactivity with synthetic fibrils (Figure 7.5).  There was evidence of non-specific binding 
to WT liver tissue homogenate with the PEGylated peptide—a finding not entirely 
unexpected due to the size of the peptide but one that must be taken into consideration 
when evaluating in vivo data.  Autoradiography was used to determine if there was non-
specific binding to tissue in vivo. 
 Prior to the injection of PEG-p5R+14 in ApoA2c amyloid-laden mice, the 
PEGylated peptide and p5R+14 were administered to cohorts of WT mice in a pilot 
study to assess potential off-target binding and to investigate the extended serum half-
life of PEG-p5R+14.  Mice were injected with ~ 100 μCi of either 125I-PEG-p5R+14 or 
125I-p5R+14, and uptake times were 15 min (n = 2 for PEG-p5R+14 and n = 1 for 
p5R+14) or 1 h (n = 2 per peptide).  SPECT/CT imaging was performed on mice that 
were allotted an uptake time of 1 h (n = 1 mouse per peptide).  All seven mice 
underwent necropsies to obtain tissues for biodistribution measurements and ARG.  
Due to the size of PEGylated conjugates, clearance through tissues such as the 
kidneys, lungs, spleen and lymph nodes is typically lower than that observed with non-
PEGylated peptides [428].  Thus, renal clearance was expected to be lower with  
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Figure 7.5:  Radiopurity and fibril reactivity assays.  (A)  SDS-PAGE analysis of 
radioiodinated PEG-p5R+14 and p5R+14 after 40 min exposure.  No free isotope was 
detected in the samples.  Since PEG was neutral, the SDS buffer did not interact with it 
making the peptides migrate as the same size in both reduced and non-reduced 
samples.  (B) Peptide binding assays.  Both peptides exhibited binding to rVλ6Wil fibrils.  
The PEGylated peptide had higher background binding than 125I-p5R+14 which was 
made evident with WT liver reactivity. 
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125I-PEG-p5R+14 in comparison to 125I-p5R+14 in healthy mice.  Results from the 
biodistribution measurements indicated that, at 15 min pi, the presence of radiotracer in 
the kidneys was greater than 4-fold higher in the mouse that received 125I-p5R+14; 
although less pronounced, the same trend was observed at 1 h pi with mice that 
received the 125I-p5R+14 having a 2-fold higher % ID/g than mice injected with the 
PEGylated peptide.  Additionally, the radioiodide accumulation in the stomach—a direct 
indication of the dehalogenation of injected radiotracers and uptake by halide 
symporters present in the stomach [416]—was 2-fold higher at both 15 min and 1 h pi 
for the non-PEGylated peptide (Figure 7.6). These data suggest that the peptides were 
processed differently within WT mice and that the dehalogenation, and likely the 
clearance, of 125I-p5R+14 was accelerated versus the larger 125I-PEG-p5R+14.  Images 
comparing the distribution of these radiotracers at 1 h pi are shown (Figure 7.7). 
 The in vivo detection of ApoA2c amyloid with these peptides was next analyzed.  
Given that we had observed a distinct difference in biological processing of the two 
peptides in WT mice, the analysis in diseased mice was extended to 1 h and 4 h pi with 
the hypothesis that, after 4 h, the PEGylated peptide would have accumulated to a 
greater extent in the amyloid (determined with biodistribution measurements after 
confirmation of peptide:amyloid co-localization by CR and ARG observation) as 
compared to observations made at 1 h.  For the in vivo study, ApoA2c mice (11 weeks 
post 100 μg AEF injection) were administered ~ 100 μCi of either radiotracer and were 
euthanized at 1 h or 4 h pi (n = 3/peptide/time point).  The necropsies of all mice 
included harvesting portions of muscle, liver, pancreas, spleen, both kidneys, stomach, 
upper intestine, lower intestine, heart and lung for biodistribution measurements and  
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Figure 7.6:  Biodistribution of 125I-PEG-p5R+14 and 125I-p5R+14 in WT mice at 15 
min and 1 h pi.  These biodistribution measurements revealed that the two peptides 
were processed differently in healthy mice.  At 15 min pi, there was a higher % ID/g of 
125I-p5R+14 (red) in the kidneys and stomach indicating a higher level of clearance and 
dehalogenation in comparison to the larger peptide (blue).  At 1 h pi, the same trend 
was present. These data support the notion that PEGylated p5R+14 is processed more 
slowly than p5R+14 in healthy mice. 
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Figure 7.7:  SPECT/CT images displaying the distribution of 125I-PEG-p5R+14 and 
125I-p5R+14 in WT mice at 1 h pi.  Both sets of images were scaled to the same 
threshold for comparable visualization.  The images on the left show a coronal view of 
the distribution of these two radiotracers.  At 1 h pi, there was uptake in the thyroid (T) 
and stomach (S) with both peptides.  Sagittal views on the right also show uptake in the 
stomach of these mice.  These regions of uptake are likely a result of dehalogenation of 
the peptide and accumulation of free iodide.  There is evidence, however, that the 
PEGylated peptide may have remained in circulation for longer than the non-PEGylated 
peptide due to a visibly greater amount of disperse radioactivity seen with this peptide in 
both sets of images. 
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histological examination.  Additionally, the tongue and the cecum—sites possibly 
affected by ApoA2c amyloid—were taken to be analyzed by ARG to better determine 
the severity of amyloid burden. 
Results comparing the biodistribution of both peptides at 1 h and 4 h pi are 
displayed (Figure 7.8).  These graphs display the average of 3 mice.  There was no 
significant difference between the peptides at 1 h pi.  However, there was slightly higher 
PEG-p5R+14 in the liver and lower intestines, this finding was also observed in ApoA2c 
tissues at 4 h pi.  The increased accumulation of PEGylated peptide in the liver and 
intestines may have been due to the preferential route of clearance of the larger peptide 
(hepatobiliary) versus the renal clearance associated with the non-PEGylated p5R+14. 
These results suggest that the two peptides behave more similarly in the presence of 
amyloid in vivo than they do in healthy mice with no amyloid.  Upon examination of 
tissue autoradiographs, amyloid coverage with 125I-p5R+14 (see Figure 5.8) and 125I-
PEG-p5R+14 (Figure 7.9) confirmed similar amyloid-binding behavior between the two 
peptides. 
 
7.4. Conclusions 
A lack of full ApoA2c amyloid coverage had been observed in autoradiographs of 
tissue sections with 125I-p5R+14; this led to the investigation of strategically modified 
peptides to potentially enhance ApoA2c amyloid-targeting based on two reasonable 
hypotheses.  Data suggests that the arginine-rich, high affinity peptide may suffer from a  
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Figure 7.8:  Biodistribution of peptides 125I-PEG-p5R+14 and 125I-p5R+14 in 
ApoA2c mice.  At 1 h and 4 h pi, the peptides behaved similarly in vivo.  These data 
suggest that PEGylation of p5R+14 may alter the metabolism of the peptide, but it did 
not improve amyloid targeting. 
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Figure 7.9:  Autoradiographs of 125I-PEG-p5R+14 in ApoA2c amyloid-laden 
tissues.  The distribution of black silver grains confirmed peptide co-localization with 
amyloid in various tissues.  Comparison of these images with those seen in Figure 5.8 
suggest that 125I-p5R+14 and 125I-PEG-p5R+14 bind similarly to amyloid in vivo. 
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“binding-site barrier” effect which can hinder the extent of amyloid coverage in vivo 
[371].  This prompted the use of a lysine-rich variant of p5R+14, designated p5+14, with 
the hypothesis that a peptide with less affinity for amyloid would penetrate deeper into 
the mass and provide a better representation of the pathology.  This study yielded 
results that were incongruent with the hypothesis—125I-p5+14 did not improve amyloid 
coverage.  Experiments were then conducted with a larger, N-terminal-PEGylated 
version of p5R+14 which was thought to enhance the serum half-life of the peptide 
without sacrificing the arginine residues believed to facilitate the observed peptide-
amyloid interaction.  A larger targeting agent was hypothesized to undergo altered 
catabolism (i.e. slower rate), thus increasing its serum half-life and allowing for 
enhanced amyloid contact and improved accessibility and coverage.  Evaluation of 
PEG-p5R+14 in WT mice suggested that it was, indeed, catabolized differently as 
compared to the non-PEGylated peptide, but in ApoA2c amyloid-laden mice, the 
peptides were nearly indistinguishable which also did not support the hypothesis.  
Although full coverage was never reached, p5R+14 remained the most effective peptide 
for ApoA2c amyloid targeting in vivo.   
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Chapter 8 
A non-dehalogenable, novel peptide for amyloid targeting 
 
8.1. Overview 
 In the previous chapter, modified peptide variants of p5R+14 were examined as 
amyloid-targeting agents in the murine model of ApoA2c amyloidosis.  Experiments with 
the lysine-rich and PEGylated variants revealed that altering the affinity or size of the 
peptide, respectively, was incapable of improving ApoA2c amyloid coverage as 
evidenced in ARGs.  Given that peptides are typically cleared rapidly from circulation, 
an alternative technique addressing half-life extension as a way to counteract this and 
improve amyloid uptake—one which did not alter the size of the peptide—was 
employed. 
There are two enantiomers of amino acids: the L-type conformation and, its 
“mirror image”, the D-type conformation (Figure 8.1).  In nature, most amino acids are L-
type; except for those found within some bacteria, the D-types of amino acids are 
commonly considered to be “non-natural” structures and are resistant to degradation—a 
characteristic of D-amino acids which has been exploited in the development of certain 
peptide-based drugs [433].  Data suggests that substitution of L-amino acids with the D-
form can lead to stabilization through the increased resistance to protease degradation 
and prolonged half-life of peptides [433, 434].  Some clinically available peptides, which 
are analogues of luteinizing hormone releasing hormone (LHRH), have been developed 
as drugs (e.g., Triphorelin, leuprolide, buserelin, goserelin and nafarelin).  These  
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Figure 8.1:  Illustration of both the L-type and D-type conformations of valine.  
With the exception of glycine, all amino acids can exist in one of two forms.  This figure 
demonstrates both the L and D forms of the amino acid, valine.  The two enantiomers 
are mirror images of each other.  In nature, most amino acids exist in the L-type 
conformation.  (Image taken from [433]). 
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reagents contain D-amino acids in certain positions, and as a result, they have 
prolonged reactivity in vivo [434, 435].  One clinically available, peptide-based 
antagonist of LHRH, Cetrorelix, incorporates D-amino acids at 5 different positions 
rendering the peptide resistant to degradation for up to 50 hours [436].  Other LHRH 
antagonists without non-natural amino acids are reported to circulate in the serum for 
only a maximum of a few hours before complete degradation [434, 437].  A more recent 
study evaluating the oostatic potential of a peptide containing D-amino acids indicates 
that the modified peptide had decreased catabolism and degraded at a significantly 
lower rate when compared to L-form of the peptide; this observation was likely due to 
decreased enzymatic degradation of the peptide bonds neighboring the non-natural D-
amino acids [438].   
Given that the incorporation of D-amino acids can enhance the serum half-life of 
peptides in vivo without increasing the size of the targeting agent, we hypothesized that 
this approach might result in improved ApoA2c amyloid uptake and detection.  
Therefore, we evaluated the amyloid-binding potential of a modified peptide p5 variant.  
This peptide, designated p43, was altered at the N-terminus by substitution of GGG at 
the N-terminal with D-amino acid forms of AQA (the GGG had to be substituted 
because there is no enantiomer for glycine).  The p43 binding and catabolism 
characteristics were compared to historic p5 data to determine if D-amino acid 
incorporation could enhance half-life and amyloid uptake.  Another peptide, designated 
p50, was synthesized as an additional control peptide for p43 to better determine 
whether any differences in reactivity were simply due to the amino acid substitution or 
the incorporation of D-enantiomers—p50 contained L-type AQA at the N-terminus.  
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These peptides were radiolabeled with I-125 and initially tested in the ex vivo binding 
assay to ensure that the modifications did not hinder reactivity of the peptide with 
amyloid-laden tissue.  Observations in this assay prompted in vivo evaluations of the 
peptides in both AA amyloid and WT mice.  The in vivo studies revealed that 
incorporation of D-amino acids altered more than was expected. 
 
8.2. Ex vivo tissue binding assays with 125I-p43 and 125I-p50 
 To determine if D-amino acid incorporation these modifications of peptide p5 
hindered the peptide-amyloid interaction, binding of radioiodinated p43 and p50 AA to 
amyloid-laden mouse tissue homogenates (Section 3.10.1) was tested.  The reactivity 
of p43 with AA amyloid-laden liver and spleen confirmed that the modifications made to 
this p5 variant did not interfere with its binding to AA amyloid.  In fact, the data showed 
that p43 had enhanced binding to these tissue homogenates as compared to the parent 
peptide (> 70% and > 60%, respectively) while maintaining the low, non-specific 
reactivity that p5 established with healthy tissues (~ 5%, Figure 8.2A).  Interestingly, the 
reactivity of 125I-p43 with AA tissues was not reproduced when ApoA2c tissues (liver, 
spleen, heart and lung) were tested.  With all ApoA2c tissues, decreased peptide 
binding (even less than p5 binding), with the exception of the liver, was observed 
(Figure 8.2B).  This was a counterintuitive finding since p43 bound well to AA amyloid, 
and a similar outcome was expected with ApoA2c amyloid.  This finding was seen in 
two independent preparations of ApoA2c amyloid-containing tissue homogenates.  Of 
all the peptides that have been evaluated, the most effective in vivo ApoA2c amyloid-
targeting was p5R+14 (Chapter 4).  The increased helicity achieved by incorporation of  
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Figure 8.2:  Ex vivo peptide-binding assays with 125I-p43 and 125I-p5.  (A)  Peptide 
binding assays on AA and WT tissues.  The data showed that 125I-p43 (red) exhibited 
greater binding to both AA liver and spleen compared to the parent peptide, 125I-p5 
(green).  The enhanced binding with 125I-p43 did not cause higher non-specific binding 
compared to 125I-p5 as evidenced by similar percentages of the peptides bound to WT 
liver tissue.  (B) Peptide binding assays on ApoA2c tissues.  Binding with peptide 125I-
p43 to ApoA2c tissues was much less impressive than the binding established with AA 
tissues.  There was minimal binding in each tissue with both peptides, but 125I-p43 was, 
unexpectedly, even less effective than 125I-p5 with this type of amyloid.   
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arginine residues as well as an additional 4 positively charged residues (total of 12 
arginine residues) likely resulted in the optimal ApoA2c binding in vivo.  Peptides p43 
and p5, both containing 8 positively charged Lys residues, clearly did not possess the 
necessary characteristics for efficient ApoA2c amyloid-binding. 
Peptide p50, the all-L-amino acid peptide control for p43, was not tested in the 
ApoA2c amyloid system due to p43’s unimpressive binding.  Instead, p50 was 
evaluated for positive AA binding with both liver and spleen homogenates.  Reactivity 
with these tissues was similar to that seen with p5 and lower than the binding observed 
with p43 (Figure 8.3).  Given that peptide p50 exhibited reduced AA amyloid interaction 
as compared to p43, the data indicated that an N-terminal composed of non-natural, D-
type AQA residues enhanced binding compared to that observed with a peptide 
containing N-terminal L-type AQA residues or N-terminal GGG residues. 
To assess the “affinity” of the binding with amyloid, the peptides were subjected 
to sodium chloride (NaCl) titrations on AA liver and AA spleen.   It was hypothesized 
that p43 would bind with greater affinity to AA amyloid than p50 based on its increased 
retention in PBS.  This hypothesis was tested using the following NaCl concentrations: 
0.15 M (equivalent to PBS), 0.25 M, 0.5 M, 0.75 M and 1.0 M.  The data revealed that 
p43, in the presence of both the liver and spleen homogenates, required a higher 
concentration of NaCl (~ 0.1 – 0.25 M greater) to interrupt the electrostatic peptide-
amyloid interaction and reduce binding by 50% (IC50) as compared to p50 (Figure 8.4).  
These data supported the hypothesis that p43 binds AA amyloid with slightly higher 
affinity as compared to p50.  Also, because we observed greater binding to the amyloid 
of p43 at each salt concentration, it suggests that there are more “binding sites” for the  
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Figure 8.3:  Ex vivo peptide-binding assay demonstrating 125I-p50 reactivity with 
AA tissues and WT liver.  Amyloid reactivity with the L-type N-terminal AQA peptide 
p5 variant was established, and data revealed that 125I-p50 positively binds to AA 
amyloid in both the liver and spleen.  The reactivity was less than that previously 
established with p43 in this assay, however.  Non-specific binding to WT liver was low, 
and similar to that seen previously with both p43 and p5. 
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Figure 8.4:  NaCl titrations assessing 125I-p43 and 125I-p50 affinity for AA liver and 
spleen homogenates.  Concentrations up to 1.0 M of NaCl were used in the peptide 
binding assay to demonstrate the affinity of both 125I-p43 (red) and 125I-p50 (blue) to AA 
liver and spleen.  As shown in the graphs on the left, there was a higher percentage of 
125I-p43 bound to both tissues in all concentrations of NaCl than was observed with 125I-
p50.  When the data were plotted against the percentage of maximum peptide bound to 
pellet (value obtained in PBS alone), the IC50 for 125I-p43 (yellow stars) was determined 
to be slightly higher than the IC50 for 125I-p50 (black stars) with both tissues. 
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p43 peptide.  It may be that p43 binds HS and fibrils in the amyloid, whereas p50 (and 
p5) may only bind HS.  Since positive reactivity with AA amyloid had been established, 
we then assessed peptides p43 and p50 in the H2/IL-6 murine model of amyloidosis to 
elucidate whether they could effectively detect amyloid in vivo. 
 
8.3. Time course biodistribution and SPECT/CT studies with 125I-p43 and 125I-p50 
Peptide 125I-p43 
 It was previously shown that both p43 and p50 bind to AA amyloid in the pull 
down peptide binding assay.  Since p43 did not effectively bind to ApoA2c amyloid, 
further comparisons of p43 and p50 focused on the AA mouse.  Given that p43 
contained D-amino acids, we were uncertain of how the peptide would “behave” in vivo.  
The AA homogenate binding assay suggested that binding to AA amyloid was 
enhanced, which would facilitate uptake by amyloid in diseased mice.  To determine if 
preferential AA amyloid binding of p43 could be reproduced in vivo, cohorts of AA mice 
(n = 3 per time point), at ~ 6 – 8 weeks post injection of AEF, were administered 
radioiodinated p43 or p50 iv in the lateral tail vein and euthanized at either 1 h, 4 h or 24 
h pi for SPECT/CT imaging, tissue biodistribution measurements and 
microautoradiography.  The radiopurity of the peptide samples was established by SDS-
PAGE and amyloid reactivity confirmed by AA liver homogenate binding (Figure 8.5).  
To characterize potential non-specific, off-target binding associated with these peptides, 
WT mice were also administered the radiotracers and examined at the same time points 
post injection.   
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Figure 8.5: Radiopurity and amyloid-reactivity of the radiolabeled peptides.  (A) 
SDS-PAGE analysis of radioiodinated p43 and p50.  The gel shows there was no 
detectable free iodide in the peptide samples.  (B) Ex vivo assessment of peptide 
reactivity with AA liver and WT liver.  The data indicate that both peptides behaved as 
expected in the peptide-binding assay with positive reactivity to AA liver (~ 60 – 70%) 
and < 5% reactivity with WT liver. 
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The tissue biodistribution data generated by using gamma counting of 125I-p43 in 
AA mice revealed uptake of the radiotracer (~ > 10 %ID/g) in the liver, pancreas, spleen 
and intestines—all common sites of AA amyloid deposition (Figure 8.6).  This uptake 
was observed at each time point, which indicated that the peptide-amyloid interaction 
occurred within 1 hour of radiotracer injection, and the interaction was stable for at least 
24 h (Figure 8.6).  The post mortem SPECT/CT imaging confirmed the biodistribution 
data, revealing uptake in tissues that exhibited the highest % ID/g and showing stability 
of 125I-p43 binding to amyloid-laden tissues up to at least 24 h pi, i.e. liver, spleen and 
pancreas (Figure 8.7).  This prolonged amyloid reactivity was previously observed with 
125I-p5 in the tissues of AA mice (see Figure 1.27) [416]. 
In WT mice, however, there was an interesting discrepancy in the biodistribution 
of 125I-p43 when compared to the historical 125I-p5 data.  Accumulation of radioiodide—
liberated when radioiodinated peptide tracers encounter deiodinase enzymes in the liver 
and kidneys [416]—in both the stomach and thyroid of mice injected with 125I-p5 was 
observed due to the presence of sodium-iodide symporters in the stomach and thyroid.  
SPECT/CT imaging of 125I-p5 in WT mice revealed expected uptake in both the stomach 
and thyroid within 1 h pi (Figure 8.8).  In WT mice injected with 125I-p43, however, 
dehalogenation was not present.  This was evidenced by a lack of free iodide 
accumulation in the stomach and thyroid in images and tissue biodistribution (Figure 
8.9) values that were lower than that seen for 125I-p5 (~ 20 %ID/g with 125I-p5 and ~ 1 
%ID/g with 125I-p43) in the stomach.  Instead, only the kidneys in WT mice with 125I-p43 
achieved a % ID/g high enough (~ 40%) to be visualized with SPECT/CT imaging 
(Figure 8.10A).  The whole body 125I-p43 activity was most prominent in the SPECT/CT  
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Figure 8.6:  Biodistribution measurements of 125I-p43 in a time course study with 
AA mice.  These graphs demonstrated the uptake of 125I-p43 in ApoA2c mice at various 
time points pi.  There was evidence of accumulation of radiotracer in the liver, pancreas, 
spleen and intestines at each time point.  The kidney binding gradually decreased over 
time as unbound radiotracer was catabolized.  Each dataset on the graph represents an 
individual mouse. 
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Figure 8.7:  Representative SPECT/CT images of 125I-p43 in AA mice at 1 h, 4 h 
and 24 h pi.  The distribution of radiotracer 125I-p43 at 1 h pi demonstrated that there 
was uptake in the liver (L), spleen (Sp), pancreas (P) and intestines (I).  The stomach 
(St; green arrow) remained empty for the time course duration.  There was evidence of 
125I-p43 accumulation in amyloid-laden tissues up to 24 h pi. 
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Figure 8.8:  3D SPECT/CT representation of 125I-p5 in a WT mouse.  This image 
displays uptake of liberated free iodide in the stomach and thyroid of a WT mouse at 1 h 
pi.  (Image adapted from [409]. 
 
 
Figure 8.9:  Biodistribution of 125I-p43 in WT mice.  The graph shows mean 
distribution (n = 3) in WT mice at each time point pi.  At 1 h pi (blue), the radiotracer was 
present in the liver and kidneys.  All tissues were “clear” by 4 h pi (red), and by 24 h pi 
(green), the biodistribution of 125I-p43 was nearly completely diminished.  Notice the lack 
of accumulation of free iodide in the stomach at any time point. This suggested that the 
peptide radiotracer was, unexpectedly, not dehalogenated in vivo. 
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Figure 8.10: Representative SPECT/CT images of 125I-p43 in WT mice at 1 h, 4 h 
and 24 h pi.  (A) Axial images demonstrating renal accumulation at various times pi.  
The renal uptake of 125I-p43 is most prominent at 1 h pi and is no longer evident by 4 or 
24 h pi. (B)  Whole body images demonstrating the distribution of 125I-p43.  These 
images display uptake of the radiotracer in the kidneys (K) and liver (L) at 1 h pi.  The 
kidneys are cleared by the 4 h pi time point leaving only trace amounts of peptide 
clearing through the intestines.  By 24 h pi, there was no evidence of any radiotracer in 
the image. 
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images at 1 h pi and progressively diminished in the 4 and 24 h pi images (Figure 
8.10B).  The lack of 125I sequestration by the stomach and thyroid suggested that p43 
had been catabolized without undergoing dehalogenation—an unexpected outcome.  
When compared to the parent peptide, p5, the incorporation of AQA D-amino acids at 
the N-terminal in p43 resulted in alternative catabolic processing of the radiotracer.  
However, instead of exhibiting a longer serum half-life prior to its dehalogenation and 
clearance (which was the expected biological behavior), the peptide avoided renal and 
hepatic deiodinases altogether.  Since radiolabeling of peptides with 125I results in 
incorporation into the L-tyrosine residue, we anticipated that the dehalogenation 
enzymes would “recognize” and act upon the iodinated amino acid; instead, the N-
terminal D-amino acids appeared to have a “protective” effect over the radiolabeled 
tyrosine residue, resulting in no dehalogenation.  Although this characteristic of p43 was 
unforeseen, we speculated that it could offer an advantageous property for AA amyloid 
imaging.  With other peptides, dehalogenation in the kidneys makes renal amyloid 
imaging improbable at early time points pi because the tracer is slowly catabolized and 
125I is liberated; with p43, however, a lack of dehalogenation and rapid renal clearance 
could theoretically be exploited for imaging amyloid-laden regions in the kidneys by 
SPECT/CT imaging at very early time points. 
The microautoradiographs (ARG) of 125I-p43 in harvested AA tissues revealed 
that the radiotracer specifically co-localized with amyloid at all time points examined as 
demonstrated by the accumulation of black silver grains in regions of tissues that were 
also Congophilic (i.e. amyloid) in consecutive tissue sections.  Representative ARG of 
various tissues at different time points are shown (Figure 8.11).  In healthy tissues, ARG  
200 
 
 
Figure 8.11:  Co-localization of 125I-p43 to AA amyloid at various time points pi.  
Microautoradiography (ARG; 20 X) shows distribution of the peptide (black silver 
grains), and Congo red (CR; 20 X) birefringence displays amyloid distribution in the 
tissues.  Peptide is shown to co-localize with amyloid in all tissues.  The distributions 
seen in the spleen and heart were at 1 h pi, the pancreas was at 4 h pi and the kidney 
and stomach were at 24 h pi. 
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indicated that there was dense accumulation of 125I-p43 in the glomeruli, Bowman’s 
capsules and proximal tubules (likely luminal) of the kidney, in addition to binding to, 
presumably, hyaline cartilage associated with tracheal tissue at 1 h pi.  No other tissues 
revealed 125I-p43 binding.  Both the renal radioactivity and cartilage binding were much 
diminished at 4 h pi.  The radiotracer distribution in the kidneys at this time point was 
detected in the distal tubules—indicative of natural radiotracer clearance.  “Off-target” 
binding to cartilage was likely the result of peptide interaction with the 
glycosaminoglycan, chondroitin sulfate, in the tracheal cartilage.  With a sulfation 
pattern similar to heparin (see Figure 1.5), the interaction of a heparin-binding peptide 
derivative, such as p43, with chondroitin sulfate would not be implausible.  Indeed, we 
have seen this with most of our amyloid-reactive peptides.  By 24 h pi, the black silver 
grains that were previously present in the kidneys and associated with cartilage tissue 
had diminished, indicating that the radiotracer had cleared and that the non-specific 
binding that 125I-p43 demonstrated was seemingly weak and temporary (Figure 8.12).  
Although the incorporation of D-amino acids in peptide p43 had not dramatically 
altered the blood half-life as was initially hypothesized, discovery of its new 
characteristic (i.e. non-dehalogenation) adds value to its potential clinical use.  If, by 24 
h pi, the peptide was fully cleared through the kidneys in a manner which did not result 
in dehalogenation of the radiotracer, then injection of radiolabeled p43 into a patient 
with a heavy renal amyloid burden could be used to specifically image amyloid rather 
than be attributed to radiotracer clearance.  Since renal involvement is common in all 
AL, AA and ALect2 patients and yields a poor prognosis, the use of a radiotracer which  
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Figure 8.12:  Autoradiograph visualization of 125I-p43 binding to healthy kidney 
and cartilage tissue at various time points pi.  The accumulation in the kidney seen 
at 1 h pi is primarily within the Bowman’s capsules and renal tubules.  At 4 h and 24 h 
pi, the density of radiotracer uptake in the kidney diminished which indicated clearance.  
The off-target binding observed in the tracheal cartilage was likely due to peptide 
reactivity with chondroitin sulfate.  This interaction was transient, however, which was 
evidenced by decreased peptide binding observed at 4 h pi and a lack of peptide 
binding to cartilage at 24 h pi.  No other tissues within WT mice demonstrated 125I-p43 
accumulation at any time point. 
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could determine the amyloid load in this particular organ may have clinical merit as a 
diagnostic agent or as a tool to monitor the response to therapies. 
 
Studies with 125I-p50 
 The previous studies determined that p43 exhibited different biological behavior 
in vivo when compared to historical p5 data.  The incorporation of N-terminal D-amino 
acids was likely the factor which resulted in a non-dehalogenable product, but this 
hypothesis could not be confirmed without similarly testing p50 in AA and WT mice.  
Peptide p50 has the same amino acid sequence as p43, but there are no D-amino 
acids.  Examining p50 in AA and WT mice would determine if the different biological 
behavior observed with p43 was a result of substituting N-terminal GGG residues with 
AQA or a result of incorporating D-amino acids.  Therefore, p50 was analyzed in AA 
and WT mice to examine amyloid reactivity and dehalogenation.  The same 
experimental conditions were used to examine the 125I-p50 radiotracer in AA (~ 6 – 8 
weeks post AEF induction) and WT mice.  SPECT/CT imaging was performed after 
mice were euthanized at 1 h, 4 h or 24 h pi. 
The images and mean tissue biodistribution measurements (at 1 h pi) of 125I-p50 
in WT mice indicated that this peptide behaved similarly to 125I-p5 rather than 125I-p43 in 
vivo as was suggested by the uptake of liberated 125I in the stomach (31 %ID/g) and 
thyroid and a lack of radiotracer accumulation in the kidneys (9 %ID/g) (Figure 8.13A).  
Additionally, the images and mean tissue biodistribution measurements (at 1 h pi) of 
125I-p50 in AA mice revealed positive uptake in amyloid-laden tissues such as the liver  
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Figure 8.13:  SPECT/CT images of 125I-p50 in WT and AA mice at 1 h, 4 h and 24 h 
pi.  (A)  Distribution of radiotracer in WT mice.  There was evidence of 125I-p50 
dehalogenation at all each time point due to free iodide uptake in the stomach (St) and 
thyroid (T).  By 24 h pi, the stomach had cleared.  Notice that at 1 h pi, there was no 
accumulation of radiotracer in the kidneys (K) which was in stark contrast to that seen 
with 125I-p43.  (B)  Distribution of radiotracer in AA mice.  125I-p50 accumulated in AA 
amyloid-laden tissues such as the liver (L), spleen (Sp), pancreas (P) and intestines (I).  
The radiotracer uptake was stable and was still visible at 24 h pi. 
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(17 %ID/g), spleen (19 %ID/g), pancreas (35 %ID/g) and upper/lower intestines (28 and 
10 %ID/g, respectively) (Figure 8.13B).   The uptake of 125I-p50 was stable enough to 
provide positive amyloid imaging up to at least 24 h pi.  The whole-body distribution in 
AA mice was similar to that observed with both peptides p5 and p43 indicating that all of 
the radiotracers, regardless of biological processing, were capable of targeting AA 
amyloid in multiple tissues.  Confirmation of the preferential binding of 125I-p50 to 
amyloid deposition over healthy tissue was similarly evidenced by ARG analysis of 
representative AA and WT tissue sections (Figures 8.14 and 8.15).  Based on these 
findings, we speculate that, since 125I-p50 behaved more similarly to 125I-p5 than 125I-
p43 in AA and WT mice, it confirmed that it was the incorporation of AQA D-amino 
acids, not simply the N-terminal sequence, which resulted in a non-dehalogenable 
peptide capable of detecting AA amyloid.  
 
8.4. Dynamic PET/CT analysis of 125I-p43 in WT mice 
 Recently, we published a study in which dynamic PET/CT imaging was 
performed to better characterize the in vivo biokinetic profile of radioiodinated p5 in live 
WT and AA mice [416].   Analysis of dynamic PET/CT data, i.e. generation of time 
activity curves (TAC) for various organs of interest, was performed.  These curves of the 
dynamic distribution of 124I-p5 from the time it was injected, made possible the analysis 
of the uptake and clearance of the radiotracer in each organ.  To gain insight into the 
non-dehalogenable nature of p43, dynamic PET/CT scans were conducted on WT mice, 
and data were compared to the published TAC for p5.  Since it was thought that the  
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Figure 8.14: Microautoradiographs displaying 125I-p50 in amyloid-laden tissues 
representative of various time points pi.  These tissues demonstrate the ability of 
peptide p50 (black silver grains) to preferentially target amyloid within several tissues at 
1 h, 4 h and 24 h pi.  The radiotracer does not bind healthy tissue within these sections. 
 
 
Figure 8.15:  Microautoradiographs demonstrating a lack of 125I-p50 accumulation 
in various WT tissues.  These images confirm that 125I-p50 does not bind healthy 
tissue in vivo. 
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dehalogenation of these peptides primarily takes place in the kidneys, the TAC for this 
organ was expected to differ between 124I-p43 and 124I-p5. 
Dynamic PET/CT imaging requires the use of a positron emitting radioisotope.  
With a half-life of 4.2 days, radioiodination with iodine-124 (124I) was performed for this 
study.  Radiolabeling of peptide p43 with 124I was achieved as described in Section 3.6.  
The product was diluted with sterile PBS such that each administered dose was ~ 200 
µCi.  Since this type of imaging was conducted with live animals, the mice were 
administered isoflurane anesthesia (2 % in air) prior to, and throughout the duration of 
the procedure (see Section 3.12.2).  The PET data were analyzed using the Inveon 
Research Workplace software (Siemens).  Time activity curves were created by drawing 
regions of interest over the heart, kidneys, thyroid and bladder of a co-registered 
PET/CT image since these organs represent blood pool and sites of catabolism and 
iodide uptake.  Given that we expected dissimilarities between the dynamic renal 
distribution of 124I-p43 and 124I-p5, the generated TAC of the kidneys was compared to 
the historical p5 kidney TAC data [416]. 
The data indicated that the profiles of the radiotracers in WT mice did, indeed, 
differ in the kidneys (Figure 8.16).  With 124I-p5, the peak renal accumulation value 
occurred between 7 and 8 min pi followed by rapid clearance of the radiotracer from the 
organ; with 124I-p43, however, the peak renal value occurred approximately 10 min later 
(~ 17 min pi), and the radioactivity was cleared at a much slower rate from the kidney 
than was observed with 124I-p5.  The delay in peak uptake that was observed with 124I-
p43 may suggest that this radiotracer had a slightly extended serum half-life prior to 
renal catabolism.  Since p43 was designed as a p5 variant containing D-amino acids to  
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Figure 8.16: Time activity curves depicting renal accumulation and clearance of 
124I-p43 and 124I-p5.  The peak renal uptake values were measured.  The curves 
demonstrate that 124I-p43 (green) took ~ 10 min longer to reach maximum accumulation 
in the kidneys as compared to 124I-p5 (red).  The black stars pinpoint the respective 
peak renal activity time points.  The two peptides differed in clearance of the tracers as 
well which was shown by the different shapes of the curves; 124I-p43 had a broad peak 
in the kidneys, and 124I-p5 had a sharp peak indicating much more rapid clearance of 
radioactivity of the latter.  The y-axes are not scaled equally due to the differing 
amounts of radioactivity injected in the two studies.  (Historical 124I-p5 data was taken 
from [416] to create the image.) 
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possibly extend the half-life of the peptide, this was a gratifying finding that was not 
obvious in the previous SPECT/CT study.   
In regard to the observed difference in renal clearance, 124I-p5 was 
dehalogenated within the kidneys which resulted in a TAC that partially depicted the 
loss of free iodide to the blood instead of radiolabeled peptide to the bladder.  This 
would further explain why the curve for 124I-p5 revealed a sharper peak as compared to 
124I-p43.  With the latter peptide, the TAC was broad, indicating that the radiotracer was 
retained within the kidney for a longer time period.  Instead of monitoring the loss of 
liberated iodide from the kidney, the p43 TAC was indicative of the movement of 
radiolabeled p43, presumably intact, into the bladder.  The previously described 
SPECT/CT time course also indicated the presence of 124I-p43 in the renal tubules of 
WT mice at 1 h pi (see Figure 8.12), which further confirmed the extended presence of 
the radiotracer in the kidneys. 
Since the 125I-p43 radiotracer was resistant to dehalogenation, the stomach was 
devoid of radioactivity, and the thyroid only contained minimal amounts of radioiodide 
(Figure 8.10).  Analysis of the dynamic PET/CT TAC for the heart, kidney, liver, thyroid 
and bladder was then performed.  These curves indicated uptake and rapid clearance 
from the heart (blood pool), a delayed accumulation and prolonged clearance from the 
kidneys, slight uptake and steady level of radiotracer in the liver and minimal amounts of 
radiotracer in the thyroid as evidenced by very little accumulation toward the end of the 
120 min acquisition (Figure 8:17A).  The TAC for the bladder revealed steady 
accumulation that eventually plateaued; due to the high amount of radioactivity in this 
organ, it dominated the plot of TAC and was, thus, only shown in one of the graphs  
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Figure 8.17: Time activity curves for 124I-p43 in WT mice.  (A) Curves depicting the 
accumulation and clearance of the heart, thyroid, liver and kidneys.  The TAC showed 
rapid clearance from the heart (red), slight uptake in the thyroid (black), little 
accumulation in the liver (purple) that remained steady for the 120 min acquisition and 
delayed uptake in the kidney with slow clearance that was achieved by ~ 80 min pi.  (B) 
TAC including bladder accumulation.  The bladder (blue) began a steady accumulation 
of radiotracer at the beginning of the acquisition and eventually plateaued at ~ 60 min.   
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(Figure 8.17B).  These curves support our hypothesis that 124I-p43, in a WT mouse, 
exhibited slow renal clearance (relative to p5) and bladder accumulation which 
suggested that the peptide could be followed throughout the duration of the acquisition.  
It is noteworthy that little or no bladder radioactivity was observed when 124I-p5 was 
injected into WT mice [416].  This is an especially interesting finding that could be 
clinically beneficial in certain circumstances.  If, for instance, a patient were to receive a 
dose of 124I-p43 peptide and be imaged at an appropriate time pi, the lack of 
dehalogenation of the radiotracer would, theoretically, allow for accumulation and 
visualization of peptide bound to scant amyloid deposits in the kidneys, stomach, 
pancreas and spleen of patients with amyloidosis.  If the radiotracer is prone to 
dehalogenation, accumulation of free iodide in the stomach could make visualization of 
amyloid deposits in nearby regions nearly impossible. 
 
8.5. Conclusions 
Development of a peptide with non-natural, D-amino acid incorporation was an 
attempt to address issues with the relatively short half-life associated with peptide 
radiotracers.  Incorporation of amino acids that are not naturally recognized by 
biological enzymes was the strategy to extend peptide half-life in order to enhance the 
time-frame in which the radiotracer could be taken up by amyloid in vivo.  It was 
hypothesized that this type of modification would improve peptide bioavailability without 
altering the size, which may hinder its targeting capabilities.  
212 
 
Studies conducted ex vivo revealed that the D-amino acid peptide variant, p43, 
(like the p5 reagent) was incapable of binding to ApoA2c amyloid.  In contrast, peptide 
p43 effectively targeted AA pathology by using both ex vivo and in vivo measures.  The 
peptide was shown to bind more efficiently to amyloid-laden tissue homogenates ex 
vivo as compared to the parent peptide, p5.  The alternative control peptide for these 
studies, p50 (no D-amino acids), was shown to bind in a similar fashion to p5.  Thus, 
incorporation of D-amino acids modestly enhanced uptake and affinity for AA in the ex 
vivo binding assays. 
The in vivo analyses with p43 revealed its effectiveness at targeting whole body 
amyloid burden in H2/IL-6 AA amyloid-laden mice.  It was in WT mice, however, where 
the most interesting findings were made with p43.  Instead of undergoing 
dehalogenation of the Tyr residue, which has been shown in multiple studies with 125I-p5 
[293, 416], the peptide avoided dehalogenase enzymes within the kidneys, and the 
radioiodination remained intact.  This was shown by using SPECT/CT, biodistribution 
studies and analyses of TAC from dynamic PET/CT imaging.  The control peptide made 
with only L-type amino acids, p50, did not display these properties.  Additionally, 
dynamic PET/CT revealed that the peak renal uptake time of 124I-p43 was 
approximately 10 min longer than the uptake time published for 124I-p5 in healthy mice.  
Serum half-life extension may account for this delay.  Thus, the incorporation of N-
terminal D-type AQA immediately in front of the L-Tyr in p5 resulted in a non-
dehalogenable peptide capable of effectively and specifically targeting AA amyloid in 
vivo with slightly extended serum bioavailability.  This peptide could meet clinical needs 
that other amyloid-reactive peptides have not been able to achieve. 
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Chapter 9 
Summary and future directions 
 
Summary of data presented: 
 In the US, there are approximately 3500 new diagnoses of amyloidosis every 
year, and this number is expected to rise with greater clinical awareness and improved 
detection systems.  The prognoses for these patients varies, but those with cardiac 
involvement have a considerably less favorable prognosis.  In an attempt to facilitate a 
more complete and accurate diagnosis, we have begun a program developing 
molecular imaging techniques using amyloid-reactive tracers such that a non-invasive 
“picture” of amyloid burden in patients may be established.  There is an unmet clinical 
need for a facile method of quantitatively detecting whole body amyloid burden in 
patients. 
 To this end, we have developed synthetic, amyloid-reactive peptides for use as 
radiotracers with SPECT/CT or PET/CT molecular imaging to detect amyloid deposition, 
using as a preclinical test-bed transgenic murine models of amyloidosis.  In this thesis 
we tested a series of hypotheses and characterized a panel of peptides that could, one 
day, provide clinical benefit for the early detection of multiple types of amyloidosis. 
Here I summarize the findings of this thesis describing our ongoing developmental 
and translational research: 
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 Polybasic, synthetic, heparin-binding peptides have been shown to bind both AA 
amyloid-laden tissue homogenates and synthetic AL fibrils in ex vivo pull down 
assays. 
 
 Peptide affinity for ApoA2c amyloid-laden tissue homogenates ex vivo, however, 
increased according to the series p5, p5R and p5R+14, which exhibited the 
highest affinity for this substrate. 
 
 Dual-isotope SPECT/CT imaging in association with tissue radioactivity 
biodistribution measurements, and SPECT image analyses revealed that peptide 
125I-p5R+14 provided more complete information on the whole body amyloid 
burden in ApoA2c mice as compared to 99mTc-p5 in the same animal. 
 
 Autoradiographic analyses of 125I-p5R+14 in ApoA2c amyloid-laden mouse 
tissues confirmed specific peptide co-localization with amyloid; however, amyloid 
deposits in certain tissues, notably the spleen, lung and heart, exhibited variable 
and incomplete uptake of the peptide radiotracer.  Instead, a “binding site barrier” 
effect was observed in these tissues, likely due to the high affinity binding of the 
peptide to the dense ApoA2c amyloid deposits in these organs.  This observation 
suggested that 125I-p5R+14 imaging of amyloid may underestimate the extent of 
true amount of amyloid deposition in vivo. 
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 A comparative study of peptide p5R+14 binding to ApoA2c amyloid-laden tissues 
in vivo and ex vivo was performed to study the incomplete uptake of peptide by 
amyloid in vivo.  These analyses showed that the peptide “underestimated” the 
amount of amyloid in vivo in the spleen, lungs and heart, as compared to ex vivo 
uptake of the peptide.  These experiments showed that the peptide binding sites 
in these tissues may be “inaccessible” in vivo since ex vivo homogenization 
increased peptide reactivity. 
 
 A modified peptide was developed to potentially improve in vivo ApoA2c amyloid-
targeting and uptake.  Since Wall et al. demonstrated that an arginine-rich 
peptide resulted in higher affinity for amyloid and a binding site barrier effect in 
AA amyloid-laden tissues [371], we hypothesized that a lysine variant of p5R+14, 
designated p5+14, would penetrate regions of dense ApoA2c amyloid deposits 
that were untouched by p5R+14 due to its lower affinity for the deposits.  
SPECT/CT imaging, tissue radioactivity biodistribution measurements and 
autoradiographic analyses of 125I-p5+14 in ApoA2c amyloid mice yielded data 
that did not support this hypothesis, however, and revealed that 125I-p5R+14 was 
a more effective at ApoA2c amyloid-targeting. 
 
 While 125I-p5R+14 specifically and effectively bound ApoA2c amyloid in vivo, the 
radiotracer was unable to completely decorate (cover) dense amyloid deposits.  
Lowering peptide affinity by substituting lysine for arginine residues in the peptide 
did not enhance amyloid coverage; thus, we developed another peptide 
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radiotracer which addressed a different physical property— the serum half-life.  
Peptides have short bioavailability in vivo due to their small size [410-412], which 
led to our hypothesis that extending the serum half-life of the peptide radiotracer 
may enhance amyloid-targeting due to its longer exposure to amyloid.  
Therefore, a PEGylated p5R+14 peptide (20 kDa PEG) was synthesized and 
evaluated in both WT and ApoA2c mice.  Data from these studies indicated that 
catabolism of 125I-PEG-p5R+14 differed from that seen with unmodified 125I-
p5R+14 as evidenced by hepatobiliary clearance of the larger peptide compared 
to renal clearance with the non-PEGylated peptide.  SPECT imaging indicated 
that, at 1 h pi, there was a higher concentration of 125I-PEG-p5R+14 in WT mice 
as compared to 125I-p5R+14 suggesting that the serum half-life was modestly 
extended.  The serum bioavailability did not, however, enhance amyloid-targeting 
efficacy.  Autoradiographic analyses suggested the two peptides exhibited similar 
amyloid-binding throughout all tissues. 
 
 Peptide p5R+14 was the most effective at binding ApoA2c amyloid, but despite 
modifications its amyloid targeting abilities remained sub-optimal.  To further 
investigate this limitation, an alternative method for serum half-life extension—the 
use of peptides containing non-natural, D- amino acids—led to the development 
and investigation of peptide p43, a variant of p5 with D-type AQA residues 
replacing GGG at the N-terminal.  Ex vivo “pull down” binding assays using 125I-
p43 showed its AA amyloid-binding potential exceeded that of 125I-p5, but much 
like p5, it was incapable of binding ApoA2c amyloid; thus, p5R+14 remained the 
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most effective ApoA2c amyloid-targeting agent.  Based on our studies using AA 
and ApoA2c amyloid-peptide interactions we speculated that the composition of 
ApoA2c amyloid differs in nature relative to AA amyloid, e.g. the HSPG/fibril 
content may vary, which could influence successful peptide-amyloid interactions. 
 
 Because p43 did not effectively bind ApoA2c amyloid ex vivo, we determined its 
in vivo characteristics instead in both AA amyloid-laden H2/IL-6 and WT mice.  
SPECT/CT imaging, tissue radioactivity biodistribution measurements and ARG 
at 1 h, 4 h and 24 h pi revealed that 125I-p43, like 125I-p5, specifically bound AA 
amyloid in numerous tissues.  In WT mice, however, 125I-p43 exhibited behavior 
unlike that previously observed with 125I-p5 [293].  At 1 h pi, there was evidence 
of 125I-p43 in the renal cortices, but at later time points pi, the renal activity rapidly 
diminished.  Remarkably, no radioiodide was detected in the stomach or thyroid 
at any time point, which indicated that the radiotracer was not dehalogenated—
an unexpected finding based on peptide p5 data.   
 
 The lack of dehalogenation of p43 was directly related to the presence of the D-
amino acids at the N-terminal rather than simply substitution of AQA amino acids.  
This was confirmed in studies with p50, a peptide with the same amino acid 
sequence as p43 but with all L-entantiomers.  The in vivo reactivity of p50 in AA 
and WT mice showed behavior similar to peptide p5, which proved that the D-
enantiomers were responsible for protecting p43 from dehalogenase activity. 
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 To further characterize p43 in vivo, dynamic PET/CT imaging was performed 
using live WT mice.  Analysis of PET images revealed the peak uptake time in 
the kidneys was 124I-p43 was 10 min longer than that seen for 124I-p5 [416], likely 
indicating serum half-life extension.  These studies also confirmed that 124I-p43 
was not dehalogenated as evidenced by accumulation of radioactivity in the 
bladder.  Thus, p43 was characterized as a non-dehalogenable, amyloid-binding 
peptide with slightly enhanced serum bioavailability—it offered properties of 
amyloid-imaging that no other examined peptide could achieve. 
 
Future Directions: 
 The use of biological agents as imaging radiotracers is not a novel approach to 
disease detection.  The data presented in this thesis and recent publications, validate 
the use of peptides for the detection of amyloidosis—a devastating disease which would 
benefit from early detection to improve patient survival.  Our data indicated that there 
were unique characteristics associated with each of the peptides evaluated, which may 
make them more suitable for the clinical detection of certain types of amyloid disease.  
For instance, the enhanced binding of peptides with an additional 4 positively charged 
amino acids (e.g., p5R+14 or p5+14) may allow detection of scant amyloid deposits in 
vivo where high-affinity targeting is required; such would be the case in early disease 
detection where amyloid deposits are relatively small and the likelihood of detection 
would increase with a high-affinity, amyloid-binding reagent.  In addition, diseases 
where small amyloid deposits form such as in cases of type 2 diabetes or cerebral 
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amyloid angiopathy in the brains of the elderly may benefit from a high affinity peptide 
imaging agent that would not suffer from the binding site barrier effect.  Furthermore, 
the lack of dehalogenation of peptides with N-terminal, D- amino acids neighboring the 
iodinated tyrosine, may enhance the likelihood of detecting pancreatic or gastric amyloid 
deposits in patients with type 2 diabetes or AL/AA amyloidosis, respectively.  Without 
dehalogenation, there would not be uptake of free iodide in the stomach, which could 
hinder the visualization of amyloid deposits in in organs in close proximity to the 
stomach.  Although we did not identify a single peptide to address all unmet clinical 
needs for amyloid detection, the many characteristics identified during these studies can 
be exploited for the detection of certain amyloid-associated conditions.   
Defining the utility of peptides with unique characteristics and optimizing them for 
appropriate amyloid detection strategies would be clinically invaluable.  Since cardiac 
and renal amyloidosis are associated with the most critical conditions in patients, earlier 
detection of such deposits should be the focus of peptide optimization for imaging.  
Combining and exploiting certain properties that were identified in this thesis may yield 
a superior peptide for targeting these types of deposition; the serum plasma half-life and 
avoidance of dehalogenation associated with D-amino acid incorporation  of the 
extended, high-affinity peptide p5R+14 could provide the characteristics needed for 
successful detection of amyloid in the heart and kidneys of patients with AL.  This 
combination of biochemical properties may also be advantageous in pancreatic amyloid 
detection.  Therefore, future experiments that focus on optimizing and combining certain 
peptide characteristics should be conducted to assess hypothetically improved amyloid-
targeting agents. 
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In the long term, before peptides are translated into the clinic, additional pre-
clinical studies would need to be performed to ensure there are no adverse issues 
associated with toxicology or immunogenicity in mice.  Additionally, it may be valuable 
to evaluate certain of the newly developed peptides in another species.  This could be 
possible working in conjunction with the UT College of Veterinary Medicine, i.e. type 2 
diabetic cats could receive a non-dehalogenable peptide radiolabeled with 123I (T½ = 13 
h) to assess radiotracer efficacy in detecting pancreatic AIAPP.  Once sufficient 
preliminary data has been generated to justify a human clinical trial, GMP grade 
material would be developed and tested prior to applying to the FDA for approval to 
translate the reagent into human clinical trials. 
A dire need for disease detection and monitoring exists for patients with 
amyloidosis around the world since approved strategies are not universally available, do 
not provide information for all critical organs, or do not target both AL and ATTR amyloid 
deposition—the two types most commonly seen in patients.  The use of peptides as 
imaging agents for these diseases has yielded promising results, and transitioning these 
reagents into clinical trials could provide more information about the amyloid burden in 
patients than has been generated with other clinically available reagents.  As has been 
stated by many researchers and physicians in the field, earlier detection is the key to 
fighting this devastating disease. 
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